AU685209C - Substituted morpholine derivatives and their use as therapeutic agents - Google Patents
Substituted morpholine derivatives and their use as therapeutic agentsInfo
- Publication number
- AU685209C AU685209C AU13223/95A AU1322395A AU685209C AU 685209 C AU685209 C AU 685209C AU 13223/95 A AU13223/95 A AU 13223/95A AU 1322395 A AU1322395 A AU 1322395A AU 685209 C AU685209 C AU 685209C
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- compound
- bis
- trifluoromethyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims description 20
- 229940124597 therapeutic agent Drugs 0.000 title description 4
- 150000002780 morpholines Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims description 526
- 150000001875 compounds Chemical class 0.000 claims description 327
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 119
- 239000000203 mixture Substances 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 84
- 238000006243 chemical reaction Methods 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 59
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 55
- 229940002612 prodrug Drugs 0.000 claims description 52
- 239000000651 prodrug Substances 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 51
- -1 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-3-(S)-(4- fluorophenyl)-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methylmorpholine Chemical class 0.000 claims description 49
- 239000000460 chlorine Substances 0.000 claims description 46
- 229910052757 nitrogen Inorganic materials 0.000 claims description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 39
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- 206010047700 Vomiting Diseases 0.000 claims description 19
- 108060008037 tachykinin Proteins 0.000 claims description 19
- 102000003141 Tachykinin Human genes 0.000 claims description 18
- 239000011737 fluorine Substances 0.000 claims description 18
- 229910052731 fluorine Inorganic materials 0.000 claims description 18
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 17
- 125000006413 ring segment Chemical group 0.000 claims description 17
- 150000001412 amines Chemical class 0.000 claims description 15
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 14
- 229910052801 chlorine Inorganic materials 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 208000019695 Migraine disease Diseases 0.000 claims description 9
- 206010027599 migraine Diseases 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 4
- 125000003363 1,3,5-triazinyl group Chemical class N1=C(N=CN=C1)* 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- KLGSKHBWMXMJRX-JAMKYWPSSA-N (2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-[[2-(2-pyrrolidin-1-ylethyl)triazol-4-yl]methyl]morpholine Chemical compound O([C@@H]([C@@H]1C=2C=CC=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC(=N1)C=NN1CCN1CCCC1 KLGSKHBWMXMJRX-JAMKYWPSSA-N 0.000 claims description 2
- HOQIUENSTHVBTO-CXAHNHKCSA-N (2r,3s)-3-(4-fluorophenyl)-2-[(1r)-1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-4-[[5-(pyrrolidin-1-ylmethyl)-2h-triazol-4-yl]methyl]morpholine Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(F)C=2)C(F)(F)F)CCN1CC1=NNN=C1CN1CCCC1 HOQIUENSTHVBTO-CXAHNHKCSA-N 0.000 claims description 2
- RENWFOYENNEQJW-HLAWJBBLSA-N (2s)-2-[3,5-bis(trifluoromethyl)phenyl]-2-[(2r,3s)-3-(4-fluorophenyl)-4-(1h-1,2,4-triazol-5-ylmethyl)morpholin-2-yl]oxyethanol Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](CO)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC=1N=CNN=1 RENWFOYENNEQJW-HLAWJBBLSA-N 0.000 claims description 2
- 150000003920 1,2,4-triazines Chemical class 0.000 claims description 2
- CJNSUMDYKMFCEV-ZNZBMKLDSA-N 1-[3-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1h-1,2,4-triazol-5-yl]-n,n-dimethylmethanamine Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(CN(C)C)=N1 CJNSUMDYKMFCEV-ZNZBMKLDSA-N 0.000 claims description 2
- HKSPYQLHTAGSCY-YZGWKJHDSA-N 5-[[(2r,3s)-2-[(1s)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](CO)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NC(=O)NN1 HKSPYQLHTAGSCY-YZGWKJHDSA-N 0.000 claims description 2
- JJLCJGNYSKTWDS-YZGWKJHDSA-N 5-[[(2r,3s)-3-(4-fluorophenyl)-2-[(1s)-1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-hydroxyethoxy]morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](CO)C=2C=C(C=C(F)C=2)C(F)(F)F)CCN1CC1=NC(=O)NN1 JJLCJGNYSKTWDS-YZGWKJHDSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052701 rubidium Inorganic materials 0.000 claims description 2
- TXWIQVZPNNMIMO-VFRFXQOFSA-N (2r,3s)-4-[[5-(azetidin-1-ylmethyl)-2h-triazol-4-yl]methyl]-3-(4-fluorophenyl)-2-[(1r)-1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]morpholine Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(F)C=2)C(F)(F)F)CCN1CC1=NNN=C1CN1CCC1 TXWIQVZPNNMIMO-VFRFXQOFSA-N 0.000 claims 1
- MGEUZFSNEOPBGZ-FGTMMUONSA-N 5-[(2r,3s)-2-[(1s)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethoxy]-3-phenylmorpholin-4-yl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound C1([C@@H]2N(CCO[C@@H]2O[C@H](CO)C=2C=C(C=CC=2)C(F)(F)F)C=2NNC(=O)N=2)=CC=CC=C1 MGEUZFSNEOPBGZ-FGTMMUONSA-N 0.000 claims 1
- CPUNIFUDLWTUMF-YZGWKJHDSA-N 5-[[(2r,3s)-2-[(1s)-1-[3-fluoro-5-(trifluoromethyl)phenyl]-2-hydroxyethoxy]-3-phenylmorpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound O([C@@H]([C@@H]1C=2C=CC=CC=2)O[C@H](CO)C=2C=C(C=C(F)C=2)C(F)(F)F)CCN1CC1=NC(=O)NN1 CPUNIFUDLWTUMF-YZGWKJHDSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 197
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 139
- 238000005160 1H NMR spectroscopy Methods 0.000 description 124
- 239000000243 solution Substances 0.000 description 105
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 86
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 80
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- 235000019439 ethyl acetate Nutrition 0.000 description 68
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 229940093499 ethyl acetate Drugs 0.000 description 61
- 229910001868 water Inorganic materials 0.000 description 60
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 54
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 48
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 47
- 239000003921 oil Substances 0.000 description 41
- 235000019198 oils Nutrition 0.000 description 41
- 239000000047 product Substances 0.000 description 36
- 239000002904 solvent Substances 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 31
- 239000000377 silicon dioxide Substances 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 27
- 229910000027 potassium carbonate Inorganic materials 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 239000012267 brine Substances 0.000 description 22
- 235000011181 potassium carbonates Nutrition 0.000 description 22
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 20
- 239000006260 foam Substances 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000543 intermediate Substances 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 14
- 102100024304 Protachykinin-1 Human genes 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 101800003906 Substance P Proteins 0.000 description 9
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 101800000399 Neurokinin A Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000003863 ammonium salts Chemical class 0.000 description 5
- YNBJMIXWGPOBGE-UHFFFAOYSA-N carbanide;cyclopenta-1,3-diene;titanium(4+) Chemical compound [CH3-].[CH3-].[Ti+4].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YNBJMIXWGPOBGE-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- 238000003760 magnetic stirring Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 5
- JAIGTTPBXVVFPN-UHFFFAOYSA-N methyl n-[(1-amino-2-chloroethylidene)amino]carbamate Chemical compound COC(=O)NNC(=N)CCl JAIGTTPBXVVFPN-UHFFFAOYSA-N 0.000 description 5
- 208000033808 peripheral neuropathy Diseases 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- HEAUFJZALFKPBA-JPQUDPSNSA-N (3s)-3-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-JPQUDPSNSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical group O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 4
- SGJNTLFXOBLTGB-UHFFFAOYSA-N 4-(4-azidobut-2-ynyl)morpholine Chemical compound [N-]=[N+]=NCC#CCN1CCOCC1 SGJNTLFXOBLTGB-UHFFFAOYSA-N 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- NHXYSAFTNPANFK-HDMCBQFHSA-N Neurokinin B Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(O)=O)C1=CC=CC=C1 NHXYSAFTNPANFK-HDMCBQFHSA-N 0.000 description 4
- 101800002813 Neurokinin-B Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 102100033009 Tachykinin-3 Human genes 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- JMVUVZICZVJGJY-INIZCTEOSA-N (3s)-4-benzyl-3-phenylmorpholin-2-one Chemical compound O=C([C@@H]1C=2C=CC=CC=2)OCCN1CC1=CC=CC=C1 JMVUVZICZVJGJY-INIZCTEOSA-N 0.000 description 2
- RKQFDYXUAACCJJ-INIZCTEOSA-N (4s)-4-benzyl-3-[2-(4-fluorophenyl)acetyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1CC(=O)N1C(=O)OC[C@@H]1CC1=CC=CC=C1 RKQFDYXUAACCJJ-INIZCTEOSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WAKMMQSMEDJRRI-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC(C(Cl)=O)=CC(C(F)(F)F)=C1 WAKMMQSMEDJRRI-UHFFFAOYSA-N 0.000 description 2
- BGAKSLBTFLVNAH-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC(C(F)(F)F)=C1 BGAKSLBTFLVNAH-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000027601 Inner ear disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 108010072901 Tachykinin Receptors Proteins 0.000 description 2
- 102000007124 Tachykinin Receptors Human genes 0.000 description 2
- 241000159243 Toxicodendron radicans Species 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000454 anti-cipatory effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- HYTACLVSJIFYBY-UHFFFAOYSA-N azane;dichloromethane;methanol Chemical compound N.OC.ClCCl HYTACLVSJIFYBY-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
- 208000006275 fascioliasis Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- NLGUJOVLAXLSMX-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-ethylethanamine Chemical compound C=1C=CC=CC=1COP(N(CC)CC)OCC1=CC=CC=C1 NLGUJOVLAXLSMX-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000005505 thiomorpholino group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 230000002455 vasospastic effect Effects 0.000 description 2
- 201000005539 vernal conjunctivitis Diseases 0.000 description 2
- 208000027491 vestibular disease Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WDPABLGLTMNYIY-KBJGYGKASA-N (2r,3s)-4-(4-azidobut-2-ynyl)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine Chemical compound C1([C@@H]2N(CC#CCN=[N+]=[N-])CCO[C@@H]2O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=CC=C(F)C=C1 WDPABLGLTMNYIY-KBJGYGKASA-N 0.000 description 1
- LCRCODPYSHSWAR-AWEZNQCLSA-N (2s)-2-(benzylazaniumyl)-2-phenylacetate Chemical compound [NH2+]([C@H](C(=O)[O-])C=1C=CC=CC=1)CC1=CC=CC=C1 LCRCODPYSHSWAR-AWEZNQCLSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- GSZAAEJBPFTBKG-INIZCTEOSA-N (3s)-4-benzyl-3-(4-fluorophenyl)morpholin-2-one Chemical compound C1=CC(F)=CC=C1[C@H]1C(=O)OCCN1CC1=CC=CC=C1 GSZAAEJBPFTBKG-INIZCTEOSA-N 0.000 description 1
- OJOFMLDBXPDXLQ-VIFPVBQESA-N (4s)-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-VIFPVBQESA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- AEMWUHCKKDPRSK-UHFFFAOYSA-N (ne)-n-diazo-2,4,6-tri(propan-2-yl)benzenesulfonamide Chemical compound CC(C)C1=CC(C(C)C)=C(S(=O)(=O)N=[N+]=[N-])C(C(C)C)=C1 AEMWUHCKKDPRSK-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- DBKCSIPPGZAVSZ-UHFFFAOYSA-N 1,3-diacetyl-4,5-bis(bromomethyl)imidazol-2-one Chemical compound CC(=O)N1C(CBr)=C(CBr)N(C(C)=O)C1=O DBKCSIPPGZAVSZ-UHFFFAOYSA-N 0.000 description 1
- BIUYFEZYHHFFFW-UHFFFAOYSA-N 1,3-diacetyl-4-(bromomethyl)imidazol-2-one Chemical compound CC(=O)N1C=C(CBr)N(C(C)=O)C1=O BIUYFEZYHHFFFW-UHFFFAOYSA-N 0.000 description 1
- FFINGVWTWRUHPW-UHFFFAOYSA-N 1,4-bis(chloromethyl)triazole Chemical compound ClCC1=CN(CCl)N=N1 FFINGVWTWRUHPW-UHFFFAOYSA-N 0.000 description 1
- RCHDLEVSZBOHOS-UHFFFAOYSA-N 1,4-dichlorobut-2-yne Chemical compound ClCC#CCCl RCHDLEVSZBOHOS-UHFFFAOYSA-N 0.000 description 1
- USRYEHHMJIRICK-ZNZBMKLDSA-N 1-[5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-2h-triazol-4-yl]-n,n-dimethylmethanamine Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNN=C1CN(C)C USRYEHHMJIRICK-ZNZBMKLDSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical group N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- AMLDZYCRKRBTAA-UHFFFAOYSA-N 10,29-diphenyl-12,15,18,21,24,27-hexaoxapentacyclo[26.8.0.02,11.03,8.031,36]hexatriaconta-1(28),2(11),3,5,7,9,29,31,33,35-decaene Chemical compound O1CCOCCOCCOCCOCCOC2=C(C=3C=CC=CC=3)C=C3C=CC=CC3=C2C(C2=CC=CC=C2C=2)=C1C=2C1=CC=CC=C1 AMLDZYCRKRBTAA-UHFFFAOYSA-N 0.000 description 1
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
- SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- IVHKZCSZELZKSJ-UHFFFAOYSA-N 2-hydroxyethyl sulfonate Chemical compound OCCOS(=O)=O IVHKZCSZELZKSJ-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RUJYJCANMOTJMO-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 RUJYJCANMOTJMO-UHFFFAOYSA-N 0.000 description 1
- LOUVAUMOCKBVKX-UHFFFAOYSA-N 3-[[2-methyl-5-(piperazin-1-ylmethyl)triazol-4-yl]methyl]morpholine Chemical compound CN1N=C(C(=N1)CC1COCCN1)CN1CCNCC1 LOUVAUMOCKBVKX-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- VUPCJHPGDJPXKV-UHFFFAOYSA-N 4,5-bis(chloromethyl)-1h-imidazole;hydrochloride Chemical compound Cl.ClCC=1N=CNC=1CCl VUPCJHPGDJPXKV-UHFFFAOYSA-N 0.000 description 1
- BAHINWGFSAJRRT-UHFFFAOYSA-N 4-(1h-1,2,4-triazol-5-ylmethyl)morpholine Chemical compound N1=CNN=C1CN1CCOCC1 BAHINWGFSAJRRT-UHFFFAOYSA-N 0.000 description 1
- AVIDCDJMJFUSGQ-UHFFFAOYSA-N 4-[[5-(morpholin-4-ylmethyl)-2h-triazol-4-yl]methyl]morpholine Chemical compound N=1NN=C(CN2CCOCC2)C=1CN1CCOCC1 AVIDCDJMJFUSGQ-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- MDYHLUJCPDRJNB-UHFFFAOYSA-N C(C1=CC=CC=C1)ON(P(CC)CC)OCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)ON(P(CC)CC)OCC1=CC=CC=C1 MDYHLUJCPDRJNB-UHFFFAOYSA-N 0.000 description 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- XPIYDBVXVJNFJP-UHFFFAOYSA-N N-methyl-2-[5-(morpholin-4-ylmethyl)-1,2,4-triazol-1-yl]ethanamine Chemical compound CNCCN1N=CN=C1CN1CCOCC1 XPIYDBVXVJNFJP-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 description 1
- 102400000097 Neurokinin A Human genes 0.000 description 1
- 102000046798 Neurokinin B Human genes 0.000 description 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 244000258044 Solanum gilo Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- RGQSLWIHQBUVEX-LADGPHEKSA-N [(2r,3s)-4-benzyl-3-phenylmorpholin-2-yl] 3-fluoro-5-(trifluoromethyl)benzoate Chemical compound FC(F)(F)C1=CC(F)=CC(C(=O)O[C@@H]2[C@@H](N(CC=3C=CC=CC=3)CCO2)C=2C=CC=CC=2)=C1 RGQSLWIHQBUVEX-LADGPHEKSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000971 adrenergic beta-2 receptor antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- STOASOOVVADOKH-UHFFFAOYSA-N but-3-ynyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCC#C)C=C1 STOASOOVVADOKH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- MKNXBRLZBFVUPV-UHFFFAOYSA-L cyclopenta-1,3-diene;dichlorotitanium Chemical compound Cl[Ti]Cl.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 MKNXBRLZBFVUPV-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- NSBNXCZCLRBQTA-UHFFFAOYSA-N dibenzyl bis(phenylmethoxy)phosphoryl phosphate Chemical compound C=1C=CC=CC=1COP(OP(=O)(OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)(=O)OCC1=CC=CC=C1 NSBNXCZCLRBQTA-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- FBELJLCOAHMRJK-UHFFFAOYSA-L disodium;2,2-bis(2-ethylhexyl)-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCC(CC)CC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CC(CC)CCCC FBELJLCOAHMRJK-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- VVDUZZGYBOWDSQ-UHFFFAOYSA-M eschenmoser's salt Chemical compound [I-].C[N+](C)=C VVDUZZGYBOWDSQ-UHFFFAOYSA-M 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011832 ferret model Methods 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- ZDQQNZRQRARBNB-UHFFFAOYSA-N methyl 2-bromo-2-(4-fluorophenyl)acetate Chemical compound COC(=O)C(Br)C1=CC=C(F)C=C1 ZDQQNZRQRARBNB-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WFJRIDQGVSJLLH-UHFFFAOYSA-N methyl n-aminocarbamate Chemical compound COC(=O)NN WFJRIDQGVSJLLH-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XYAJYERDOYDSQH-UHFFFAOYSA-N n-(2-chloro-1-hydrazinylethylidene)formamide Chemical compound NNC(CCl)=NC=O XYAJYERDOYDSQH-UHFFFAOYSA-N 0.000 description 1
- WNPORCRRSCZMSO-UHFFFAOYSA-N n-[(z)-(1-amino-2-chloroethylidene)amino]formamide Chemical compound ClCC(/N)=N\NC=O WNPORCRRSCZMSO-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Description
~ ! ~
«
SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
5 This invention relates to a class of aromatic compounds which are useful as tachykinin antagonists. More particularly, the compounds of the invention contain an amine-substituted azo-heterocyclic moiety.
The tachykinins are a group of naturally occurring peptides found widely distributed throughout mammalian tissues, both within the
10 central nervous system and in peripheral nervous and circulatory systems.
The tachykinins are distinguished by a conserved carboxyl-terminal sequence: Phe-X-Gly-Leu-Met-NH2
At present, there are three known mammalian tachykinins
15 referred to as substance P, neurokinin A (NKA, substance K, neuromedin L) and neurokinin B (NKB, neuromedin K) (for review see J.E. Maggio, Peptides (1985) 6(suppl. 3), 237-242). The current nomenclature designates the three tachykinin receptors mediating the biological actions of substance P, NKA and NKB as the UK., NK_ and NK_ receptors, respectively.
20 Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and
25 other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, proliferative vitreoretinopathy, irritable bowel syndrome and disorders of bladder function including cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin Receptors and Tachykinin
Receptor Antagonists", CA. Maggi, R. Patacchini, P. Rovero and A. Giachetti, J. Auton. Pharmacol. (1993) 13, 23-93.
For instance, substance P is believed inter alia to be involved in the neurotransmission of pain sensations [Otsuka et al, "Role of Substance P as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia" in 1982 Substance P in the Nervous System, Ciba Foundation Symposium 91 , 13-34 (published by Pitman) and Otsuka and Yanagisawa, "Does Substance P Act as a Pain Transmitter?" TIPS (1987) 8, 506-510], specifically in the transmission of pain in migraine (B.E.B. Sandberg et al, J. Med Chem, (1982) 25, 1009) and in arthritis [Levine et al Science (1984) 226, 547-549].
Tachykinins have also been'implicated in gastrointestinal (Gl) disorders and diseases of the Gl tract such as inflammatory bowel disease [Mantyh et al Neuroscience (1988) 25(3), 817-37 and D. Regoli in "Trends in Cluster Headache" Ed. Sicuteri et al Elsevier Scientific Publishers, Amsterdam (1987) page 85)] and emesis [F. D. Tattersall et al, Eur. J. Pharmacol., (1993) 250, R5-R6]. It is also hypothesised that there is a neurogenic mechanism for arthritis in which substance P may play a role [Kidd et al "A Neurogenic Mechanism for Symmetrical Arthritis" in The Lancet, 11 November 1989 and Grόnblad et al, "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in J. Rheumatol. (1988) 1_5(12), 1807-10]. Therefore, substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid arthritis and osteoarthritis, and fibrositis [O'Byrne et al, Arthritis and Rheumatism (1990) 33, 1023-8]. Other disease areas where tachykinin antagonists are believed to be useful are allergic conditions [Hamelet et al, Can. J. Pharmacol.
Physiol. (1988) 66, 1361-7], immunoregulation [Lotz et al, Science (1988) 241, 1218-21 and Kimball et al, J. Immunol. (1988) 141.(10), 3564-9] vasodilation, bronchospasm, reflex or neuronal control of the viscera [Mantyh et al, PNAS (1988) 85, 3235-9] and, possibly by arresting or slowing
-\ ». β-amyloid-mediated neurodegenerative changes [Yankner et al, Science
- (1990) 250. 279-82] in senile dementia of the Alzheimer type, Alzheimer's disease and Down's Syndrome.
Tachykinin antagonists may also be useful in the treatment of 5 small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon et al, Cancer Research (1992) 52, 4554-7].
Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Luber-Narod et al, poster C.I.N.P. XVIIIth Congress, 28th June-2nd July 1992], and in io disorders of bladder function such as bladder detrusor hyper-reflexia {Lancet, 16th May 1992, 1239).
It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, 15 vasospastic diseases such as angina and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic 20 lupus erythmatosus (European patent specification no. 0 436 334), ophthalmic disease such as conjuctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989). 25 European patent specification no. 0 577 394 (published 5th
" January 1994) discloses morpholine and thiomorpholine tachykinin receptor antagonists of the general formula
1a wherein R is a large variety of substituents;
2a 3a
R and R are inter alia hydrogen;
4a
R is inter alia
5a
R is inter alia optionally substituted phenyl;
R , R and R are a variety of substituents;
Xa is O, S, SO or SO2;
Ya is inter alia O; and
Za is hydrogen or C^alkyl.
We have now found a further class of non-peptides which are potent antagonists of tachykinins, especially of substance P.
It is desirable that compounds may be administered orally and by injection. Compounds have now been discovered which act as potent non-peptide tachykinin antagonists and which, by virtue of their advantageous aqueous solubility, are particularly easily formulated for administration by both the oral and injection routes, for example in aqueous media.
Furthermore, the compounds of the present invention possess a particularly advantageous profile of activity having potent antagonist activity at the NKT receptor and a long duration of action. The compounds of the present invention, and in particular their pharmaceutically acceptable acid addition salts, are also particularly suited to a wide variety of pharmaceutical formulations by virtue of their stability.
The present invention provides compounds of the formula (I):
( I ) wherein
R is hydrogen, halogen, C. alkyl, C 1-6 alkoxy, CF NO,, CN, a b
SR , SOR , S02R , CO.R , CONR R , C, .alkenyl, C '_2-6.a' lkynyl or C 1.-4.alkyl substituted by C^alkoxy, where R and R each independently represent hydrogen or C^alkyl;
2
R is hydrogen, halogen, C alkyl, C alkoxy substituted by
C^alkoxy or CF3;
3 R is hydrogen, halogen or CF3;
4
R is hydrogen, halogen, C^alkyl, C^alkoxy, CF3, NO2, CN, SRa, SORa, S02Ra, C02Ra, CONRaRb, C^alkenyl, CMalkynyl or C^alkyl a b substituted by C^alkoxy, where R and R each independently represent hydrogen or C1_4alkyl; R5 is hydrogen, halogen, C1_6alkyl, C^alkoxy substituted by
C.^alkoxy or CF3;
6
R is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O, =S or a
group, and optionally substituted by a group of the formula ZNR7R8 where Z is C1 6alkylene or C3^cycloalkylene;
R7 is hydrogen, C1_4alkyl, C^7cycloalkyl or C3 7cycloalkylC1 4alkyl, or C2 4alkyl substituted by C. 4al oxy or hydroxyl;
8
R is hydrogen, C^alkyl, O-.-.cycloalkyl or Cg.-.cycloalkylC^alkyl, or C^alkyl substituted by one or two substituents selected from C^alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;
7 8 or R , R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or
optionally substituted by a
or hydroxyl group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH or NR moiety where R is C^alkyl optionally substituted by hydroxy or C1 lalkoxy; or R7, R8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms; or Z, R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom;
9a 9b 9a
R and R are each independently hydrogen or C.^alkyl, or R
9b and R are joined so, together with the carbon atoms to which they are attached, there is formed a C-_7 ring; X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo; and
Y is a C1 4alkyl group optionally substituted by a hydroxyl group; with the proviso that if Y is Cι.4alkyl, R6 is substituted at least by a group of formula ZNR7R8 as defined above; and pharmaceutically acceptable salts and prodrugs thereof.
Certain particularly apt compounds of the present invention
1 include those wherein R is hydrogen, C.^alkyl, C1 4alkoxy, halo or CF3.
2
Most aptly R is hydrogen, C.^alkyl, C^alkoxy, halogen or CF3.
3
Most aptly R is hydrogen, fluorine, chlorine or CF3.
Favourably R is fluorine, chlorine or CF3.
2
Favourably R is hydrogen, fluorine, chlorine or CF3.
3
Favourably R is hydrogen, fluorine, chforine or CF3.
1 2
Preferably R and R are in the 3 and 5 positions of the phenyl ring.
More preferably R is 3-fluoro or 3-CF3.
2 More preferably R is 5-fluoro or 5-CF3.
3 More preferably R is hydrogen.
Most preferably R is 3-F or 3-CF., R is 5-CF, and R is hydrogen.
Most aptly R is hydrogen.
5 Most aptly R is hydrogen, fluorine, chlorine or CF3.
4 5
Preferably R is hydrogen and R is hydrogen or 4-fluoro.
9a 9b
Most aptly R and R are each independently hydrogen or methyl.
9a 9b
Preferably R is hydrogen. Preferably R is hydrogen. Most
9a 9b preferably R and R are both hydrogen.
From the foregoing it will be appreciated that a particularly apt sub-group of compounds of this invention are those of the formula (la) and pharmaceutically acceptable salts and prodrugs thereof:
da) wherein A is fluorine or CF3;
2 A is fluorine or CF,;
3
A is fluorine or hydrogen;
6 and X, Y and R are as defined in relation to formula (I).
According to a second or further aspect of the present invention, a preferred class of compound of formula (I) or (la) is that wherein Y represents a
group substituted by a hydroxy group; or a pharmaceutically acceptable salt or prodrug thereof.
According to a further or alternative aspect of the present invention, another preferred class of compound of formula (I) or (la) is that wherein Y represents a Chalky! group, with the proviso that R6 is substituted at least by a group of the formula ZNR7R8 as defined above; or a pharmaceutically acceptable salt or prodrug thereof.
According to another aspect of the present invention, a further preferred class of compound of formula (I) or (la) is that wherein Y represents a
group; and R6 represesents a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O or =S and substituted by a group of the formula ZNR7R8 where Z is C^alkylene or C^cycloalkylene; R7 is hydrogen, C1 ,alkyl, C^cycloalkyl or C-^cycloalkylC^alkyl, or C-^alkyl substituted by C1 }alkoxy or hydroxyl;
8
R is hydrogen, C^alkyl, C^cycloalkyl or C^7cycloalkylC1-4alkyl, or C^alkyl substituted by one or two substituents selected from C.^alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;
7 8 or R , R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second
nitrogen atom which will be part of a NH or NR moiety where R is C^alkyl optionally substituted by hydroxy or C^alkoxy; or Z, R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; or a pharmaceutically acceptable salt or prodrug thereof.
According to yet another aspect of the present invention, a preferred class of compounds of formula (I) or (la) is that wherein
Y represents a
group; and
6 R is a 5-membered or 6-membered heterocyclic ring containing
2 or 3 nitrogen atoms optionally substituted by =O or =S and substituted by a
7 8 group of the formula ZNR R where
Z is C^alkylene or C^cycloalkylene;
R is hydrogen or C^alkyl, or C^alkyl substituted by C^alkoxy
8 or hydroxyl, R is hydrogen or C^alkyl or C^alkyl substituted by C.^alkoxy, hydroxyl or a 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;
7 8 or R , R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by a hydroxy group, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH or NRC moiety where Rc is C.^alkyl optionally substituted by hydroxy or C^alkoxy;
7 or Z, R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; or a pharmaceutically acceptable salt or prodrug thereof.
According to a further aspect of the present invention, another preferred class of compound of formula (I) or (la) is that wherein
Y represents a d^alkyl group substituted by a hydroxyl group; and
R is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O or =S and optionally
7 8 substituted by a group of the formula ZNR R where Z is C^alkylene or C^cycloalkylene; R is hydrogen or C1^alkyl, or C^alkyl substituted by C^alkoxy
8 or hydroxyl, R is hydrogen or C1 Jalkyl or C^alkyl substituted by C.^alkoxy or hydroxyl;
7 8 or R , R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom or a second nitrogen atom which will be part of a NH or NRC moiety where Rc is C^alkyl optionally substituted by hydroxy or C^alkoxy; or Z, R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; or a pharmaceutically acceptable salt or prodrug thereof.
According to another aspect of the present invention, a further preferred class of compound of formula (I) or (la) is that wherein
6
R is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =0 or =S and optionally
7 8 substituted by a group of the formula ZNR R where Z is C1 6alkylene or C3^cycloalkyl; R is hydrogen or C1 4alkyl, or C.^alkyl substituted by C.^alkoxy
8 or hydroxyl, R is hydrogen or C1 4alkyl or C2 4alkyl substituted by C^alkoxy or hydroxyl;
7 8 or R , R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an
oxygen ring atom or a second nitrogen atom which will be part of a NH or NR moiety where R is C^alkyl optionally substituted by hydroxy or C^alkoxy; or Z, R and the nitrogen atom to which that are attached form a heteroaliphatic ring to 4 to 7 ring atoms which may optionally contain an oxygen ring atom; or a pharmaceutically acceptable salt or prodrug thereof.
A preferred group Y for compounds of the formulae (I) or (la) is the CH2OH group.
Another preferred group Y for compounds of the formulae (I) or (la) is the CH3 group.
Particularly apt values for X for compounds of the formulae (I) or (la) include CH2, CH(CH3) and CH2CH2 of which the CH2 group is preferred.
Favourably R is a 5-membered ring
6 6
I Inn ppaarrttiiccuullaarr,, RR mmaayy,, bbeeaarriinngg iinn mmiinntd the proviso in the definition of formula (I), represent a heterocyclic ring selected from:
R
Particularly preferred heterocyclic rings represented by R6 are selected from:
Most especially, R may represent a heterocyclic ring selected from:
A particularly preferred heterocyclic ring represented by R is:
One favoured group of compounds of this invention are of the formula (lb) and pharmaceutically acceptable salts and prodrugs thereof:
( lb )
1 2 3 wherein A , A and A are defined in relation to formula (la) and wherein Z, R7 and R8 are as defined in relation to formula (I).
A further favoured group of compounds of the present invention are of the formula (lc) and pharmaceutically acceptable salts and prodrugs thereof:
wherein A1, A2 and A3 are as defined in relation to formula (la) and Q1 is CH or N or C-ZNR7R8 wherein Z, R7 and R8are as defined in relation to formula
(D-
Another favoured group of compounds of the present invention are of the formula (Id) and pharmaceutically acceptable salts and prodrugs thereof:
( Id) wherein A , A and A are defined in relation to formula (la), Q is CH or N and Z, R7 and R8 are as defined in relation to formula (I).
With respect to compounds of the formulae (I), (la), (lb), (lc) and (Id), Z may be a linear, branched or cyclic group. Favourably Z contains 1 to 4 carbon atoms and most favourably 1 or 2 carbon atoms. A particularly favourable group Z is CH2. With respect to compounds of the formulae (I), (la), (lb), (lc) and (Id), R may aptly be a C^alkyl group or a C.^alkyl group substituted by
8 a hydroxyl or C1 2alkoxy group, R may aptly be a C1 }alkyl group or a C^alkyl
7 8 group substituted by a hydroxyl or C1 2alkoxy group, or R and R may be linked so that, together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl, piperidyl, morpholino, thiomorpholino, piperazino or piperazino group substituted on the nitrogen atom by a C^alkyl group or a C2^alkyl group substituted by a hydroxy or C1 2alkoxy group.
7 8
Where the group NR R represents a heteroaliphatic ring of 4 to
7 ring atoms and said ring contains a double bond, a particularly preferred group is 3-pyrroline.
Where the group NR7R8 represents a non-aromatic azabicyclic ring system, such a system may contain between 6 and 12, and preferably between 7 and 10, ring atoms. Suitable rings include
5-azabicyclo[2.1.1 Jhexyl, 5-azabicyclo[2.2.1 jheptyl, 6-azabicyclo[3.2.1 joctyl, 2-azabicyclo[2.2.2]octyl, 6-azabicyclo[3.2.2]nonyl, 6-azabicyclo[3.3.1]nonyl,
6-azabicyclo[3.2.2]decyl, 7-azabicyclo[4.3.1 jdecyl,
7-azabicyclo[4.4.1]undecyl and 8-azabicyclo[5.4.1]dodecyl, especially
5-azabicyclo[2.2.1]heptyl and 6-azabicyclo[3.2.1 joctyl.
8
Where R represents a C-^alkyl group substituted by a 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, 0 and S, suitable rings include pyrrolidino, piperidino, piperazino, morpholino, or thiomorpholino. Particularly preferred are nitrogen containing heteroaliphatic rings, especially pyrrolidino and morpholino rings.
7 8
Particularly suitable moieties ZNR R include those wherein Z
7 8 is CH2 or CH2CH2 and NR R is amino, methyiamino, dimethylamino, diethylamino, azetidinyl, pyrrolidino and morpholino.
7 8
Further preferred moieties represented by ZNR R are those wherein Z is CH2 or CH2CH2, R represents hydrogen, C^alkyl or
8
C^cycloalkyl and R is Chalky I substituted by one or two substituents selected from hydroxy, C1 2alkoxy, azetidinyl, pyrrolidino, piperidino, morpholino or thiomorpholino.
In particular, Z is preferably CH2 and NR7R8 is preferably dimethylamino, azetidinyl or pyrrolidino, especially dimethylamino.
With regard to compounds of the formulae (la), (lb), (lc) and
1 2 3
(Id), A is preferably fluorine or CF3; A is preferably CF3; and A is preferably fluorine.
As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.
The cycloalkyl groups referred to herein may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. A suitable cycloalkylalkyl group may be, for example, cyclopropylmethyl.
As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. Examples of suitable alkenyl groups include vinyl and allyl. A suitable alkynyl group is propargyl.
When used herein the term halogen means fluorine, chlorine, bromine and iodine. The most apt halogens are fluorine and chlorine of which fluorine is preferred.
Specific compounds within the scope of this invention include:
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(2,3-dihydro-5-(N,N- dimethylamino)methyl-2-oxo-1 ,3-imidazol-4-yl)methyl-3-(S)-(4-fluorophenyl) morpholine;
4-(2,3-dihydro-5-(N,N-dimethylamino)methyl-2-oxo-1 ,3-imidazol-4-yl)methyl- 3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(thfluoromethyl)phenyl) ethoxy)morpholine;
3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(thfluoromethyl)phenyl) ethoxy)-4-(2,3-dihydro-2-oxo-5-pyrrolidinomethyl-1 ,3-imidazol-4- yl)methylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(2,3-dihydro-2-oxo-5-pyrrolidinomethyl-1 ,3-imidazol-4-yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(2,3-dihydro-5-(4-hydroxypiperidino)methyl-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine; 3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl) ethoxy)-4-(2,3-dihydro-5-morpholinomethyl-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(2,3-dihydro-5-morpholinomethyl-2-oxo-1 ,3-imidazol-4-yl)methylmorpholine; 4-(5-azetidinylmethyl-2,3-dihydro-2-oxo-1 ,3-imidazol-4-yl)methyl-2-(R)-(1 -
(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(2,3-dihydro-5-(N-methylpiperazinyl)methyl-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(2,3-dihydro-5-(N-(2-morpholinoethyl)aminomethyl)-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(2,3-dihydro-2-oxo-5-(N-(2-pyrrolidinoethyl)aminomethyl)-1 ,3-imidazol-4- yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(N-(N'-methylaminoethyl)-1 ,2,4-triazol-3-yl)methylmorpholine; and pharmaceutically acceptable salts or prodrugs thereof.
Further preferred compounds within the scope of the present invention include:
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(5-(N-methylaminomethyl)-1 ,2,3-thazol-4-yl)methylmorpholine;
4-(5-aminomethyl)-1 ,2,3-triazol-4-yl)methyl-2-(R)-(1 -(R)-(3,5- bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(5-pyrrolidinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
4-(5-(azetidinylmethyl)-1 ,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)-2-(R)-
(1-(R)-(3-fluoro-5-(thfluoromethyl)phenyl)ethoxy)morpholine;
3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl) ethoxy)-4-(5-(pyrrolidinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fiuoro-5-(trifluoromethyl)phenyl) ethoxy)-4-(5-(morpholinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
4-(5-(N,N-dimethylaminomethyl)-1 ,2,3-triazol-4-yl)methyl-3-(S)-(4- fluorophenyl)-2-(R)-(1-(R)-(3-(thfluoromethyl)phenyl)ethoxy)morpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(5-(N'-methylpiperazinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-(1 -(2- pyrrolidinoethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-phenyl-4-(2-(2- pyrrolidinoethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(5-(morpholinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine; 4-(5-azetidinylmethyl)-1 ,2,3-triazol-4-yl)methyl-2-(R)-(1 -(R)-(3,5- bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(5-(pyrrolinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5- (bis(methoxyethyl)aminomethyl)-1 ,2,3-thazol-4-yl)methyl-3-(S)-(4- fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(2-chloro-5- morpholinomethyl-1 ,3-imidazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;
2-(R)-( 1 -(R)-(3, 5-bis(trif luoromethyl)phenyl )ethoxy)-4-(5-( N , N- dimethylaminomethyl)-1 ,3-imidazol-4-yl)methyl-3-(S)-(4-fluorophenyl) morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N- dimethylaminomethyl)-1 ,2,4-triazol-3-yl)methyl-3-(S)-(4-fluorophenyl) morpholine; 2-(R)-(1-(R)-(3,5-bis(thfluoromethyl)phenyl)ethoxy)-4-(5-N-(2,2- dimethoxyethyl)-N-methylaminomethyl)-1 ,2,3-triazol-4-yl)methyl-3-(S)- phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(thfluoromethyl)phenyl)ethoxy)-4-(5-(2- methoxyethyl)aminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N-(2-methoxyethyl)-
N-methyl)aminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N-isopropyl-N-(2- methoxyethyl)aminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N-cyclopropyl-N-(2- methoxyethyl)aminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-N,N- dibutylaminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-N,N- diisoρropylaminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; and pharmaceutically acceptable salts or prodrugs thereof.
Yet further preferred compounds within the scope of the present invention include: 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4- fluorophenyl)-4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)methylmorpholine;
2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4- fluorophenyl)-4-(1 ,2,4-triazol-3-yl)methylmorpholine;
4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)methyl-3-(S)-(4-fluorophenyl)-2-(R)-(1- (S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
4-(2,3-dihydro-2-oxo-1 ,3-imidazol-4-yl)methyl-2-(R)-(1-(S)-(3,5- bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl) morpholine;
4-(2,3-dihydro-2-oxo-5-pyrrolidinomethyl-1 ,3-imidazol-4-yl)methyl-2-(R)-(1- (S)-(3,5-bis(trifiuoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl) morpholine;
4-(2,3-dihydro-3-oxo-1 ,2,4-thazol-5-yl)-3-(S)-phenyl-2-(R)-(1-(S)-(3-
(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
4-(2,3-dihydro-3-oxo-1 ,2,4-thazol-5-yl)methyl-2-(R)-(1-(S)-(3-fluoro-5- (thfluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-phenylmorpholine;
2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-4-(2,3-dihydro-
3-oxo-l , 2, 4-triazol-5-yl)-3-(S)-phenylmethylmorpholine;
3-(S)-phenyl-4-(1 ,2,4-triazol-3-yl)-2-(R)-(1-(S)-3-(trifluoromethyl)phenyl)-2- hydroxyethoxy)morpholine;
and pharmaceutically acceptable salts or prodrugs thereof.
Further preferred compounds within the scope of the present invention are described in the Examples described herein.
In a further aspect of the present invention, the compounds of formula (I) will preferably be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.
For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.
The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.
Thus, for example, certain preferred prodrugs may not be antagonists of tachykinin, particularly substance P, activity to any significant extent (or not at all). Such compounds, however, are still advantageous in treating the various conditions described herein, especially where an injectable formulation is preferred.
The advantages of a prodrug may lie in its physical properties, such as enhanced water solubility for parenteral administration compared with the parent drug, or it may enhance absorption from the digestive tract, or it may enhance drug stability for long-term storage. Ideally a prodrug will improve the overall efficacy of a parent drug, for example, through the reduction of toxicity and unwanted effects of drugs by controlling their absorption, blood levels, metabolism, distribution and cellular uptake.
A particularly preferred class of prodrugs of the compounds of the present invention is that wherein the hydroxyl moiety of the group Y in formula (I) (when Y if Chalky! substituted by hydroxyl) is derivatized.
It will be appreciated that a further class of prodrugs of the compounds of the present invention is that wherein the heterocyclic group
6 represented by R in formula (I) is derivatized, or alternatively, wherein both the hydroxyl moiety of the group Y (when Y is
substituted by hydroxyl) and the heterocyclic group represented by R6 in formula (I) are derivatized.
Suitable prodrug derivatives include:
(a) -(CHR10)n-PO(OH)O-.M+;
(b) -(CHR1°)n-PO(0-)2.2M+;
(c) -(CHR1°)n-PO(0-)2.D2+; (d) -(CHR10)n-SO3-.M+;
(e) -COCH2CH2CO2-.M+;
(f) -COH;
(g) -CO(CH2)nN(R10)2; and (h) -(CH(R10)O)n-COR11, wherein n is zero or 1 ;
+ M is a pharmaceutically acceptable monovalent counterion;
2+
D is a pharmaceutically acceptable divalent counterion;
10
R is hydrogen or C1 3alkyl; and R is a group selected from -O(CH2)2NH3 +.M"; -O(CH, 2)',2NH, 2(R12) /+.•M•"";> -OCH- ',2COW2 "' M+;
-OCH(CO2 ".M+)CH2CO2 ".M+; -OCH2CH(NH3 +)C02 "; -OC(CO " M+)(CH O " M+),; and
12 in which M is a pharmaceutically acceptable monovalent counterion, and R is hydrogen, C1 4alkyl or C2 }alkyl substituted by a hydroxyl or C. 4alkoxy group.
Particularly preferred prodrug derivatives are:
(b) -(CHR1°)n-PO(O-)2.2M+;
(c) -(CHR10)n-PO(O-)2.D2+; especially where n is zero.
The term "parent molecule", "parent compound" or "parent drug" refers to the biologically active entity that is released via enzymatic action of a metabolic or catabolic process, or via a chemical process following administration of the prodrug. The parent compound may also be the starting material for the preparation of its corresponding prodrug.
While all of the usual routes of administration are useful with the above prodrugs, the preferred routes of administration are oral and intravenous. After gastrointestinal absorption or intravenous administration, the prodrugs are hydrolyzed or otherwise cleaved in vivo to the corresponding parent compounds of formula (I), or a pharmaceutically acceptable salt thereof. Since the parent compounds may less than optimally soluble in aqueous solutions, the above prodrugs provide a distinct advantage by virtue of their relatively enhanced aqueous solubility.
Examples of negative monovalent counterions defined herein as "M " include acetate, adipate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, citrate, ethanesulfonate, fumarate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, malate, maleate, methanesulfonate, 2-naphthalenesulfonate, oxalate, pamoate, persulfate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, tosylate (p-toluenesulfonate), and undecanoate.
Base salts (which are pharmaceutically acceptable monovalent cations defined herein as "M " or pharmaceutically acceptable divalent
2+ cations defined herein as "D ", if appropriate) include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as aluminium, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with
+ amino acids such as arginine, lysine, ornithine, and so forth. If M is a
+ monovalent cation, it is recognised that if the definition 2M is present, each
of M may be the same or different. In addition, it is similarly recognised that
+ 2+ if the definition 2M is present, a divalent cation D may instead be present. Also, the basic nitrogen-containing groups may be quatemized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl and dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides like benzyl bromide and others. The non-toxic physiologically acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.
The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.
A particularly preferred sub-class of prodrugs of the compounds of the present invention is that defined by the formula (le) and pharmaceutically acceptable salts thereof:
< I e >
1 2 3 A 5 6 9a 9b wherein R , R , R , R , R , R , R , R and X are as defined in relation to formula (I) and P in a circle is PO(OH)0".M+, PO(0") 2M+, or PO(0"),.D2+.
Another preferred sub-class of prodrugs of the compounds of the present invention is that defined by the formula (If) and pharmaceutically acceptable salts thereof:
( If ) 1 2 3 6 wherein A , A and A are as defined in relation to formula (la), X and R are as defined in relation to formula (I), and P in a circle is PO(OH)O~.M+, PO(O-)2.2M+, or PO(O")2.D2+.
An especially preferred sub-group of prodrugs of the compounds of the present invention is that defined by formula (Ig) and pharmaceutically acceptable salts thereof:
wherein A , A and A are as defined in relation to formula (la), Q is as defined in relation to formula (lc) and P in a circle is PO(OH)0".M+, PO(O")2.2M+, or PO(O")2.D2+.
A yet further preferred sub-group of prodrugs of the compounds of the present invention is that defined by formula (Ih) and pharmaceutically acceptable salts thereof:
( Ih) 1 2 3 1 2 wherein A , A and A are as defined in relation to formula (la), Q and Q are as defined in relation to formulae (lc) and (Id), respectively, and P in a circle is PO(OH)O-.M+, PO(O-)2.2M+, or PO(O-)2.D2+.
Specific prodrug derivatives within the scope of this invention include: 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-3-(S)-(4- fluorophenyl)-4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)methylmorpholine;
2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-3-(S)-(4- fluorophenyl)-4-(1 ,2,4-triazol-3-yl)methylmorpholine;
4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)methyl-2-(R)-(1-(S)-3-fiuoro-5- (trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-3-(S)-phenylmorpholine;
2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-4-(2,3- dihydro-3-oxo-1 ,2,4-triazol-5-yl)methyl-3-(S)-phenylmorpholine; and pharmaceutically acceptable salts thereof.
With regard to compounds of the formulae (If), (Ig) and (Ih), A
2 3 is preferably fluorine or CF3; A is preferably CF3; and A is preferably fluorine.
The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.
The compounds according to the invention have at least three asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
The preferred compounds of the formula (I), (la), (lb), (lc), (Id), (le), (If), (Ig) and (Ih) will have the 2- and 3- substituent cis and the preferred stereochemistry at the 2-position is that possessed by the compound of Example 1 (i.e. 2-(R)-), the preferred stereochemistry of the 3-position is that possessed by the compound of Example 1 (i.e. 3-(S)), and the preferred stereochemistry of the carbon to which the group Y is either (R) when Y is Ci ialkyl (e.g. methyl) or (S) when Y is Chalky! substituted by hydroxy (e.g. CH2OH). Thus for example as shown in formula (Ii)
d )
The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in association with a pharmaceutically acceptable carrier.
Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate. The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical
vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl- pyrrolidone or gelatin. Preferred compositions for administration by injection include those comprising a compound of formula (I), as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).
Suitable surface-active agents include anionic agents such as sodium bis-(2-ethylhexyl)sulfosuccinate (docusate sodium), cationic agents, such as alkyltrimethylammonium bromides, (e.g. cetyltrimethylammonium bromide (cetrimide)), and in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g. Tween™ 20, 40, 60, 80 or 85) and other sorbitans (e.g. Span™ 20, 40, 60, 80 or 85). Compositions with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
Suitable emulsions may be prepared using commercially available fat emulsions, such as Intralipid™, Liposyn™, Infonutrol™,
Lipofundin™ and Lipiphysan™. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. egg phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example gylcerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%. The fat
emulsion will preferably comprise fat droplets between 0.1 and 1.0μm, particularly 0.1 and 0.5μm, and have a pH in the range of 5.5 to 8.0. Particularly preferred emulsion compositions are those prepared by mixing a compound of formula (I) with Intralipid™ or the components thereof (soybean oil, egg phospholipids, glycerol and water).
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
The present invention futher provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), which process comprises bringing a compound of formula (I) into association with a pharmaceutically acceptable carrier or excipient.
The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, including senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as MS and ALS and other neuropathological disorders such as peripheral neuropathy, for
example diabetic and chemotherapy-induced neuropathy, and postherpetic and other neuralgias; small cell carcinomas such as small cell lung cancer; respiratory diseases, particularly those associated with excess mucus secretion such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis and asthma, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis, rheumatoid arthritis, pruritis and sunburn; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (Gl) disorders and diseases of the Gl tract such as disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis, including acute, delayed or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intercranial pressure, in particular, for example, drug or radiation induced emesis or post¬ operative nausea and vomiting; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that
attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.
The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting. The compounds of formula (I) are particularly useful in the treatment of emesis, including acute, delayed or anticipatory emesis, such as emesis induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, motion, surgery, migraine, and variations in intercranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis induced by antineoplastic (cytotoxic) agents including those routinely used in cancer chemotherapy.
Examples of such chemotherapeutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophyllotoxin; and cytotoxic antibiotics.
Particular examples of chemotherapeutic agents are described, for instance, by D. J. Stewart in Nausea and Vomiting: Recent Research and Clinical Advances, Eds. J. Kucharczyk et al, CRC Press Inc., Boca Raton, Florida, USA (1991 ) pages 177-203, especially page 188. Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin
(adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla et al in Cancer Treatment Reports (1984) 68(1 ), 163-172].
The compounds of formula (I) are also of use in the treatment of emesis induced by radiation including radiation therapy such as in the treatment of cancer, or radiation sickness; and in the treatment of post¬ operative nausea and vomiting. It will be appreciated that the compounds of formula (I) may be presented together with another therapeutic agent as a combined preparation for simultaneous, separate or sequential use for the relief of emesis. Such combined preparations may be, for example, in the form of a twin pack. A further aspect of the present invention comprises the compounds of formula (I) in combination with a 5-HT3 antagonist, such as ondansetron, granisetron or tropisetron, or other anti-emetic medicaments, for example, a dopamine antagonist such as metoclopramide. Additionally, a compound of formula (I) may be administered in combination with an anti- inflammatory corticosteroid, such as dexamethasone. Furthermore, a compound of formula (I) may be administered in combination with a chemotherapeutic agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available dosage forms of the known therapeutic agents for use in such combinations will be suitable. When tested in the ferret model of cisplatin-induced emesis described by F. D. Tattersall et al, in Eur. J. Pharmacol., (1993) 250, R5-R6, the compounds of the present invention were found to attenuate the retching and vomiting induced by cisplatin.
The compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteroarthritis, rheumatoid arthritis and especially migraine.
The present invention further provides a compound of formula (I) for use in therapy.
According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.
The present invention also provides a method for the the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).
For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically active agent. For example, for the treatment of respiratory diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a β2-adrenergic receptor antagonist or tachykinin antagonist which acts at NK-2 receptors. The compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.
The present invention accordingly provides a method for the treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator. The present invention also provides a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.
The excellent pharmacological profile of the compounds of the present invention offers the opportunity for their use in therapy at low doses thereby minimising the risk of unwanted side effects.
In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.
For example, in the treatment of conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
In the treatment of emesis using an injectable formulation, a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 2 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.
According to a general process (A), the compounds according to the invention may be prepared from compounds of formula (II)
( I D 1 2 3 4 5 wherein R , R , R , R , R and Y are as defined in relation to formula (I) by reaction with a compound of formula (III):
1 6a
X -X-R (III)
6a where X is as defined in relation to formula (I), R is a group of the formula
6 1
R as defined in relation to formula (la) or a precursor therefor and X is a
6a leaving group such as bromine or chlorine; and, if R is a precursor group,
6 converting it to a group R (in which process any reactive group may be protected and thereafter deprotected if desired).
This reaction may be performed in conventional manner, for example in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate. According to another process (B), compounds of formula (I)
G 7 β wherein R represents 1 ,2,3-thazol-4-yl substituted by CH2NR R , and X is -CH -, may be prepared by reaction of a compound of formula (IV)
with an azide, for example, sodium azide in a suitable solvent such as dimethylsulphoxide at a temperature of between 40°C and 100°C, followed
7 8 by reduction of the carbonyl group adjacent to -NR R using a suitable reducing agent such as lithium aluminium hydride at at a temperature between -10°C and room temperature, conveniently at room temperature.
Alternatively, according to a process (C), compounds of formula
6 7 8
(I) wherein R represents 1 ,2,3-triazol-4-yl substituted by CH2NR R , and X is -CH -, may be prepared by reaction of a compound of formula (V)
7 8 with an amine of formula NHR R , in a suitable solvent such as an ether, for example, dioxan, at elevated temperature, for example, between 50°C and 100°C, in a sealed tube, or the like. This reaction is based upon that described in Chemische Berichte (1989) 122, p. 1963.
According to another process, (D), compounds of formula (I)
6 wherein R represents substituted or unsubstituted 1 ,3,5-triazine may be prepared by reaction of intermediates of formula (VI):
(VI ) with substituted or unsubstituted 1 ,3,5-triazine.
The reaction is conveniently effected in a suitable organic solvent, such as acetonitrile, at elevated temperature, such as 80-90°C, preferably about 82°C.
According to a further process, (E), compounds of formula (I)
6 wherein R represents substituted or unsubstituted 1 ,2,4-triazine may be prepared by reaction of an intermediate of formula (VII) with a dicarbonyl compound of formula (VIII):
(VI I I )
(VII )
35 7 8 wherein R represents H or a suitable substituent such as ZNR R
The reaction is conveniently effected in a suitable organic solvent, such as an ether, e.g. tetrahydrofuran, conveniently at ambient temperature.
According to a further process (F), compounds of formula (I)
6 wherein R represents a substituted 1 ,2,4-triazolyl group may be prepared by reaction of an intermediate of formula (II) with a compound of formula (IX)
( IX ) wherein X is as defined in relation to formula (I), Hal is a halogen atom, for
18 example, bromine, chlorine or iodine and R is H, CONH2 or OCH3 (which is converted to an oxo substituent under the reaction conditions), in the presence of a base, followed where necessary by conversion to a compound of formula (I), for example, by reduction of the CONH2 group to CH2NH2. Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate. The reaction is conveniently effected in an anhydrous organic solvent such as, for example, anhydrous dimethylformamide, preferably at elevated temperature, such as about 140°C.
A suitable reducing agent for the group CONH2 is lithium aluminium hydride, used at between -10°C and room temperature. According to another process, (G), compounds of formula (I)
6 wherein R represents thioxotriazolyl may be prepared from intermediates of formula (X)
(X ) by reaction with a compound of formula HNCS, in the presence of a base.
Suitable bases of use in the reaction include organic bases such as, for example, 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The reaction is conveniently effected in a suitable organic solvent, such as alcohol, e.g. butanol.
Further details of suitable procedures will be found in the accompanying Examples.
Compounds of formula (I) may also be prepared from other compounds of formula (I) using suitable interconversion procedures. For example, compounds of formula (I) wherein X represents C alkyl may be prepared from compounds of formula (I) wherein X represents C1 4alkyl substituted by oxo by reduction, for example, using borane or lithium aluminium hydride. Suitable interconversion procedures will be readily apparent to those skilled in the art.
Intermediates of formula (IV) may be prepared from intermediates of formula (II) by reaction with an acetylene compound of formula HC≡C-CH2-Hal in the presence of a base such as potassium carbonate in a suitable solvent such as dimethylformamide, conveniently at room temperature, followed by reaction of the resultant acetylene
7 8 intermediate with an amide of formula Hal-CO-NR R in the presence of suitable catalysts including bis(triphenylphosphine) palladium(ll) chloride,
copper(l) iodide and triphenylphosphine in a suitable solvent such as triethylamine, preferably at reflux.
Intermediates of formula (V) may be prepared from a compound of formula (XI)
(XI ) wherein Hal is a halogen atom, for example, chlorine, bromine or iodine, especially chlorine, by reaction with an azide, for example, sodium azide in a suitable solvent such as dimethylsulphoxide at or below room temperature. Compounds of formula (XI) may be prepared by a dropwise addition of an intermediate of formula (II) to a dihaloacetylene of formula
Hal-CH2-C≡C-CH2-Hal where each Hal is independently chlorine, bromine or iodine, especially chlorine. The reaction is conveniently effected in a suitable solvent such as dimethylformamide in the presence of a base such as potassium carbonate. Intermediates of formula (VI) may be prepared from intermediates of formula (II) by reaction with a compound of formula Hal-X-C(NH)NH2, where Hal and X are as previously defined.
Intermediates of formula (VII) may be prepared from intermediates of formula (II) by reaction with a compound of formula Hal-X-C(NH)NHNH-Boc, wherein Hal and X are as previously defined and Boc stands for t-butoxycarbonyl, followed by deprotection under acidic conditions.
Compounds of formula (VIII) are commercially available or may be prepared from commercially available compounds by known methods.
Compounds of formula (IX) may be prepared as described in J. Med. Chem., (1984) 27, 849. Intermediates of formula (X) may be prepared from the corresponding ester by treatment with hydrazine. The reaction is conveniently effected in a suitable organic solvent, such as an alcohol, for example, ethanol, at elevated temerpature.
6
For compounds wherein R is a heterocycle substituted by a
7 8 ZNR R group where Z is CH2, certain favoured compounds of formula (I) may be prepared from a corresponding compound with a hydrogen atom in
7 8 place of the ZNR R . Thus, for example a compound of the formula (I) β 7 8 wherein R is an imidazolinone group carrying a CH2NR R moiety may be
7 8 prepared from a corresponding compound lacking the CH2NR R moiety by
7 8 reaction with formaldehyde and an amine NHR R under conventional
Mannich reaction conditions, for example in methanol with heating. If desired
7 8 , a pre-formed reagent such as R R N+=CH2.I~ may be employed and a tertiary amine such as t ethylamine used as acid acceptor.
6
Alternatively a compound of formula (I) wherein R is an
7 8 imidazolinone group lacking a CH2NR R may be reacted with paraformaldehyde and an amine for example a secondary amine such as pyrrolidine to give a compound wherein the imidazolinone ring is substituted
7 8 7 8 by CH2NR R where R , R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom or a second nitrogen atom which will be part of a NH or NR moiety, where R is as previously defined.
This reaction may be performed in a conventional manner, for instance, in a suitable solvent such as an alcohol, for example, methanol at an elevated temperature up to the boiling point of the solvent.
A further alternative method for the preparation of certain compounds of formula (I) involves the reaction of an intermediate of formula (II) as defined above with one of the compounds of formula (XII):
(XI I )
wherein each LG, which may be the same or different, is a leaving group, such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or, in particular, a halogen atom, (e.g. bromine, chlorine or iodine) and X and Z are as defined in formula (I), followed by reaction of the resultant compound with
7 8 7 8 an amine NHR R to complete the ZNR R moiety.
This reaction is conveniently effected in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate. It will be appreciated that, where necessary, reactive groups may be protected, thus for example, the NH groups of an imidazolinone of formula (Xlla) may be protected by any suitable amine protecting group such as an acetyl group.
The preferred phosphate prodrugs of the compounds of the present invention may be prepared in a stepwise manner from a compound of formula (I) wherein Y is, for example, -CH2OH-.
Thus, the hydroxy compound is first treated with dibenzyloxydiethylaminophosphine in a suitable solvent such as tetrahydrofuran, preferably in the presence of an acid catalyst such as tetrazole. The resultant compound (Y = CH2OP(OCH2Ph)2) is then oxidised
using, for example, 4-methylmorpholine-N-oxide to give the dibenzyl-protected phosphate. Deprotection by catalytic hydrogenation or transfer hydrogenation (palladium catalyst on carbon and ammonium formate), in a suitable solvent such as methanol at reflux, yields the desired phosphate prodrug which may be converted to any desired salt form by conventional methodology.
In an alternative two-step method, the hydroxy compound of formula (I) may be reacted with a suitable base such as sodium hydride in tetrahydrofuran, and tetrabenzylpyrophosphate added to yield the dibenzyl- protected phosphate which may be deprotected as described above.
The compounds of the formula (II) may be prepared as shown
1 1 2 3 in the following Scheme in which Ar represents the R , R , R substituted
2 4 5 phenyl group; Ar represents the R , R substituted phenyl group and Ph represents phenyl:
PhCHO, Pd/C THF, NaOH, H2
Ar"-CH (NH- ) CO-H Ar -CH (NHCH,Ph) CO, Na
ethyl acetate/IPA
(YJ H or C1_3alkyl)
L-Selectride is lithium tri-sec-butylborohydride.
The following references describe methods which may be applied by the skilled worker to the chemical synthesis set forth above once the skilled worker has read the disclosure herein:
(i) D.A. Evans et al., J. Am. Chem. Soc, (1990) 112, 4011.
(ii) I. Yanagisawa et al., J. Med. Chem., (1984) 27, 849.
(iii) R. Duschinsky et al., J. Am. Chem. Soc, (1948) 70, 657.
(iv) F.N. Tebbe et al., J. Am. Chem. Soc, (1978) 100, 3611.
(v) N.A. Petasis et al., J. Am. Chem. Soc, (1990) 112, 6532.
(vi) K. Takai et al., J. Org. Chem., (1987) 52, 4412.
The Examples disclosed herein produce predominently the preferred isomers. The unfavoured isomers are also produced as minor components. If desired they may be isolated and employed to prepare the various stereoisomers in conventional manner, for example chromatography using an appropriate column. However, the skilled worker will appreciate that although the Examples have been optimized to the production of the preferred isomers, variation in solvent, reagents, chromatography etc can be readily employed to yield the other isomers.
It will be appreciated that compounds of the formula (I) wherein
6 R contains an =O or =S substituent can exist in tautomeric forms. All such tautomeric forms and mixtures thereof are included within this invention.
6
Most aptly the =O or =S substituent in R is the =O substituent.
Where they are not commercially available, the intermediates of formula (III) above may be prepared by the procedures described in the accompanying Examples or by alternative procedures which will be readily apparent to one skilled in the art.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic
Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and
P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons,
1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. The exemplified compounds of this invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No.
WO 93/01 165. The compounds or, in the case of prodrugs, the parent compounds, were found to be active with IC^ at the NKi receptor of less than
10nM on said test method.
DESCRIPTION 1 (SM4-Fluorophenyl)qlvcine
Via Chiral Synthesis:
Step A: 3-(4-Fluorophenyl)acetyl-4-(S)-benzyl-2-oxazolidinone An oven-dried, 1 L 3-necked flask, equipped with a septum, nitrogen inlet, thermometer, and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 5.09g (33.0mmol) of 4-fluorophenylacetic acid in 100ml of anhydrous ether. The solution was cooled to -10°C and treated with 5.60ml (40.0mmol) of t ethylamine followed by 4.30ml (35.0mmol) of trimethylacetyl chloride. A white precipitate formed immediately. The resulting mixture was stirred at -10°C for 40 minutes, then cooled to -78°C.
An oven-dried, 250ml round bottom flask, equipped with a septum and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 5.31 g (30.0mmol) of 4-(S)-benzyl-2- oxazolidinone in 40ml of dry THF. The solution was stirred in a dry ice/acetone bath for 10 minutes, then 18.8ml of 1.6M n-butyllithium solution in hexanes was slowly added. After 10 minutes, the lithiated oxazolidinone solution was added, via cannula, to the above mixture in the 3-necked flask. The cooling bath was removed from the resulting mixture and the temperature was allowed to rise to 0°C. The reaction was quenched with 100ml of saturated aqueous ammonium chloride solution, transferred to a 11 flask, and the ether and THF were removed in vacuo. The concentrated mixture was partitioned between 300ml of methyiene chloride and 50ml of water and the layers were separated. The organic layer was washed with 100ml of 2N aqueous hydrochloric acid solution, 300ml of saturated aqueous sodium bicarbonate
solution, dried over magnesium sulfate and concentrated in vacuo. Flash chromatography on 400g of silica gel using 3:2 v/v hexanes/ether as the eluant afforded 8.95g of an oil that slowly solidified on standing. Recrystallisation from 10:1 hexanes/ether afforded 7.89g (83%) of the title compound as a white solid: mp 64-
66°C. MS (FAB): m/z 314 (M++H, 100%), 177 (M-ArCH2CO+H, 85%). 1H NMR (400MHz, CDCI3) δ 2.76 (1 H, dd, J=13.2, 9.2), 3.26 (dd, J=13.2, 3.2), 4.16-4.34 (4H, m), 4.65 (1H, m), 7.02-7.33 (9H, m). Anal. Calcd for Cι8H16FNO3; C, 69.00; H, 5.15; N, 4.47; F, 6.06; Found: C, 68.86; H, 5.14; N, 4.48; F, 6.08.
Step B: 3-((S)-Azido-(4-fluorophenvn)acetyl-4-(S)-benzyl-2- oxazolidinone
An oven-dried, 11 3-necked flask, equipped with a septum, nitrogen inlet, thermometer, and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 58.0ml of 1 M potassium bis(thmethylsilyl)amide solution in toluene and 85ml of THF and was cooled to -78°C. An oven-dried 250ml round- bottomed flask, equipped with a septum and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 7.20g
(23.0mmol) of 3-(4-fluorophenyl)acetyl-4-(S)-benzyl-2- oxazolidinone (from Step A) in 40ml of THF. The acyl oxazolidinone solution was stirred in a dry ice/acetone bath for 10 minutes, then transferred, via cannula, to the potassium bis(thmethylsilyl)amide solution at such a rate that the internal temperature of the mixture was maintained below -70°C. The acyl oxazolidinone flask was rinsed with 15ml of THF and the rinse was added, via cannula, to the reaction mixture and the resulting mixture was stirred at -78°C for 30 minutes. An oven-dried, 250ml
round-bottomed flask, equipped with a septum and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 10.89g (35.0mmol) of 2,4,6-triisopropylphenylsulfonyl azide in 40ml of THF. The azide solution was stirred in a dry ice/acetone bath for 10 minutes, then transferred, via cannula, to the reaction mixture at such a rate that the internal temperature of the mixture was maintained below -70°C. After 2 minutes, the reaction was quenched with 6.0ml of glacial acetic acid, the cooling bath was removed and the mixture was stirred at room temperature for 18 hours. The quenched reaction mixture was partitioned between
300ml of ethyl acetate and 300ml of 50% saturated aqueous sodium bicarbonate solution. The organic layer was separated, dried over magnesium sulfate, and concentrated in vacuo. Flash chromatography on 500g of silica gel using 2:1 v/v, then 1 :1 v/v hexanes/methylene chloride as the eluant afforded 5.45g (67%) of the title compound as an oil. IR Spectrum (neat, cm"1): 2104, 1781 , 1702. 1H NMR (400MHz, CDCI3) δ 2.86 (1 H, dd, J=13.2, 9.6), 3.40 (1 H, dd, J=13.2, 3.2), 4.09-4.19 (2H, m), 4.62-4.68 (1 H, m), 6.14 (1 H, s), 7.07-7.47 (9H, m). Anal. Calcd. for C18H15FN4O3; C 61.01 ; H, 4.27; N, 15.81 ; F, 5.36; Found: C, 60.99; H, 4.19; N, 15.80; F,
5.34.
Step C: (S)-Azido-(4-fluorophenvDacetic acid
A solution of 5.40g (15.2mmol) of 3-((S)-azido-(4- fluorophenyl))acetyl-4-(S)-benzyl-2-oxazolidinone (from Step B) in
200ml of 3:1 v/v THF/water was stirred in an ice bath for 10 minutes. 1.28g (30.4mmol) of lithium hydroxide monohydrate was added in one portion and the resulting mixture was stirred cold for 30 minutes. The reaction mixture was partitioned between 100ml of
methyiene chloride and 100ml of 25% saturated aqueous sodium bicarbonate solution and the layers were separated. The aqueous layer was washed with 2 x 100ml of methyiene chloride and acidified to pH 2 with 2N aqueous hydrochloric acid solution. The resulting mixture was extracted with 2 x 100ml of ethyl acetate; the extracts were combined, washed with 50ml of saturated aqueous sodium chloride solution, dried over magnesium sulfate, and concentrated in vacuo to afford 2.30g (77%) of the title compound as an oil that was used in the following step without further purification. IR Spectrum (neat, cm"1): 2111 , 1724. 1H NMR
(400MHz, CDCI3) δ 5.06 (1 H, s), 7.08-7.45 (4H, m), 8.75 (1H, br s).
Step D: (SM4-Fluorophenyl)olvcine
A mixture of 2.30g (11.8mmol) of (S)-azido-(4- fluorophenyl)acetic acid (from Step C), 250mg 10% palladium on carbon catalyst and 160ml 3:1 v/v water/acetic acid was stirred under an atmosphere of hydrogen for 18 hours. The reaction mixture was filtered through Celite and the flask and filter cake were rinsed well with -11 of 3:1 v/v water/acetic acid. The filtrate was concentrated in vacuo to about 50ml of volume. 300ml of toluene was added and the mixture concentrated to afford a solid. The solid was suspended in 1 :1 v/v methanol/ether, filtered and dried to afford 1.99g (100%) of the title compound. 1H NMR (400MHz, D2O+ NaOD) δ 3.97 (1 H, s), 6.77 (2H, app t, J=8.8), 7.01 (2H, app t, J=5.6).
Via Resolution:
Step A' (4-Fluorophenyl)acetyl chloride
A solution of 150g (0.974mol) of 4-(fluorophenyl)acetic acid and 1 ml of N.N-dimethylformamide in 500ml of toluene at 40°C was treated with 20ml of thionyl chloride and heated to 40°C. An additional 61.2ml of thionyl chloride was added dropwise over 1.5 hours. After the addition, the solution was heated at 50°C for 1 hour, the solvent was removed in vacuo and the residual oil was distilled at reduced pressure (1.5mmHg) to afford 150.4g (89.5%) of the title compound, bp=68-70°C.
Step B': Methyl 2-bromo-3-(4-fluorophenv0acetate
A mixture of 150.4g (0.872mol) of 4-(fluorophenyl)acetyl chloride (from Step A') and 174.5g (1.09mol) of bromine was irradiated at 40-50°C with a quartz lamp for 5 hours. The reaction mixture was added dropwise to 400ml of methanol and the solution was stirred for 16 hours. The solvent was removed in vacuo and the residual oil was distilled at reduced pressure (1.5mmHg) to afford 198.5g (92%) of the title compound, bp=106-110°C.
Step C: Methyl (±H4-fluorophenyl)glvcine A solution of 24.7g (0.1 mol) of methyl 2-bromo-2-(4- fluorophenyl)acetate (from Step B') and 2.28g (0.01 mol) of benzyl triethylammonium chloride in 25ml of methanol was treated with 6.8g (0.105mol) of sodium azide and the resulting mixture was stirred for 20 hours at room temperature. The reaction mixture was filtered; the filtrate was diluted with 50ml of methanol and hydrogenated in the presence of 0.5g of 10% Pd/C at 50 psi for 1 hour. The solution was filtered and the solvent removed in vacuo. The residue was partitioned between 10% aqueous sodium carbonate solution and ethyl acetate. The organic phase was
washed with water, saturated aqueous sodium chloride solution dried over magnesium sulfate and concentrated in vacuo to afford 9.8g of the title compound as an oil.
Step D': Methyl (SH4-fluorophenvQqlvcinate
A solution of 58.4g of methyl (±) 4-(fluorophenyl)glycinate (from Step C) in 110ml of 7:1 v/v ethanol/water was mixed with a solution of 28.6g (0.0799mol) of O,O'-(+)-dibenzoyltartaric acid ((+)-DBT) (28.6g, 0.0799mol) in 110ml of 7:1 v/v ethanol:water and the resulting solution was allowed to age at room temperature. Ethyl acetate (220ml) was added after crystallisation was complete and the resulting mixture was cooled to -20°C and filtered to afford 32.4g of methyl (S)-(4-fluorophenyl)glycinate, (+)-DBT salt (ee=93.2%). The mother liquors were concentrated in vacuo and the free base was liberated by partitioning between ethyl acetate and aqueous sodium carbonate solution. A solution of free base, so obtained, in 110ml of 7:1 v/v ethanol/water was mixed with a solution of 28.6g (0.0799mol) of O,O'-(-)-dibenzoyltartaric acid ((-)- DBT) (28.6g, 0.0799mol) in 110ml of 7:1 v/v ethanol.water and the resulting solution was allowed to age at room temperature. Ethyl acetate (220ml) was added after crysallisation was complete and the resulting mixture was cooled to -20°C and filtered to afford 47.0g of methyl (R)-(4-fluorophenyl)glycinate, (-)-DBT salt (ee=75.8%). Recycling of the mother liquors and addition of (+)- DBT gave a second crop of 7.4g of (S)-(4-fluorophenyl)glycinate,
(+)-DBT salt (ee=96.4%). The two crops of the (S)-amino ester (39.8g) were combined in 200ml of 7:1 v/v ethanol/water, heated for 30 minutes and cooled to room temperature. Addition of ethyl acetate, cooling, and filtration afforded 31.7g of (S)-(4-
fluorophenyl)glycinate, (+)-DBT salt (ee > 98%). Enantiomeric excess was determined by chiral HPLC (Crownpak CR(+) 5% MeOH in aq HCIO4 pH2 1.5ml/min 40°C 200nm).
A mixture of 17.5g of (S)-(4-fluorophenyl)glycinate, (+)-DBT salt and 32ml of 5.5N HCI (32ml) was heated at reflux for 1.5 hours.
The reaction mixture was concentrated in vacuo and the residue was dissolved in 40ml of water. The aqueous solution was washed (3 x 30ml of ethyl acetate) and the layers were separated. The pH of the aqueous layer was adjusted to 7 using ammonium hydroxide and the precipitated solid was filtered to afford 7.4g of the title compound (ee=98.8%).
DESCRIPTION 2 4-Benzyl-3-(SH4-fluorophenv0-2-morpholinone
Step A: N-Benzyl-(SH4-fluorophenvπαlvcine A solution of 1.87g (11.05mmol) of (S)-(4-fluorophenyl)-glycine (from Description 1 ) and 1.12ml (11.1 mmol) of benzaldehyde in 11.1 ml of 1 N aqueous sodium hydroxide solution and 11 ml of methanol at 0°C was treated with 165mg (4.4mmol) of sodium borohydride. The cooling bath was removed and the resulting mixture was stirred at room temperature for 30 minutes. Second portions of benzaldehyde (1.12ml (11.1 mmol)) and sodium borohydride (165mg (4.4mmol) were added to the reaction mixture and stirring was continued for 1.5hours. The reaction mixture was partitioned between 100ml of ether and 50ml of water and the layers were separated. The aqueous layer was separated and filtered to remove a small amount of insoluble material. The filtrate was acidified to pH 5 with 2N aqueous hydrochloric acid solution
and the solid that had precipitated was filtered, rinsed well with water, then ether, and dried to afford 1.95g of the title compound. 1H NMR (400MHz, D2O + NaOD) δ 3.33 (2H, AB q, J=8.4), 3.85 (1 H, s), 6.79-7.16 (4H, m).
Step B: 4-Benzyl-3-(SM4-fluorophenvO-2-morpholinone A mixture of 1.95g (7.5mmol) of N-benzyl (S)-(4- fluorophenyl)glycine, 3.90ml (22.5mmol) of N,N-diisopropyl- ethylamine, 6.50ml (75.0mmol) of 1 ,2-dibromoethane and 40ml of N,N-dimethylformamide was stirred at 100°C for 20 hours
(dissolution of all solids occurred on warming). The reaction mixture was cooled and concentrated in vacuo. The residue was partitioned between 250ml of ether and 100ml of 0.5N potassium hydrogen sulfate solution and the layers were separated. The organic layer was washed with 100ml of saturated aqueous sodium bicarbonate solution, 3 x 150ml of water, dried over magnesium sulfate, and concentrated in vacuo. Flash chromatography on 125g of silica gel using 3:1 v/v hexanes/ether as the eluant afforded 1.58g (74%) of the title compound as an oil. 1H NMR (400MHz, CDCI3) δ 2.65 (1 H, dt, J=3.2, 12.8), 3.00 (1 H, dt, J=12.8, 2.8), 3.16
(1 H, d, J=13.6), 3.76 (1 H, d, J=13.6), 4.24 (1 H, s), 4.37 (1 H, dt, J=13.2, 3.2), 4.54 (1 H, dt, J=2.8, 13.2), 7.07-7.56 (9H, m).
DESCRIPTION 3 4-Benzyl-2-(RH3.5-bis(trifluoromethyl)benzoyloxyV3-(SH4- fluorophenvPmorpholine
A solution of 2.67g (lO.Ommol) of 4-benzyl-3-(S)-(4- fluorophenyl)-2-morpholinone (Description 2) in 40ml of dry THF was cooled to -78°C. The cold solution was treated with 12.5ml of
1.0M L-Selectride® solution in THF, maintaining the internal reaction temperature below -70°C. The resulting solution was stirred cold for 45 minutes and the reaction was charged with 3.60ml(20.0mmol) of 3,5-bis(trifluoromethyl)benzoyl chloride. The resulting yellow mixture was stirred cold for 30 minutes and the reaction was quenched with 50ml of saturated aqueous sodium bicarbonate solution. The quenched mixture was partitioned between 300ml of ether and 50ml of water and the layers were separated. The organic layer was dried over magnesium sulfate. The aqueous layer was extracted with 300ml of ether; the extract was dried and combined with the original organic layer. The combined organics were concentrated in vacuo. Flash chromatography on 150g of silica gel using 37:3 v/v hexanes/ether as the eluant afforded 4.06g (80%) of the title compound as a solid. 1H NMR (200MHz, CDCI3) δ 2.50 (1 H, dt, J=3.4, 12.0), 2.97 (1 H, app d, J=12.0), 2.99 (1H, d, J=13.6), 3.72-3.79 (1 H, m), 3.82 (1 H, d, J=2.6), 4.00 (1 H, d, J=13.6), 4.20 (dt, J=2.4, 11.6), 6.22 (1 H, d, J=2.6), 7.22-7.37 (7H, m), 7.57 (2H, app d, J=6.8), 8.07 (1 H, s), 8.47 (2H, s). MS (FAB) m/z 528 (M+H, 25%), 270 (100%). Anal. Calcd for C_6H_oF7NO3: C, 59.21 ; H, 3.82; N, 2.66; F, 25.21. Found:
C, 59.06; H, 4.05; N, 2.50; F, 25.18.
DESCRIPTION 4 4-Benzyl-2-(R)-(1-(3.5-bis(trifluoromethvnphenyl)ethenyloxy)-3- (S)-(4-fluorophenyl)morpholine
Step A: Dimethyl titanocene
A solution of 2.49g (lO.Ommol) of titanocene dichloride in 50ml of ether in the dark at 0°C was treated with 17.5ml of 1.4M
methyllithium solution in ether maintaining the internal temperature below 5°C. The resulting yellow/orange mixture was stirred at room temperature for 30 minutes and the reaction was quenched by slowly adding 25g of ice. The quenched reaction mixture was diluted with 50ml of ether and 25ml of water and the layers were separated. The organic layer was dried over magnesium sulfate and concentrated in vacuo to afford 2.03g (98%) of the title compound as a light-sensitive solid. The dimethyl titanocene could be stored as a solution in toluene at 0°C for at least 2 weeks without apparent chemical degradation. 1H NMR (200MHz, CDCI3) δ -0.15 (6H, s), 6.06 (1 OH, s).
Step B: 4-Benzyl-2-(R)-(1-(3.5-bis(trifluoromethvnphenvn ethenyloxy)-3-(SM4-fluorophenv0morpholine A solution of the compound of Description 3 (2.50g, 4.9mmol) and 2.50g (12.0mmol) of dimethyl titanocene (from Step A) in 35ml of 1:1 v/v THF/toluene was stirred in an oil bath at 80°C for 16 hours. The reaction mixture was cooled and concentrated in vacuo. Flash chromatography on 150g of silica gel using 3:1 v/v hexanes/methylene chloride as the eluant afforded 1.71 g (69%) of the title compound as a solid. An analytical sample was obtained via recrystallisation from isopropanol: 1H NMR (400MHz, CDCI3) δ 2.42 (1 H, dt, J=3.6, 12.0), 2.90 (1 H, app d, J=12.0), 2.91 (1 H, d, J=13.6), 3.62-3.66 (1 H, m), 3.72 (1 H, d, J=2.6), 3.94 (1 H, d, J=13.6), 4.09 (1 H, dt, J=2.4, 12.0), 4.75 (1 H, d, J=3.2), 4.82 (1 H, d,
J=3.2), 5.32 (1 H, d, J=2.6), 7.09 (2H, t, J=8.8), 7.24-7.33 (5H, m), 7.58-7.62 (2H, m), 7.80 (1 H, s), 7.90 (2H, s); MS (FAB) 526 (M+H, 75%), 270 (100%). Anal. Calcd for C_7H22F7NO_: C, 61.72; H, 4.22; N, 2.67; F, 25.31. Found: C, 61.79; H, 4.10; N, 2.65; F, 25.27%.
DESCRIPTION 5 2-(RH1-(RH3.5-Bisftrifluoromethvnphenvnethoxy)-3-(S)-f4- fluorophenvDmorpholine The compound of Description 4 (4.0g) was dissolved in ethyl acetate (50ml) and isopropanol (16ml). To this solution was added palladium on charcoal (1.5g) and the mixture was hydrogenated at 40 psi for 36h. The catalyst was removed by filtration through Celite and the solvents were removed in vacuo. The residue was purified by flash chromatography on silica using 100% ethyl acetate and then 1-10% methanol in ethyl acetate. This afforded isomer A 500mg (15%) and isomer B 2.6g (80%) as clear oils - isomer B crystallised on standing. For the title compound: 1H NMR (400MHz, CDCI3) δ 1.16 (3H, d, J=6.8MHz), 1.80 (1 H, br s), 3.13 (1 H, dd, J=3.2, 12.4Hz), 3.23 (1 H, dt, J=3.6, 12.4Hz), 3.63 (1 H, dd,
J=2.4, 11.2Hz), 4.01 (1H, d, J=2.4Hz), 4.13 (1H, dt, J=3.2, 12.0Hz), 4.42 (1H, d, J=2.4Hz), 4.19 (1 H, q, J=6.8Hz), 7.04-7.09 (2H, m), 7.27-7.40 (4H, m), 7.73 (1H, s); MS (FAB) 438 (M+H, 75%), 180 (100%).
HCI salt formation. To a solution of the free base (0.77g) in diethyl ether (10ml) was added 1M-HCI in methanol (1.75ml). The solution was evaporated to dryness and on addition of diethyl ether crystals formed. The solution was filtered and the residue washed with diethyl ether to give the title compound hydrochloride salt mp
248-250°C. Found: C, 50.46; H, 3.85; N, 3.01 ; CI, 7.31. C2oH18F7NO_.HCI requires C, 50.70; H, 4.04; N, 2.96; CI, 7.48%.
DESCRIPTION 6 4-Benzyl-3-(SH4-fluorophenvn-2- RH3-fluoro-5- (trifluoromethvDbenzoyloxy)morpholine
The title compound was prepared from the reaction of the compound of Description 2 with 3-fluoro-5-(trifluoromethyl)benzoyl chloride according to the procedure illustrated in Description 3. H NMR (360MHz, CDCI3) δ 2.50 (1H, dt, J=3.3, 12.0), 2.96 (1H, d, J=12.0), 2.98 (1 H, d, J=13.6), 3.75 (1 H, dd, J=1.7, 11.5), 3.80 (1 H, d, J=2.5), 3.92 (1H, d, J=13.6), 4.19 (1H, dt, J=2.1 , 12.0), 6.20 (1 H, d, J=2.5), 6.99 (2H, t, J=8.7), 7.2-7.37 (5H, m), 7.51-7.55 (3H, m),
7.89 (1 H, d, J=8.4), 8.09 (1 H, s). MS (Cl+) m/z 478 (M++1 , 100%). Anal. Calcd. for C25H20F5NO3: C, 62.88; H, 4.23; N, 2.93. Found: C, 62.59; H, 4.03; N, 3.07%.
DESCRIPTION 7
4-Benzyl-3-(SH4-fluorophenyl)-2- RH1-(3-fluoro-5- (trifluoromethyl)phenvOethenyloxy)morpholine
The title compound was prepared in 85% yield from the compound of Description 6 according to the procedure illustrated in Description 4. 1H NMR (360MHz, CDCI3) δ 2.42 (1 H, dt, J=3.6,
12.0), 2.90 (1 H, d, J=12.0), 2.91 (1 H, d, J=13.6), 3.60-3.62 (1 H, m), 3.72 (1 H, d, J=2.6), 3.92 (1 H, d, J=13.6), 4.09 (1 H, dt, J=2.4, 12.0), 4.67 (1 H, d, J=2.9), 4.76 (1 H, d, J=2.9), 5.28 (1 H, d, J=2.6), 7.07 (2H, t, J=8.7), 7.2-7.37 (7H, m), 7.53 (1 H, s), 7.57-7.61 (2H, m). MS (Cl+) 476 (M+1 , 100%).
DESCRIPTION 8 3-(S -(4-Fluorophenyl)-2-(R -(1-(R -(3-fluoro-5-(t fluoromethvn phenyl)ethoxy)morpholine
The compound of Description 7 was hydrogenated according to the method illustrated in Description 5. This afforded a mixture of 2 epimeric products isomer A and isomer B (the major product) as clear oils. For the title compound: 1H NMR (360MHz, CDCI3) δ 1.42 (3H, d, J=6.6Hz), 1.91 (1 H, s), 3.11 (1 H, dd, J=3.2, 12.4Hz),
3.22 (1 H, dt, J=3.6, 12.4Hz), 3.58-3.62 (1 H, m), 4.01 (1 H, d, J=2.3Hz), 4.11 (1 H, dt, J=3.2, 12.0Hz), 4.41 (1 H, d, J=2.3Hz), 4.80 (1H, q, J=6.6Hz), 6.41 (1H, d, J=9.2Hz), 6.86 (1H, s), 7.02 (2H, t, J=8.7Hz), 7.08 (2H, d, J=9.2Hz), 7.21-7.26 (2H, m). MS (Cl+) m/z 387 (M+1 , 100%). Anal. Calcd. for C19Hi8F5NO2: C, 58.91; H, 4.69;
N, 3.62. Found: C, 58.88; H, 4.81; N, 3.76%.
DESCRIPTION 9 2- )-(1-fRV(3.5-Bis(trifluoromethyl)phenvnethoxy)-3-(S)-(4- fluorophenyl -(2.3-dihvdro-2-oxo-1 ,3-imidazol-4- vDmethylmorpholine
A mixture of the compound of Description 5 (1g), N,N-diacetyl-4- bromomethyl-2-imidazolinone (0.62g) (prepared according to the procedure of Dolan and Dushinsky JACS 1948, 70, 657) and potassium carbonate (0.63g) in 10ml of dimethylformamide was stirred at room temperature for 15 min. The reaction mixture was diluted with ethyl acetate (100ml) and was washed with water and brine. The ethyl acetate layer was dried (MgSO4) and evaporated in vacuo. The resulting oil was dissolved in ethanol (10ml), 33% ethanolic methylamine (1ml) was added and the mixture stirred at room temperature for 10 min. The mixture was concentrated in vacuo to afford a solid. Recrystallisation from ethyl acetate/methanol afforded the title compound (0.63g). mp 192- 194°C. 1H NMR (360MHz, DMSO-d6) δ 1.35 (3H, d, J=6.5Hz), 2.25
(1 H, dt, J=8.7Hz), 2.60 (1H, d, J=13.8Hz), 2.89 (1 H, d, J=11.6Hz), 3.28-3.36 (2H, m), 3.62 (1 H, d, J=10.2Hz), 4.1 (1 H, t, J=10.0Hz), 4.31 (1 H, d, J=2.7Hz), 4.92 (1 H, q, J=6.5Hz), 5.97 (1 H, s), 7.06 (2H, t, J=8.8Hz), 7.36 (2H, s), 7.65-7.85 (2H, m), 7.84 (1 H, s), 9.58 (1 H, s), 9.8 (1 H, s).
DESCRIPTION 10 3-tSV(4-Fluorophenvn-2-(R 1-(RV(3-fluoro-5- (tπfluoromethvπphenvπethoxy)-4-(2.3-dihvdro-2-oxo-1 ,3-imidazol-4- vPmethylmorpholine
The title compound was prepared from the compound of Description 8 using a procedure analogous to that of Description 9. mp 209-210°C.
(c=1.0, methanol). 1H NMR (360MHz, DMSO-dβ) δ 1.31 (3H, d, J=6.5Hz), 2.24 (1 H, dt, J=3.0, 11.9Hz), 2.6 (1 H, d, J=13.9Hz), 3.61 (1 H, d, J=11.2Hz), 4.1 (1 H, t, J=11.0Hz),
4.29 (1 H, d, J=2.3Hz), 4.8 (1 H, q, J=6.5Hz), 6.00 (1 H, s), 6.55 (1 H, d, J=9.3Hz), 6.94 (1 H, s), 7.11 (2H, t, J=8.7Hz), 7.39 (1 H, d, J=8.4Hz), 7.51 (2H, s), 9.59 (1 H, s), 9.84 (1 H, s).
DESCRIPTION 11
2-(RV(1-(R)-(3.5-Bis(trifluoromethvnphenyl)ethoxy)-3-(S)-(4- fluorophenvD-4-(1.2,4-triazol-3-yl)methylmorpholine
A solution of the compound of Description 5 (3.77g) and potassium carbonate (3.59g) in dry dimethylformamide (7ml) was stirred at room temperature for 10 min. N-Formyl-2- chloroacetamidrazone (prepared according to I. Yanagisawa, J. Med Chem. (1984), 27, 849) was added and the reaction mixture was heated at 60°C for 1 hour. The temperature was then increased to 140°C for 2h. The mixture was cooled and partitioned
between ethyl acetate and water and the organic phase was washed with water, brine, dried (MgSO4) and evaporated to give a brown oil. The residue was purified by chromatography on silica using 1-5% methanol in dichloromethane. This afforded the product as a white foam (2.99g). 1H NMR (360MHz, DMSO) δ 8.25
(1 H, s), 7.85 (1 H, s), 7.50 (2H, t), 7.37 (2H, s), 7.11 (2H, t, J=9.0Hz), 4.93 (1 H, q, J=6.6Hz), 4.32 (1 H, d, J=2.8Hz), 4.09 (1H, dt, J=11.5Hz), 3.63 (1 H, d, J=14.1Hz), 3.59 (1 H, d, J=3.0Hz), 3.17 (1 H, d, J=14.0Hz), 2.49 (1 H, dt, J=15.7Hz), 1.36 (3H, d, J=6.6Hz). MS (Cl+) m/z 519. Anal. Calcd. for C23H19F7N.A.: C, 53.29; H, 4.08;
N, 10.81 ; Found: C, 52.92; H, 3.94; N, 10.33.
DESCRIPTION 12 4-Benzyl-3-(SH4-fluorophenvn-2-(RH3-(thfluoromethyl) benzoyloxy)morpholine
The title compound was prepared from the reaction of the compound of Description 2 with 3-(trifluoromethyl)benzoyl chloride according to the procedure illustrated in Description 3. 1H NMR (360MHz, CDCI3) δ 2.48 (1 H, dt, J=12.0, 3.5), 2.94 (1 H, d, J=13.6), 3.73 (1 H, app.d, J=11.4), 3.78 (1 H, d, J=2.7), 3.91 (1 H, d, J=13.6),
4.21 (1H, dt, J=11.7, 2.4), 6.20 (1 H, d, J=2.8), 6.97 (2H, t, J=8.7), 7.25-7.37 (5H, m), 7.53 (2H, m), 7.61 (1 H, t, J=7.8), 7.84 (1 H, d, J=8.0), 8.21 (1 H, d, J=7.8), 8.30 (1 H, s). MS (Cl+) m/z 460 (M+1 , 100%).
DESCRIPTION 13 4-Benzyl-3-(S)-(4-fluoroρhenvn-2-(R -π-(3-αrifluoromethyl) phenvPethenyloxy)morpholine
The title compound was prepared from the compound of Description 12 according to the procedure illustrated in Description 4. 1H NMR (360MHz, CDCI3) δ 2.40 (1 H, dt, J=11.9, 3.6Hz), 2.87 (1H, app. d, J=11.8Hz), 2.89 (1 H, d, J=13.5Hz), 3.62 (1H, app.d, J=11.5Hz), 3.70 (1H, d, J=2.7Hz), 3.91 (1H, d, J=13.5Hz), 4.12 (1 H, dt, J=11.7, 2.4Hz), 4.62 (1 H, d, J=2.7Hz), 4.74 (1 H, d, J=2.7Hz), 5.30 (1 H, d, J=2.7Hz), 7.07 (2H, t, J=8.7Hz), 7.21-7.32 (5H, m), 7.40 (1 H, t, J=7.8Hz), 7.53-7.63 (4H, m), 7.74 (1 H, s). MS (Cf) m/z 458 (M+1 , 100%).
DESCRIPTION 14 3-(SH4-Fluorophenvn-2-(R)-(1-(R 3-(t fluoromethvnphenyl) ethoxy)morpholine
The compound of Description 13 was hydrogenated according to the method illustrated in Description 5. This afforded a mixture of 2 epime c products isomer A and isomer B in approximately equal mass as yellow oils. The title compound (isomer B): 1H NMR (360MHz, CDCI3) δ 1.43 (3H, d, J=6.6), 3.11 (1 H, dd, J=12.6, 2.9), 3.22 (1 H, dt, J=12.4, 3.7), 3.60 (1 H, dd, J=11.1 , 2.8), 3.99 (1 H, d, J=2.2), 4.13 (1 H, dt, J=11.6, 3.2), 4.42 (1 H, d, J=2.2), 4.81 (1 H, q,
J=6.6), 6.84 (1 H, d, J=7.8), 6.96-7.03 (3H, m), 7.16-7.27 (3H, m), 7.38 (1 H, d, J=7.5). MS (Cl+) m/z 370 (M+1 , 100%). Anal. Calcd. for Cι9H19F4NO2: C, 61.77; H, 5.20; N, 3.79. Found: C, 61.60; H, 5.16; N, 3.95%.
DESCRIPTION 15 4-Benzyl-3-(S)-phenyl-2-morpholinone
Step A: N-Benzyl-(S)-phenylqlvcine
A solution of 1.51 g (10.Ommol) of (S)-phenylglycine in 5ml of 2N aqueous sodium hydroxide solution was treated with 1.Oml (lO.Ommol) of benzaldehyde and stirred at room temperature for 20 minutes. The solution was diluted with 5ml of methanol, cooled to
0°C, and carefully treated with 200mg (5.3mmol) of sodium borohydride. The cooling bath was removed and the reaction mixture was stirred at room temperature for 1.5 hours. The reaction was diluted with 20ml of water and extracted with 2 x 25ml of methyiene chloride. The aqueous layer was acidified with concentrated hydrochloric acid to pH 6 and the solid that precipitated was filtered, washed with 50ml of water, 50ml of 1 :1 v/v methanol/ethyl ether and 50ml of ether, and dried to afford 1.83g (76%) of product, mp 230-232°C. Anal. Calcd for Cι5Hι5N02: C, 74.66; H, 6.27; N, 5.81. Found: C, 74.17; H, 6.19; N, 5.86.
Step B: 4-Benzyl-3-(S)-Phenyl-2-morpholinone A mixture of 4.00g (16.6mmol) of N-benzyl-(S)-phenylglycine (from Step A) 5.00g (36.0mmol) of potassium carbonate, 10.0ml of 1 ,2-dibromoethane and 25ml of N,N-dimethylformamide was stirred at 100°C for 20 hours. The mixture was cooled and partitioned between 200ml of ethyl ether and 100ml of water. The layers were separated and the organic layer was washed with 3 x 50ml of water, dried over magnesium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on 125g of silica gel eluting with 9:1 v/v, then 4:1 hexanes/ethyl ether to afford 2.41 g (54%) of the product as a solid, mp 98-100°C. 1H NMR (250MHz, CDCI3) δ 2.54-2.68 (1 H, m), 2.96 (1 H, dt, J=12.8, 2.8), 3.14 (1 H, d, J=13.3), 3.75 (1 H, d, J=13.3), 4.23 (1 H, s), 4.29-4.37 (1 H, m), 4.53
(dt, J=3.2, 11.0), 7.20-7.56 (10H, m). MS (FAB): m/z 268 (M+H; 100%). Anal. Calcd for Cι7Hι7NO2: C, 76.38; H, 6.41 ; N, 5.24. Found: C, 76.06; H, 6.40; N, 5.78.
DESCRIPTION 16
4-Benzyl-2-(RW3,5-bis(trifluoromethyl)benzoyloxy)-3-(S)- phenylmorpholine
A solution of 2.67g (lO.Ommol) of the compound of Description 15 in 40ml of dry THF was cooled to -78°C. The cold solution was treated with 12.5ml of 1.0M L-Selectride® solution in THF, maintaining the internal reaction temperature below -70°C. The resulting solution was stirred cold for 45 minutes and the reaction was charged with 3.60ml (20.0mmol) of 3,5-bis(trifluoromethyl) benzoyl chloride. The resulting yellow mixture was stirred cold for 30 minutes and the reaction was quenched with 50ml of saturated aqueous sodium bicarbonate solution. The quenched mixture was partitioned between 300ml of ether and 50ml of water and the layers were separated. The organic layer was dried over magnesium sulfate. The aqueous layer was extracted with 300ml of ether; the extract was dried and combined with the original organic layer. The combined organics were concentrated in vacuo. Flash chromatography on 150g of silica gel using 37:3 v/v hexanes/ether as the eluant afforded 4.06g (80%) of the title compound as a solid. H NMR (200MHz ppm, CDCI3) δ 2.50 (1 H, dt, J=3.4, 12.0), 2.97 (1 H, app d, J=12.0), 2.99 (1 H, d, J=13.6), 3.72-3.79 (1 H, m), 3.82
(1 H, d, J=2.6), 4.00 (1 H, d, J=13.6), 4.20 (dt, J=2.4, 11.6), 6.22 (1 H, d, J=2.6), 7.22-7.37 (7H, m), 7.57 (2H, app d, J=6.8), 8.07 (1 H, s), 8.47 (2H, s). Anal. Calcd for C_6H2ιF6NO3: C, 61.29; H, 4.16; N, 2.75; F, 22.38. Found: C, 61.18; H, 4.14; N, 2.70; F, 22.13.
DESCRIPTION 17 4-Benzyl-2-(RH1 -(3.5-bis(trifluoromethvnphenyl) ethenyloxy)-3- (S)-phenylmorpholine A solution of 2.50g (4.9mmol) of the compound of Description 16 and 2.50g (12.0mmol) of dimethyl titanocene (Description 4a), in 35ml of 1 :1 v/v THF/toluene was stirred in an oil bath at 80°C for 16 hours. The reaction mixture was cooled and concentrated in vacuo. Flash chromatography on 150g of silica gel using 3:1 v/v hexanes/methylene chloride as the eluant afforded 1.71 g (69%) of the title compound as a solid. 1H NMR (400MHz, CDCI3) δ 2.42 (1 H, dt, J=3.6, 12.0), 2.89 (app d, J=11.6), 2.92 (1 H, d, J=13.6), 3.61- 3.66 (1 H, m), 3.73 (1 H, d, J=2.8), 4.00 (1 H, d, J=13.6), 4.09 (1 H, dt, J=2.4, 11.6), 4.75 (1 H, d, J=2.8), 4.79 (1H, d, J=2.8), 5.36 (1 H, d, J=2.4), 7.23-7.41 (7H, m), 7.63 (1 H, app d, J=7.2), 7.79 (1 H, s),
7.91 (2H, s). MS (FAB) m/z 508 (M+1 , 25%). Anal. Calcd. for C27H_3F6N02: C, 63.90; H, 4.57; N, 2.76; F, 22.46. Found: C, 63.71 ; H, 4.53; N, 2.68; F, 22.66.
DESCRIPTION 18
2-(RH1-(SH3,5-Bis(trifluoromethvnphenyl)ethoxy)-3-(S)- phenylmorpholine
A mixture of the compound of Description 17 (1.5g) and 10% palladium on carbon catalyst (750mg) in a mixture of isopropanol/ethyl acetate (25ml, 3:2 v/v) was stirred under an atmosphere of hydrogen for 48h. The catalyst was removed by filtration through celite and the reaction flask and filter pad were rinsed with ethyl acetate (500ml). The filtrate was concentrated in vacuo, flash chromatography afforded epimer A (106mg) and
epimer B (899mg) as clear oils. The title compound, epimer B had the following analysis:
1H NMR (CDCI3, 400MHz) δ 1.46 (3H, d, J=6.8Hz), 1.92 (1 H, brs), 3.13 (1 H, dd, J=3.0, 12.6Hz), 3.24 (1 H, dt, J=3.6, 12.6Hz), 3.62 (1H, dd, J=3.6, 11.2Hz), 4.04 (1H, d, J=2.4Hz), 4.14 (1 H, dt,
J=3.0, 11.2Hz), 4.48 (1 H, d, J=2.4Hz), 4.90 (1 H, q, J=6.8Hz), 7.21- 7.32 (7H, m), 7.64 (1H, s). MS (Cl+) m/z 420 (M++1 , 20%), 178 (100%). Anal. Calcd. for C2oHι9F6NO2: C, 57.28; H, 4.57; N, 3.34; F, 27.18. Found: C, 57.41 ; H, 4.61 ; N, 3.29; F, 27.23.
DESCRIPTION 19 2-fR)-(1-(R)-(3.5-Bis(trifluoromethvnphenyl)ethoxy)-3-(S)- phenyl-4-(1.2.4-triazol-3-yl)methylmorpholine
This compound was prepared from the compound of Description 18 following the procedure illustrated in Description 11. MS (Cf ) m/z 501 (M++1 , 100%).
DESCRIPTION 20 4-Benzyl-2-(R)-(1-(SH3.5-bis(trifluoromethyl)phenyl)-2- hvdroxyethoxy)-3-(S)-(4-fluorophenyl)morpholine
The compound of Description 4 (12.8g) was dissolved in tetrahydrofuran (50ml) and the mixture was cooled in ice. Borane (49ml of 1.0M in tetrahydrofuran) was added dropwise and the reaction mixture was stirred at room temperature for 3hr. The solution was cooled in ice and sodium hydroxide (120ml, 1M) and hydrogen peroxide (36ml, 30 wt. %) were added dropwise cautiously. The resulting mixture was stirred for 1h, then diluted with water (200ml) and extracted with ethyl acetate (3 x 50ml). The organic extracts were washed with sodium sulfite and then brine.
The organic phase was dried (MgSO4) and evaporated to give a clear oil. Tic (50:50 ethyl acetate/hexane) indicated two main products which were separated by flash chromatography on silica using a gradient elution of 1-30% ethyl acetate in hexane. The minor product eluted first (2.3g) and the major product eluted last
(8g). The major product was isolated as a white foam. 1H NMR (360MHz, DMSO-de) δ 2.23-2.29 (1 H, m), 2.73 (1 H, d), 2.80 (1 H, d, J=13.0Hz), 3.48 (1 H, d, J=3.5Hz), 3.45-3.52 (2H, m), 3.56-3.65 (2H, m), 4.00-4.06 (1 H, m), 4.37 (1 H, d, J=3.0Hz), 4.81 (1 H, t, J=6.0Hz), 4.92 (1 H, t, J=5.5Hz), 7.14 (2H, t, J=9.0Hz), 7.23-7.33 (5H, m), 7.35
(2H, s, ArH), 7.57 (2H, t, ArH), 7.85 (1H, s, ArH). MS (Cl+) m/z 544 (M++1 , 100%).
DESCRIPTION 21 2-(R)-f1-(S)-(3.5-bis(trifluoromethvnphenvn-2-hvdroxyethoxy)-3-
(SH4-fluorophenyl)morpholine
The compound of Description 20 (8g) was dissolved in ethyl acetate (100ml) and isopropanol (50ml) and palladium on charcoal (1.5g) was added to the solution. This mixture was hydrogenated at 40 psi overnight. The catalyst was removed by filtration and the solvents were removed in vacuo. The residue was purified by flash silica chromatography using 1-10% methanol in dichloromethane as eluant. This afforded the product as a white powder (5.7g, 90%). 1H NMR (360MHz, CDCI3) δ 2.68-2.73 (1H, m), 3.03-3.15 (1 H, m), 3.43-3.65 (3H, m), 3.95 (1 H, d, J=3.0Hz), 4.12-4.22 (1 H, m), 4.40
(1 H, d, J=3.0Hz), 4.89 (1 H, t, J=7.0Hz), 6.99 (t, J=9.0Hz, ArH), 7.15 (2H, s, ArH), 7.26-7.31 (1 H, m, ArH), 7.62 (1 H, s, ArH). MS (Cl+) m/z 454 (M++1 , 100%).
DESCRIPTION 22 3-(S)-(4-Fluorophenvn-2-(RH1-(SH3-fluoro-5- (trifluoromethyl)phenyl)-2-hvdroxyethoxy)morpholine
Step A: 4-Benzyl-3- SH4-fluorophenvn-2-(RH1-(SH3-fluoro-5-
(trifluoromethvθphenyl)-2-hydroxyethoxy)morpholine
The compound of Description 7 (0.8g) was dissolved in tetrahydrofuran (5ml) at room temperature and borane (5ml, 1.0M in tetrahydrofuran) was added. The solution was stirred under nitrogen for 30 min until all starting material had reacted. Hydrogen peroxide (5ml, 29% aq.) and sodium hydroxide (10ml, 4N) were added dropwise to the cooled (0°C) solution with much effervescence. The resulting mixture was extracted with ethyl acetate, the organic phase was washed with sodium bisulfite and brine, dried (MgSO4) and evaporated to afford a colourless oil (1g).
This material was not purified further but reacted as described in the following step.
Step B: 3-(SH4-Fluorophenyl)-2-(R 1-(SH3-fluoro-5- (thfluoromethyl)phenyl)-2-hvdroxyethoxy)morpholine
The compound of (a) above (1g) was dissolved in ethyl acetate/2-propanol (20ml, 3:1 ) and treated with Pd on carbon (100mg). The mixture was hydrogenated at 60 psi for 12h. The catalyst was removed by filtration and the solvent was removed in vacuo. The residue was purified by medium pressure chromatography on silica (Lobar) using 5% methanol in dichloromethane as eluant. The product was recrystallised from ether. 1H NMR (360MHz, DMSO-d6) δ 2.77-3.04 (3H, m), 3.36-3.51 (2H, m), 3.93 (1 H, br s), 4.05-4.13 (1 H, m), 4.36 (1 H, d, J=2.0Hz),
4.72 (1 H, t, J=5.0Hz), 4.98 (1 H, t, J=7.0Hz), 6.66 (1 H, d, J=9.2Hz), 6.89 (1 H, s), 7.10 (2H, t, J=9.0Hz), 7.33-7.37 (2H, m), 7.41 (1 H, d, J=9.0Hz); MS (Cl+) m/z 404 (M++1 , 100).
DESCRIPTION 23
N-Carbomethoxy-2-chloroacetamidrazone (CICH2C(=NH)NHNHCOOCH3)
Sodium methoxide (20ml, 1 M) was added to a solution of chloroacetonitrile (54.1g) in anhydrous methanol (100ml) at 0°C. The mixture was stirred at room temperature for 30 min and then neutralised with acetic acid (1.2ml). Methyl hydrazinocarboxylate (64.5g, predistilled in vacuo) was dissolved in warm dimethylformamide (35ml) and methanol (300ml) and was added to the reaction mixture at 0°C. The mixture was stirred for 30 min and the crystalline solid which had formed was removed by filtration and washed with ethyl acetate to give the title compound: mp 138- 140°C.
DESCRIPTION 24 2-(R)-(1-(S)-(3.5-Bis(trifiuoromethvnphenvn-2-hvdroxyethoxy)-3-
(S)-phenylmorpholine
Step A: 4-Benzyl-2-(R)-(1-fS)-(3.5-Bis(trifluoromethvnphenvn-2- hvdroxyethoxy)-3-(S)-phenylmorpholine The compound of Description 17 was reacted with diborane and subsequently with basic hydrogen peroxide according to the method illustrated in Description 20. This intermediate was not purified and was reacted crude in the following step.
Step B: 2-(RH1-(SH3.5-Bis(trifluoromethyl)phenyl-2- hvdroxyethoxy)-3-fS)-phenylmorpholine
The compound of (a) above was deprotected by hydrogenolysis as described in Description 21 to afford the title compound as a white solid. 1H NMR (360MHz, CDCI3) δ 2.85 (1 H, app d,
J=11.0Hz), 3.15 (1H, dt, J=12.0, 3.5Hz), 3.58 (1H, dd, J=11.0, 3.0Hz), 3.63-3.71 (2H, m), 4.02 (1 H, d, J=3.0Hz), 4.25 (dt, J=12.0, 3.0Hz), 4.53 (1H, d, J=3.0Hz), 4.93 (1H, t, J=5.0Hz), 7.22 (2H, s), 7.35 (5H, br s), 7.67 (1 H, s). MS (Cl+) m/z 436 (M+1 , 100%).
DESCRIPTION 25 4-Benzyl-2-(R)-(3-fluoro-5-(trifluoromethyl)benzoyloxy)-3-(S)- phenylmorpholine
The compound of Description 15 was reacted with L-Selectride followed by 3-fluoro-5-(trifluoromethyl)benzoyl chloride according to the method illustrated in Description 3 to afford the title compound as a clear oil. 1H NMR (250MHz, CDCI3) δ 2.47 (1 H, dt, J=8.5, 2.5Hz), 2.93-2.97 (2H, m), 3.72-3.76 (1H, m), 3.79 (1 H, d, J=3.0Hz), 3.97 (1 H, d, J=9.5Hz), 4.17 (1H, dt, J=8.5, 2.5Hz), 6.22 (1 H, d, J=3.0Hz), 7.19-7.35 (8H, m), 7.45-7.56 (3H, m), 7.88 (1 H, brd), 8.09
(1 H, s). MS (Cl+) m/z 460 (M+1 , 100%).
DESCRIPTION 26 4-Benzyl-2-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethenyloxy)-3- (S)-phenylmorpholine
The compound of Description 25 was reacted with dimethyl titanocene according to the procedure illustrated in Description 4. This afforded the title compound as a clear oil (66%). 1H NMR (250MHz, CDCI3) δ 2.29-2.39 (1 H, m), 2.79-2.86 (2H, m), 3.53-3.64
(2H, m), 3.92 (1 H, d, J=13.5Hz), 4.00-4.09 (1 H, m), 4.61 (1 H, d, J=3.0Hz), 4.66 (1 H, d, J=3.0Hz), 5.25 (1 H, d, J=3.0Hz), 7.14-7.35 (10H, m), 7.47 (1 H, s), 7.56 (2H, brd). MS (Cl+) m/z 458 (M+1 , 100%).
DESCRIPTION 27 2-(RH1-(SW3-fluoro-5-(trifluoromethyl)phenyl)-2- hvdroxyethoxy)-3-(S)-phenylmorpholine
Step A: 4-Benzyl-2-mH1-(SH3-fluoro-5-ttrifluoromethvn phenyl)-2-hvdroxyethoxy)-3-(S)-phenylmorpholine
The compound of Description 26 was reacted with diborane followed by treatment with basic hydrogen peroxide according to the procedure illustrated in Description 20 to afford a clear oil. MS (Cl+) m/z 476 (M+1 , 100%).
Step B: 2- R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2- hydroχyethoxy)-3-(S)-phenylmorpholine
The compound of (a) above was deprotected following the method illustrated in Description 21. This afforded the title compound as a white solid. Anal. Calcd. for Cι9Hι9F4N03: C, 59.22; H, 4.97; N, 3.63. Found: C, 59.18; H, 5.12; N, 3.62%. MS (Cl+) m/z 386 (M+1 , 100%).
DESCRIPTION 28
4-Benzyl-3-(SVphenyl-2-(RH3-(trifluoromethvnbenzoyloxy) morpholine
Prepared from the compound of Description 15 following the method illustrated in Description 3. 1H NMR (250MHz, CDCI3) δ
2.47 (1H, dt), 2.89-2.99 (2H, m), 3.69-3.82 (2H, m), 3.98 (1 H, d), 4.23 (1 H, dt), 6.22 (1 H, d), 7.22-7.40 (8H, m), 7.54-7.66 (3H, m), 7.83 (1 H, d), 8.22 (1H, d), 8.31 (1H, s).
DESCRIPTION 29
4-Benzyl-3-(S)-phenyl-2-(R)-(1-f3-trifluoromethvnphenyl) ethenyloxy)morpholine
Prepared from the compound of Description 28 following the method illustrated in Description 4. 1H NMR (250MHz, CDCI3) δ 2.41 (1 H, dt), 2.84-2.96 (2H, m), 3.58-3.66 (1 H, m), 3.72 (1 H, d,
3.99 (1 H, d), 4.13 (1 H, dt), 4.63 (1 H, d), 4.72 (1 H, d), 5.34 (1 H, d), 7.21-7.43 (9H, m), 7.50-7.68 (4H, m), 7.75 (1 H, s).
DESCRIPTION 30 3-(S)-Phenyl-2-fR)-(1-(SW3-(trifluoromethvnphenyl)-2- hvdroxyethoxy)morpholine
Step A: 4-Benzyl-3-(S)-phenyl-2-(R 1-(SH3- (tπfluoromethyl)phenyl)-2-hydroxyethoxy)morpholine Prepared from the compound of Description 29 following the method illustrated in Description 20.
Step B: 3-fS)-Phenyl-2-(R)-f1-.S)-f3-(trifluoromethyl)phenylV2- hvdroxyethoxy)morpholine This was carried through without purification to the title compound following the method illustrated in Description 21. 1H NMR (250MHz, CDCI3) δ 2.81 -2.90(1 H, br d), 3.16 (1 H, dt), 3.54- 3.68 (3H, m), 4.02 (1 H, d), 4.28 (1 H, dt), 4.53 (1 H, d), 4.85-4.92
(1 H, m), 6.85 (1 H, d), 6.99 (1 H, s), 7.15-7.24 (1 H, m), 7.34-7.45 (6H, m).
EXAMPLE 1 2-(R)-(1-(R)-(3.5-Bis(trifluoromethyl)phenvnethoxy)-4-(2.3- dihvdro-5-(N.N-dimethylaminomethyl)-2-oxo-1.3-imidazol-4- v0methyl-3-(SW4-fluorophenyl)morpholine
The compound of Description 9 (0.35g) was treated with N,N- dimethylmethyleneammonium iodide (0.48g) and triethylamine (111 μl) in tetrahydrofuran (10ml) and the mixture was heated at reflux for 4h. The solvent was removed in vacuo and the residue was purified by chromatography on silica using 1-10% methanol in dichloromethane as eluant to afford the title compound (0.2g).1H NMR (250MHz, CDCI3) δ 9.72 (1H, s), 9.68 (1H, s), 7.86 (1H, s), 7.50-7.60 (2H, m), 7.36 (2H, s), 7.07 (2H, t, J=8.8Hz), 4.96-4.89
(1H, q, J=6.5Hz), 4.31 (1H, d, J=2.7Hz), 4.08 (1H, t, J=10.1Hz), 3.62 (1H, d, J=10.1Hz), 3.34 (2H, s), 3.24 (1 H, d, J=13.6Hz), 3.00 (1 H, d, J=13.4Hz), 2.85 (1 H, d, J=11.1 Hz), 2.62 (1 H, d, J=13.6Hz), 2.25 (1 H, t, J=11 Hz), 2.01 (6H, s), and 1.35 (3H, d, J=6.5Hz). MS (Cl+) m/z 591 (M+1 ).
EXAMPLE 2 4-f2.3-Dihvdro-5-(N.N-dimethylaminomethvn-2-oxo-1.3- imidazol-4-yl)methyl-3-(S)-(4-fluorophenvn-2-fR)-(1-(R)-(3-fluoro-5- (trifluoromethvDphenyOethoxy)morpholine
Prepared from the compound of Description 10 by a procedure analogous to that of Example 1. 1H NMR (250MHz, CDCI3) δ 1.38 (3H, d, J=6.2Hz), 2.22 (6H, s), 2.78 (1 H, d, J=14Hz), 2.92 (1 H, d, J=11.2Hz), 3.14 (2H, app. q, J=14Hz), 3.34 (1 H, d, J=2.8Hz), 3.46
(1H, d, J=11.2Hz), 3.60 (1 H, d, J=10Hz), 4.22 (2H, m), 4.26 (1 H, d, J=2.8Hz), 4.74 (1 H, q, J=6.2Hz), 6.32 (1 H, d, J=8.4Hz), 6.72 (1 H, s), 7.06 (3H, t, J=8.4Hz), 7.36 (2H, br s), 8.70 (1 H, br s), 9.20 (1 H, br s).
EXAMPLE 3 3-(SH4-Fluorophenvn-2-(RH1-(RH3-fluoro-5- (trif I uorometh vπphenv0ethoxy)-4-(2.3-d ih vdro-2-oxo-5- Pyrrolidinomethyl-1.3-imidazol-4-vDmethylmorpholine A mixture of the compound of Description 10, (0.1 g), paraformaldehyde (0.012g) and pyrrolidine (0.04ml) in methanol (2ml) was heated at 90°C for 1h. An additional aliquot of paraformaldehyde (12mg) was added to the mixture and heating was continued for a further 30 min. The mixture was cooled and the solvent was removed in vacuo. The residue was purified by chromatography on silica using 0.5% aqueous ammonia and 5% methanol in dichloromethane. This afforded the product as a foam. The product was further purified as the hydrochloride salt: mp 157- 9°C. 1H NMR (250MHz, (free base) CDCI3) δ 1.40 (3H, t, J=6.2Hz), 1.72 (4H, br s), 2.41 (4H, br s), 2.76 (1 H, d, J=12.9Hz), 2.92 (1 H, d,
J=11.2Hz), 3.14-3.50 (5H, m), 3.62 (1 H, d, J=11.2Hz), 4.16 (1 H, d, J=12.9Hz), 4.26 (1 H, d, J=2.8Hz), 4.71 (1 H, q, J=6.2Hz), 6.30 (1H, d, J=8.4Hz), 6.75 (1 H, s), 7.06 (3H, t, J=8.4Hz), 7.34 (2H, br s), 8.86 (1 H, br s), 9.14 (1 H, br s). MS (Cl+) m/z 567 (M++H).
EXAMPLE 4 2-(RH1-(RH3.5-BisαrifluoromethvnphenvnethoxyV3-(SH4- fluorophenyl)-4-(2,3-dihvdro-2-oxo-5-pyrrolidinomethyl-1 ,3- imidazol-4-vOmethylmorpholine
A solution of the compound of Description 5 (1.5g) in anhydrous dimethylformamide (15ml) was added dropwise during 5 min to a stirred solution of 4,5-bis(bromomethyl)-1 ,3-diacetyl-2- imidazolinone (1.8g) (prepared by the method of Dolan and Dushinsky JACS (1948) 70, 657) in dimethylformamide (10ml) containing potassium carbonate (1.4g) with ice-cooling. The reaction mixture was stirred for 10 min and, pyrrol idine (1.1g) was added in one portion and stirring was continued for 20 min. The reaction mixture was diluted with water (250ml) and extracted with ethyl acetate (3 x 50ml). The combined organic extracts were washed with water (2 x 50ml) and brine (1 x 50ml) and then dried (K2CO3) and concentrated in vacuo. The residue was purified by chromatography on silica using a gradient elution of dichloromethane (100%) to dichloromethane/methanol/aqueous ammonia mixtures (85:15:0.5) to provide the title compound as a foam. 1H NMR (360MHz, DMSO-d6) δ 9.63 (2H, br s), 7.84 (1 H, s), 7.53 (2H, br t), 7.36 (2H, s), 7.06 (2H, t, J=8.7Hz), 4.94-4.90 (1 H, q, J=6.5Hz), 4.31 (1 H, d, J=2.68Hz), 4.07 (1 H, t, J=11.4Hz), 3.61 (1 H, d, J =11.20Hz), 3.34 (1 H, J=2.7Hz), 3.27 (1 H, d, J=13.7Hz), 3.17 (1 H, d, J=13.4Hz), 3.00 (1 H, d, J=13.4Hz), 2.86 (1 H, d, J=11.6Hz),
2.62 (1 H, d, J=13.6Hz), 2.40-2.20 (5H, m), 1.64-1.58 (2H, m), 1.35 (3H, d, J=6.5Hz). MS (Cl+) m/z 615 (M++H).
Examples 5 to 11 in Table 1 were prepared in a similar manner to that described in Example 4 from the appropriate morpholine,
4,5-bis(bromomethyl)-1 ,3-diacetyl-2-imidazolinone and the appropriate amine.
EXAMPLE 12 2-(R)-(1-(R)-(3.5-Bis(trifluoromethvnphenvnethoxy-4-(5- (dimethylaminomethvn-1.2.3-triazol-4-vπmethyl-3-(S)-(4- fluorophenvOmorpholine Method A a) 2-(RW1-(R)-(3.5-Bis(thfluoromethvnphenvnethoxy-3-(S)-(4- fluorophenyl)-4-proparoylmorpholine
Propargyl bromide (1.9ml) was added to a stirred mixture of the compound of Description 5 (5g) and potassium carbonate (4.76g) in dry dimethylformamide at 23°C. After 15 min the reaction mixture was diluted with water (250ml) and extracted with ethyl acetate (3 x 100ml). The combined organic phases were washed with brine (1 x 100ml) then dried (K2CO3) and concentrated to leave an oil. This was purified by chromatography on silica using ethyl acetate in hexane (1 :9 then 1 :4) as eluent to afford the title compound as an oil. 1H NMR (250MHz, CDCI3) δ 1.50 (3H, d, J=6.6Hz), 2.21 (1 H, s), 2.84 (1 H, d, J=11.1 Hz), 2.97 (1 H, td, J=3.2, 11.7Hz), 3.26 (2H, d, J=1.8Hz), 3.62 (1 H, d, J=2.2Hz), 3.71 (1H,'dd, J=2.3, 11.1 Hz), 4.33 (2H, m), 4.89 (1 H, q, J=6.6Hz), 7.03 (2H, t, J=8.6Hz), 7.18 (2H, s), 7.38 (2H, br s), 7.63 (1 H, s). MS (Cl+) m/z 476 (MH, 100%).
b) 2-(RVπ-(R)-f3.5-Bis(trifluoromethvnphenvnethoxy)-4-(4- dimethylamino-4-oxo-but-2-vnvπ-3-(S)-(4-fluorophenvπmorpholine
A mixture of N,N-dimethylcarbamoyl chloride (0.195ml), cuprous iodide (2mg), bis(triphenylphosphine)palladium (II) chloride (2mg), triphenylphosphine (3mg) and the compound described in (a) above (1g) in triethylamine (4ml) was heated at 90°C for 5h in an inert atmosphere. The mixture was cooled to 23°C and methanol (1 ml) was added and the solvent was removed in vacuo. The residue
was partitioned between water and ethyl acetate and the layers were separated. The aqueous phase was extracted with ethyl acetate (2 x 20ml). The combined organic phases were washed with water, brine, dried (MgS04) and concentrated to leave an oil. The residue was purified by chromatography on silica using ethyl acetate in hexane (1 :1 ) then ethyl acetate as eluant to provide the title compound as an oil. 1H NMR (250MHz, CDCI3) δ 1.49 (3H, d, J=6.6Hz), 2.84-3.06 (2H, m), 3.00 (3H, s), 3.17 (3H, s), 3.44 (2H, s), 3.64 (1 H, br s), 3.73 (1 H, dd, J=2.0, 11.1 Hz), 4.33 (2H, m), 4.88 (1H, q, J=6.6Hz), 7.03 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.38 (2H, br s), 7.63 (1 H, s). MS (Cl+) m/z 547 (MH, 100%).
c) 2-(R)-f1-(R)-(3.5-Bis(thfluoromethyl)phenvnethoxy)-4-(5-N.N- dimethylcarboxamido-1.2.3-triazol-4-vDmethyl-3-(SH4- fluorrohenvDmorpholine
A mixture of the compound described in (b) above (1.1g) and sodium azide (0.65g) in dimethylsulphoxide (7.5ml) was heated at 70°C for 17h. The mixture was cooled to 23°C and excess dimethylsulphoxide was removed by distillation in vacuo. The residue was partitioned between brine and ethyl acetate. The layers were separated and the organic layer was washed with brine (2 x 20ml) then dried (MgSO4) and concentrated to leave an oil. This was purified by chromatography on silica using ethyl acetate in hexane (1 :2 then 1 :1 ) and then ethyl acetate as eluent to provide the title compound as a pale yellow foam.1H NMR (360MHz, CDCI3) δ 1.47 (3H, d, J=6.6Hz), 2.64 (1 H, m), 2.90 (1 H, d, J=11.6Hz), 3.09 (3H, s), 3.34 (3H, s), 3.65 (3H, m), 3.92 (1 H, d, J=15.5Hz), 4.27 (1 H, td, J=2.1 , 9.5Hz), 4.35 (1 H, d, J=2.6Hz), 4.89 (1 H, q, J=6.6Hz),
7.01 (2H, t, J=8.7Hz), 7.16 (2H, s), 7.39 (2H, br s), 7.64 (1 H, s). m/z 590 (MH, 100%).
d) 2-(R)-(1-(R)-3.5-Bisftπfluoromethyl)phenvnethoxy)-4-(5- (dimethylaminomethvn-1.2.3-triazol-4-vnmethyl-3-(SW4- fluorophenvOmorpholine
Lithium aluminium hydride (0.47ml, 1 M in tetrahydrofuran) was added dropwise to a solution of the compound described in (c) above (0.11g) in dry tetrahydrofuran (1ml) under an inert atmosphere at 23°C. After 30 min sodium hydroxide (10 drops, 1M) was added followed by water (5 drops). Ethyl acetate (50ml) was then added and the resulting mixture was filtered through a pad of Hyflo. The filtrate was concentrated in vacuo and the residue was purified by chromatography on silica using ethyl acetate in methanol (9:1 then 4:1 ) as eluant to provide the title compound as a foam.1H NMR (360MHz, CDCI3) δ 1.44 (3H, d, J=6.6Hz), 2.25 (6H, s), 2.57 (1 H, td, J=3.4, 8.55Hz), 2.90 (1 H, d, J=11.7Hz), 3.25 (1 H, d, J=14.0Hz), 3.43 (1 H, d, J=13.6Hz), 3.45 (1 H, d, J=2.2Hz), 3.53 (1 H, d, J=13.6Hz), 3.61 (1 H, d, J=11.2Hz), 3.78 (1 H, d, J=14.0Hz), 4.22 (1 H, t, J=9.3Hz), 4.32 (1 H, d, J=2.2Hz), 4.86 (1 H, q, J=6.6Hz),
7.06 (2H, t, J=8.7Hz), 7.16 (2H, s), 7.48 (2H, br s), 7.63 (1 H, s). m/z 576 (MH).
Method B 2-(RV1-fR)-(3.5-Bis(thfluoromethvnphenvnethoxy)-3-(S)-(4- fluorophenyl)-4-(4-chlorobut-2-vnyl)morpholine a) A solution of the product of Description 5 (free base, 5g) in N,N-dimethylformamide (20ml) was slowly added to a heated (50°C) solution of 1 ,4-dichlorbut-2-yne (2.2ml) and potassium
carbonate (4.8g) in N,N-dimethylformamide (20ml). The solution was heated for a further 5h at 50°C and then the solvent removed in vacuo. To the residue was added water (400ml) and the product extracted into ethyl acetate (3 x 150ml). The combined organic phase washed with water, saturated brine and dried (MgSO4). The solvent was removed in vacijo and the residue chromatographed on silica gel (eluting with 10% ethyl acetate in petroleum ether bp 60- 80°C) to give the title compound. H NMR (250MHz, CDCI3) δ 1.41 (3H, d, J=6.6Hz), 2.80 (1 H, app. t, J=10.8Hz), 2.87 (1 H, td, J=3.5Hz, 11.7Hz), 3.22 (2H, t, J=1.9Hz), 3.52 (1 H, d, J=2.8Hz),
3.68 (1 H, d, J=1.4Hz, 11.1 Hz), 4.00 (2H, t, J=1.9Hz), 4.22-4.32 (2H, m), 4.81 (1 H, q, J=6.6Hz), 6.96 (2H, t, J=8.7Hz), 7.10 (2H, s), 7.31 (2H, br s), 7.56 (1 H, s). m/z (Cl+) 524 (M+H, 100%).
b) N-(4-Azidobut-2-vnvn-2-f RH1 -(RH3.5-bis(trifluoromethyl) phenyltethoxy)-3-(SH4-fluorophenvDmorpholine
To a solution of 2-(R)-(1 -(R)-(3,5-bis(thfluoromethyl)phenyl) ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-chlorobut-2-ynyl)morpholine (4g) in dimethyl sulphoxide (17ml) was added sodium azide (0.562g). The solution was stirred for 20h and aqueous ammonium chloride and ethyl acetate were added. The organic phase was washed with water (2 times), saturated brine and dried (MgSO ). The solvent was removed in vacuo and the residue chromatographed on silica gel (eluting with 20% ethyl acetate in petroleum ether bp 60-80°C) to give the title compound. 1H NMR
(360MHz, CDCI3) δ 1.48 (3H, s, J=6.6Hz), 2.87 (1 H, app t, J=10.2Hz), 2.98 (1 H, td, J=3.6, 11.7Hz), 3.35 (2H, t, J=1.9Hz), 3.61 (1H, d, J=2.8Hz), 3.72 (1H, dq, J=1.4Hz, 10.0Hz), 3.92 (2H, t,
J=1.9Hz), 4.30-4.40 (2H, m), 4.89(1 H, q, J=6.6Hz), 7.03 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.27 (2H, br s), 7.63 (1 H, s).
c) 2-(RW1-(R -3.5-Bis(trifluoromethyl)phenvnethoxy)-4-(5- (dimethylaminomethyl)-1.2.3-thazol-4-vnmethyl-3-(S -(4- fluorophenvOmorpholine
Dimethylamine (approximately 10ml) was condensed at -80°C in a pressure tube and to this was added a solution of N-(4-azidobut- 2-ynyl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(S)- (4-fluorophenyl)morpholine (3.2g) in dioxan (15ml). The tube was sealed and the solution was heated at 90°C for 16h. The solution was evaporated to dryness and the residue chromatographed on silica gel (eluting with 5% methanol in dichloromethane containing 0.25% ammonia (SG. 0.88)) and the fractions containing the desired product were evaporated in vacuo to give the title compound. To a solution of this residue in diethyl ether was added 1M-HCI in methanol. The solution was evaporated to dryness and redissolved in diethyl ether to give crystals of the title compound hydrochloride salt m.p. 194-198°C, [α]22 D + 65.0° (c=0.5, H20). The crystals were found to be stable for at least five days at 40°C; at
40°C/75% relative humidity; at 80°C; and at 2000LUX.
EXAMPLE 13 2-(R -(1-(R)-(3.5-Bis(trifluoromethvnphenvnethoxy)-3-(S)-(4- fluorophenyl)-4-(N-(2-methylaminoethylH ,2,4-triazol-3- vDmethylmorpholine: Reqioisomer B
a) 2-(RW1-(R)-(3.5-Bis(trifluoromethvnphenvnethoxy)-4-(N- carbomethoxymethyl-1 ,2.4-triazol-3-v0methyl-3-(S)-(4- fluorophenvDmorpholine
The compound of Description 11 (2.94g), potassium carbonate (2.03g) and methyl bromoacetate (0.74ml) were heated for 45 min in dimethylformamide. The reaction was partitioned between ethyl acetate and water, washed (brine), dried (MgS04) and purified on silica using petrol-ethyl acetate mixtures. Two products, isomer A and isomer B were obtained as white foams. Isomer A: 1H NMR (360MHz, DMSO) δ 7.89 (1 H, s), 7.84 (1 H, s), 7.48 (3H, s), 7.33-7.30 (3H, m, J=10.1), 5.26 (1 H, d, J=17.8), 5.07 (1H, d, J=17.8), 4.96 (1 H, q, J=6.5), 4.39 (1 H, d, J=2.8), 4.04 (1 H, br t, J=10.1 Hz), 3.72 (3H, s), 3.58 (2H, d, J=14.0), 3.51 (1 H, d, J=2.8), 3.20 (1 H, d, J=14.0), 2.55 (1 H, d, J=11.5), 2.37 (1 H, br t, J=3.5), 1.40 (3H, d, J=6.6).
Isomer B: 1H NMR (360MHz, DMSO) δ 8.43 (1H, s), 7.82 (1H, s), 7.44 (2H, d, J=1.4), 7.37 (2H, s), 7.31-7.25 (3H, m, J=3.2), 5.16 (2H, s), 4.91 (1 H, q, J=6.5), 4.35 (1 H, d, J=2.8), 4.08 (1 H, br t, J=10.1 ), 3.69 (3H, s), 3.60 (1H, d, J=8.8), 3.55 (1 H, d, J=2.7), 3.30 (1 H, d, J=8.7), 3.08 (1H, d, J=13.7), 2.95 (1 H, d, J=11.5), 2.47 (1 H, br t, J=3.4), 1.35 (3H, d, J=6.5). MS (Cl+) m/z 573 (M+1 ).
b) 2-(R)-(1-(R)-(3.5-Bis(trifluoromethvnphenyl)ethoxy)-3-(S)-(4- fluorophenyl)-4-(N-(N'-methylcarboxamido)methyl-1 ,2,4-triazol-3- vQmethylmorpholine
Monomethylamine gas was bubbled through a solution of the compound of (a) above (375mg Isomer b) in methanol (25ml) for 10 min and then sealed for 16h. Reaction mixture was evaporated, redissolved in ethyl acetate and concentrated in vacuo to a white
solid (374mg). 1H NMR (250MHz, CDCI3) δ 8.09 (1 H, s), 7.61 (1 H, s), 7.45 (2H, br s), 7.33 (2H, s), 7.31 (1 H, br s), 7.13 (2H, br s), 4.85 (1 H, q, J=6.5Hz), 4.76 (2H, s), 4.37 (1 H, br s), 4.36 (1 H, br s), 3.85 (1 H, d), 3.66 (1 H, br s), 3.63 (1 H, br s), 3.49 (1 H, d), 3.03 (1 H, br s), 2.82 (3H, d), 2.80 (1 H, br s), 1.46 (3H, d). MS (Cl+) 573 (M++1 ).
c) 2-(R)-M-(R)-(3.5-Bis(trifluoromethvnphenvnethoxy)-3-(S)-(4- fluorophenyl)-4-(N-(2-methylaminoethvD-1 ,2,4-thazol-3- vOmethylmorpholine A cooled solution of the compound of (b) above (302mg) in tetrahydrofuran (5ml) and borane-tetrahydrofuran complex (1.59ml, 1M) was stirred for 60 min before heating (60°C) for a further 60 min. The reaction was evaporated and redissolved in CH3OH with K2CO3 before heating to reflux for 30 min. The reaction was poured into ethyl acetate, washed (water x 2, brine), dried (MgSO ).
Purification on silica using CH3OH-dichloromethane mixtures gave the title compound as colourless oil (54mg). 1H NMR (250MHz, CDCI3) δ 7.97 (1 H, s), 7.53 (1 H, s), 7.39 (2H, br s), 7.29-7.23 (3H, m, J=2.6), 7.06 (2H, s), 4.77 (1 H, q, J=6.6), 4.29 (1 H, d, J=2.9), 4.25 (1 H, br t, J=2.6), 4.13 (2H, t, J=5.7), 3.76 (1 H, d, J=14.2), 3.57
(1 H, t, J=3.5), 3.53 (1 H, d, J=2.8), 3.31 (1 H, d, J=14.1 ), 2.95 (1 H, t, J=9.3), 2.92 (2H, t, J=5.9), 2.56 (1 H, br t, J=3.5), 2.36 (3H, s), 2.16 (1 H, br s), 1.37 (3H, d, J=6.6). MS (Cl+) m/z 558 (M++1 ).
Examples 14 to 21 in Table 2 were prepared in a similar manner to that described in Example 12, Method B, via the appropriate N-(4-azidobut-2-ynyl)morpholine and the appropriate amine.
EXAMPLE 22 2-(R)-π-(R)-f3.5-Bisαrifluoromethvnphenyl)ethoxy)-3-(S)- phenyl-4-(1-(2-pyrrolidinoethyl)-1 ,2.4-triazol-3-yl)methylmorpholine
a) 2-(R)-(1- (3.5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(1-(2- oxo-2-pyrrolidinoethvO-1.2,4-triazol-3-yl)methyl-3-(S)- phenylmorpholine
A solution of the compound of Description 19 (2.86g), potassium carbonate (2.37g) and l-bromoacetylpyrrolidine (1.21g) was heated at 60°C in dimethylformamide (15ml). The mixture was cooled and partitioned between water and ethyl acetate. The organic phase was washed with water, brine and dried (MgSO4). The solvent was removed in vacuo and the residue was purified on silica using 1.5% methanol in dichloromethane as eluent. This afforded 2 products isomer A and isomer B.
Isomer A (Alkylation at 2 position of 1 ,2,4-triazole): 1H NMR (250MHz, CDCI3) δ 7.83 (1 H, s), 7.61 (1 H, s), 7.39-7.30 (5H, m), 7.16 (2H, s), 5.00 (1 H, d, J=16.4Hz), 4.88 (1H, q, J=6.6Hz), 4.67 (1 H, d, J=16.4Hz), 4.35 (1H, d, J=2.8Hz), 4.20 (1 H, br t, J=11.6Hz), 3.77 (1 H, d, J=14.4Hz), 3.62 (1 H, dd, J=11.3Hz), 3.51-3.44 (4H, m),
3.39 (1 H, s), 3.33 (1 H, d, J=14.4Hz), 2.90 (1 H, d, J=11.4Hz), 2.74 (1 H, br t, J=11.8Hz), 2.12-2.02 (2H, m), 1.97-1.86 (2H, m), 1.45 (3H, d, J=6.6Hz).
Isomer B (Alkylation at 1 position of 1 ,2,4-triazole). 1H NMR (250MHz, CDCI3) δ 8.19 (1 H, s), 7.60 (1 H, s), 7.47 (2H, br s), 7.36-
7.27 (3H, m), 7.14 (2H, s), 4.89 (2H, s), 4.85 (1 H, q, J=6.6Hz), 4.36 (1 H, d, J=2.8Hz), 4.31 (1 H, br t, J=11.4Hz), 3.86 (1 H, d, J=14.0Hz), 3.60 (1 H, dd, J=11.3Hz), 3.59 (1 H, d, J=2.7Hz), 3.53-3.48 (4H, m), 3.35 (1 H, d, J=14.1 Hz), 3.03 (1 H, d, J=11.8Hz), 2.60 (1 H, br t,
J=11.9Hz), 2.08-2.00 (2H, m), 1.94-1.84 (2H, m), 1.44 (3H, d, J=6.6Hz).
b) 2-(R)-(1-(R -f3.5-Bis(thfluoromethvnphenvnethoxy)-3-(S)- phenyl-4-(1-f2-pyrrolidinoethyl)-1.2,4-triazol-3-vπmethylmorpholine
Lithium aluminium hydride (1.0M solution in tetrahydrofuran, 1.9ml) was added to a solution of the compound described in (a) above (isomer B) in tetrahydrofuran (5ml) at 0°C. The mixture was warmed to room temperature and was stirred for 1h. The mixture was quenched (sodium hydroxide and water) and filtered through celite to remove inorganics. The filtrate was evaporated and purified on silica using 10% methanol in dichloromethane as eluent. This afforded the product as a yellow oil. 1H NMR (250MHz, CDCI3) δ 8.08 (1 H, s), 7.60 (1 H, s), 7.49 (2H, br s), 7.37-7.31 (3H, m), 7.13 (2H, s), 4.85 (1 H, q, J=6.6Hz), 4.36 (1 H, d, J=2.8Hz), 4.33-4.24
(1H, m), 4.22 (2H, t, J=6.5Hz), 3.86 (1H, dd, J=14.1Hz), 3.63 (1H, d, J=9.2Hz), 3.60 (1 H, d, J=2.9Hz), 3.38 (1 H, dd, J=14.0Hz), 3.00 (1 H, d, J=11.7Hz), 2.89 (2H, t, J=6.6Hz), 2.59 (1 H, br t, J=11.9Hz), 2.59-2.49 (4H, m), 1.79 (4H, m), 1.43 (3H, d, J=6.5Hz).
EXAMPLE 23 2-(R)-(1-(R -(3.5-Bis(trifluoromethvnphenvnethoxy)-3-(S)- phenyl-4-(2-(2-pyrrolidinoethyl)-1 ,2,4-triazol-3-yl)methylmorpholine The compound described in Example 22a (isomer A) was reacted according to the procedure described in Example 22b to afford the title compound as a yellow oil. 1H NMR (250MHz, CDCI3) δ 7.80 (1 H, s, CH), 7.61 (1 H, s, ArH), 7.53-7.48 (2H, m, PhH), 7.38- 7.34 (3H, m), 7.17 (2H, s), 4.88 (1 H, q, J=6.5Hz), 4.36 (1 H, d, J=2.9Hz), 4.34-4.20 (1 H, m), 4.23-4.07 (3H, m), 3.83 (1 H, d,
J=14.0Hz), 3.66 (1 H, m), 3.42 (1 H, d, J=2.8Hz), 3.27 (1 H, d, J=14.1Hz), 2.88-2.73 (1 H, m), 2.88-2.73 (2H, m), 2.88-2.73 (1 H, m), 2.50 (3H, br s), 1.73 (4H, br s), 1.4 (4H, d, J=6.6Hz).
EXAMPLE 24
2-(RVπ-(R)-(3.5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4- fluorophenyl)-4-(5-morpholinomethyl-1.2,3τtriazol-4-vπ methylmorpholine
This compound was prepared by the method described in Example 12 (Method A) and purified by chromatography on silica using ethyl acetate, petroleum ether (60-80°C) and methanol (3:10:0, then 1 :0:0 followed by 9:0:1 ) as eluent to afford the title compound as a white foam. 1H NMR (360MHz, CDCI3) δ 1.44 (3H, d, J=6.6Hz), 2.43 (4H, m), 2.57 (1H, dd, J=11.9, 3.4Hz), 2.90 (1 H, d, J=11.6Hz), 3.27 (1 H, d, J=14.1 Hz), 3.46-3.67 (8H, m), 3.82 (1 H, d, J=14.1 Hz), 4.23 (1 H, m), 4.32 (1 H, d, J=2.8Hz), 4.87 (1 H, m), 7.06 (2H, t, J=8.7Hz), 7.16 (2H, s), 7.48 (2H, br s), 7.64 (1H, s). MS (ES+) m/z 618 (MH+, 54%).
Examples 25 to 27 in Table 2 were prepared in a similar manner to that described in Example 12, Method B, via the appropriate N-(4-azidobut-2-ynyl)morpholine and the appropriate amine.
EXAMPLE 28 2-fR)-n-(RV(3.5-Bis(trifluoromethvnphenvnethoxy)-4-(2-chloro-
5-morpholinomethyl-1 ,3-imidazol-4-vD-3-(S)-(4-fluorophenyl) morpholine
The product from Example 7 (0.2g) and phosphorus oxychloride (0.5ml) was heated at reflux for 20 hours. The mixture was cooled
and partitioned between dichloromethane and aqueous potassium carbonate solution. The organic layer was washed (H2O), dried (MgSO4) and evaporated in vacuo. The product was purified by chromatography on silica using 100% ethyl acetate followed by 5% methanol:95% ethyl acetate to afford the title compound as an oil.
MS (ES+) m/z 651 (MH+, 100%).
EXAMPLE 29 2-(R)-(1-(RH3.5-Bis(trifluoromethyl)phenvnethoxy)-4-(5-(N.N- dimethylaminomethyl)imidazol-4-vhmethyl-3-(SW4-fluorophenvπ morpholine
4,5-Bis(chloromethyl)imidazole hydrochloride (British Patent Specification No.GB-2,068,362-A) was reacted with the compound of Description 5 according to the procedure illustrated in Example 4 to afford the title compound as a white solid. 1H NMR (250MHz,
CDCI3) δ 1.44 (3H, d, J=6Hz), 2.19 (3H, s), 2.46-2.62 (1 H, m), 2.92- 3.07 (2H, m), 3.25-3.44 (3H, m), 3.56-3.70 (2H, m), 4.16-4.33 (2H, m), 4.85 (1 H, q, J=6Hz), 7.01-7.17 (4H, m), 7.38-7.67 (4H, m). MS (ES) m/z 575 (M+1 +, 100%).
EXAMPLE 30 2-(RV(1-(R)-(3.5-Bisftrifluoromethvnphenvnethoxy)-4-(5-(N.N- dimethylaminomethyl)-1.2.4-triazol-3-v0methyl-3-(SH4- fluorophenvQmorpholine 3,5-Bis(chloromethyl)triazole (J. Het. Chem. (1986) 23, 361-
368) was reacted with the compound of Description 5 according to the procedure illustrated in Example 4 to afford the title compound as a solid. 1H NMR (250MHz, CDCI3) δ 1.27 (3H, d, J=6.6Hz), 2.15 (6H, s, CH3), 2.43 (1 H, dt, J=11.7, 3.2Hz), 2.79-2.83 (1 H, m), 3.16
(1 H, d, J=14.5Hz), 3.38 (1 H, d, J=2.8Hz), 3.43-3.48 (1 H, m), 3.48 (2H, s, CH2), 3.63 (1 H, d, J=14.5Hz), 4.12 (1 H, dt, J=11.7, 3.2Hz), 4.15 (1 H, d, J=2.8Hz), 4.69 (1H, q, J=6.6Hz), 6.85 (2H, t, J=8.75Hz), 6.97 (2H, s), 7.27 (2H, br t), 7.45 (1 H, s). MS (ES) m/z 576 (M++1 , 100%).
Examples 31 to 37 in Table 2 were prepared in a similar manner to that described in Example 12, Method B, via the appropriate N-(4-azidobut-2-ynyl)morpholine and the appropriate amine.
Examples 38 to 41 in Table 1 were prepared in a similar manner to that described in Example 4 from the appropriate morpholine, 4,5-bis(bromomethyl)-1 ,3-diacetyl-2-imidazolinone and the appropriate amine.
EXAMPLE 42 2-(RM1- )-Bis(trifluoromethv0phenyl)ethoxy)-3-(S)-f4- fluorophenyl)-4-(2.3-dihvdro-2-oxo-5-thiomorpholinomethyl-1 ,3- imidazol-4-yl)methylmorpholine S-oxide The compound of Example 38 (67mg; 1eq) was dissolved in
CF3C0 H (0.3ml) under N2 then cooled to 0° C and a solution of CF3C03H (2M in CF.CO.H; 57μl; 1.1 eq) was added. After stirring at 0° C for 1 h the solvent was removed in vacuo and the residue dissolved in EtOAC and washed with saturated aqueous. NaHCO. solution, dried (K2CO3) and concentrated to leave a yellow foam.
This was purified by column chromatography using MeOH/CH2CI2/NH3 (3:97:0.25) as eluant to provide the title compound as a white solid. 1H NMR (250MHz, CDCI3) δ 9.48 (1 H, s), 8.66 (1 H, s), 7.64 (1 H, s), 7.40 (2H, m), 7.14 (2H, s), 7.06 (2H, t,
J=8.6Hz), 4.87 (1H, q, J=6.5Hz), 4.30 (1 H, d, J=2.7Hz), 4.23 (1 H, t, J=10.0Hz), 3.65 (1 H, d, J=9.6Hz), 3.45 (1H, m), 3.75 (1 H, m), 3.36 (1 H, d, J=2.7Hz), 3.30 (1 H, d, J=14Hz), 3.20 (1 H, d, J=14Hz), 3.05- 2.60 (9H, m), 2.36 (1 H, m), 1.46 (3H, d, J=6.5Hz).
Examples 43 to 62 in Table 2 were prepared in a similar manner to that described in Example 12, Method B, via the appropriate N-(4-azidobut-2-ynyl)morpholine and the appropriate amine.
EXAMPLE 63
2-(RH1 -(R)-(3.5-Bis(trifluoromethvnphenyl)ethoxy)-4-M -(2- (N.N-disopropylamino)ethvn-1.2.4-triazol-3-v0methyl-3-(S)- phenylmorpholine
(a) 2-fR)-(1-(RM3.5-Bis(trifluoromethyl)phenvnethoxy)-4-(1-f2- hvdroxyethvπ-1.2,4-triazol-3-vπmethyl-3-(S)-phenylmorpholine
The compound of Description 19 (3.90g, 7.8mM) was heated (60°C) in dimethylformamide (20ml) containing 2-bromoethanol (1.66ml, 23.4mM) and potassium carbonate (3.23g, 23.4mM) for 2 hrs. The reaction was poured into ethyl acetate and washed with water and brine, dried (MgSO4) and evaporated. The two isomers were purified and separated on silica eluting with methanol- dichloromethane mixtures (3.06g). MS (ES+) m/z 545.
(b) 2-fR)-(1-(R)-(3.5-Bis(trifluoromethvnphenyl)ethoxy)-3-(S)- phenyl-4-(1-(2-tosyloxyethv0-1 ,2,4-triazol-3-yl)methylmorpholine
The alcohol from step (a), above, (1.81g, 3.22mM) was dissolved in dichloromethane (20ml), tosyl chloride (1.84g, 9.66mM) and triethylamine (1.34ml, 9.66mM) were added and the reaction stirred at room temperature for 18hrs. The solvent was
removed and the residue redissolved in ethyl acetate and washed with water and brine, dried (MgSO4) and evaporated. The product was purified on silica eluting with methanol-dichloromethane mixtures (1.87g).
(c) 2-(RH1 -( RH3.5-Bis(trifluoromethvDphenvDethoxy)-4-( 1 -(2- (N.N-disopropylamino)ethyl)-1.2.4-triazol-3-vnmethyl-3-(S)- phenylmorpholine
The tosylate from step (b), above, (0.29g, 0.41 mM) was dissolved in dimethylformamide (5ml), dipropylamine (0.18ml,
1.24mM) and t ethylamine (0.18ml, 1.24mM) were added and the reaction heated in a sealed tube for 18hrs. The residue was dissolved in ethyl acetate, washed with water and brine, dried (MgSO ) and evaporated. Purification on silica eluting with methanol-dichloromethane mixtures afforded the title compound
(0.095g). 1H NMR (360MHz, d6-DMSO) δ 8.31 (1 H, s), 7.82 (1H, s), 7.46-7.42 (2H, m), 7.36 (2H, s), 7.32-7.22 (3H, m), 4.89-4.92 (1 H, q, J=6.5Hz), 4.34 (1 H, d, J=2.8Hz), 4.18-4.04 (3H, m), 3.60-3.56 (3H, m), 3.09 (1H, d, J=13.6Hz), 3.94 (1H, d, J=11.5Hz), 2.71 (2H, t, J=5.8Hz), 2.44-2.40 (1 H, m), 2.30 (4H, t, J=7.0Hz), 1.34 (3H, d,
J=6.5Hz), 1.32-1.20 (4H, m) and 0.73 (6H, t, J=7.4Hz). M/S+628.
Examples 64 to 74 in Table 3 were prepared in a similar manner to that described in Example 63 from the appropriate 1 ,2,4-triazol-3- ylmethylmorpholine and the appropriate amine.
EXAMPLE 75 2-(R)-(1-(R)-3.5-Bisftrifluoromethvnphenyl)ethoxy)-4-(5-(N.N- dimethylaminomethvO-1 ,2.4-triazol-3-vOmethyl-3-(S)-(4- fluorophenvPmorpholine
(a) 2-fR)-(1-(R)-3.5-Bis(trifluoromethvnphenyl)ethoxy)-3-(S)-(4- fluorophenvO-4-(1-(tetrahvdro-2-pyranyl)-5-(N.N- dimethylaminomethv0-1 H-1.2,4-triazol-3-yl)methylmorpholine The compound of Description 5 (1g, 2.28mM) was dissolved in isopropanol (20ml), 3,5-bis(chloromethyl)-1-(tetrahydro-2-pyranyl)-
1 H-1 ,2,4-triazole (1.14g, 4.57mM) (prepared by method of Bradshaw, J. Het. Chem. (1986), 23, 361 ) and potassium carbonate (0.95g, 6.84mM) were added and the reaction heated to 60° C for 18hrs. Dimethylamine (3eq) was then added and the reagents transferred to a sealed tube and heated for a further 18hrs. The solvents were then removed and the residue purified on silica eluting with methanol dichloromethane-ammonia mixtures to yield the title compound (0.62g).
(b) 2-(R)-(1-(RV3.5-Bis(trifluoromethvnphenvnethoxy)-4-(5-
(N,N-dimethylaminomethylH .2.4-triazol-3-v0methyl-3-(SH4- fluorophenvDmorpholine
The protected amine from step (a), above, (0.62g, 0.94mM) was dissolved in methanol (15ml) and treated with HCI in methanol (1 N, 25ml) and stirred at room temperature for 1 hour. The solvent was then removed and the residue purified on silica eluting with methanol-dichloromethane ammonia mixtures to yield the title compound (0.48g). 1H NMR (250MHz,CDCi3) δ 7.45 (1 H, s), 7.30- 7.22 (2H, m), 6.97 (2H, s), 6.85 (2H, t, J=8.7Hz), 4.72-4.66 (1 H, q,
J=6.5Hz), 4.15 (1 H, d, J=2.8Hz), 4.15-4.07 (1 H, m), 3.63 (1 H, d, j=14.4Hz), 3.48 (4H, s), 3.44-3.41 (1H, m), 3.38 (1 H, d, J=2.8Hz), 3.16 (1 H, d, J=14.5Hz), 2.81 (1 H, d, J=11.1 Hz), 2.50-2.39 (1H, m), 2.15 (6H, s) and 1.27 (3H, d, J=6.6Hz). M/S ES+ 576.
EXAMPLE 76 4-(5-(N,N-Dimethylaminomethyl)-1.2.3-triazol-4-yl)methyl-3-fS)- (4-fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethvn phenyl)ethoxy)morpholine The compound of Example 57 (270mg, 0.51 mmol) was heated to 120°C with sodium thiomethoxide (178mg, 2.55mmol) in anhydrous DMF (10ml) for between 2-5 hours. The cooled solution was diluted with water (150ml), extracted with ethyl acetate (4 x 40ml), dried (MgSO4) and concentrated in vacuo to a crude oil (372mg) which was purified by flash silica gel chromatography in 5-
10% methanol/dichloromethane to yield the title compound as a viscous gum/glass (170mg, 60%). 1H NMR (360MHz,CDCI3) δ 1.31 (3H, d, J=6.6Hz), 2.17 (6H, s), 2.28 (3H, s), 2.47 (1 H, dt, J=12.1 , 3.4Hz), 2.82 (1 H, d, J=11.6Hz), 3.14 (1 H, d, J=13.9Hz), 3.35 (2H, m), 3.46 (1 H, d, J=13.5Hz), 3.52 (1 H, dd, J=11.2, 1.9Hz), 3.70 (1 H, d, J=13.9Hz), 4.14 (1 H, dt, J=11.6Hz), 4.26 (1 H, d, J=2.7Hz), 4.66 (1 H, q, J=6.5Hz), 6.64 (2H, s), 6.99 (2H, t, J=8.6Hz), 7.11 (1 H, s), 7.41 (2H, br s), 10.0-10.8 (1 H, vbr s); MS (ES+) m/z 554 (M+1 , 100%).
EXAMPLE 77 3-(SH4-Fluorophenyl)-2-(RH1-(RH3-methylthio-5- (trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidinomethyl-1 ,2.3-trιazol- 4-vQmethylmorpholine
The title compound was prepared from the compound of Example 18 according to the method of Example 76 as a foam (620mg, 81%). 1H NMR (360MHz,CDCI3) δ 1.40 (3H, d, J=6.6Hz), 1.79 (4H, br s), 2.36 (3H, s), 2.5-2.6 (5H, m), 2.87 (1 H, d, J=11.7Hz), 3.23 (1 H, d, J=13.9Hz), 3.43 (1 H, d, J=2.8Hz), 3.57- 3.64 (2H, m), 3.71 (1H, d, J=13.7Hz), 3.78 (1 H, d, J=14.0Hz), 4.21 (1 H, m), 4.33 (1 H, d, J=2.8Hz), 4.74 (1 H, q, J=6.5Hz), 6.71 (2H, s), 7.06 (2H, t, J=8.7Hz), 7.19 (1 H, s), 7.47 (2H, br s); MS (ES+) m/z 580 (M+1 , 100%).
EXAMPLE 78 3-(SH4-Fluorophenvn-2-(R)-(1-(RH3-methylthio-5- (trifluoromethvπphenyl)ethoxy)-4-(5-morpholinomethyl-1.2,3-triazol- 4-yl)methylmorpholine The title compound was prepared from compound of Example
19 according to the method of Example 76 as a foam (126mg, 66%). 1H NMR (360MHz, CDCI3) δ 1.40 (3H, s, J=6.6Hz), 2.37 (3H, s), 2.32-2.49 (4H, m), 2.54 (1 H, dt, J=11.9, 3.4Hz), 2.90 (1 H, d, J=11.7Hz), 3.25 (1 H, d, J=13.9Hz), 3.48 (1 H, d, J=13.5Hz), 3.57- 3.68 (7H, m), 3.82 (1H, d, J=14.1 Hz), 4.23 (1 H, m), 4.35 (1 H, d,
J=2.8Hz), 4.75 (1 H, q, J=6.5Hz), 6.71 (2H, s), 7.06 (2H, t, J=8.7Hz), 7.19 (1 H, s), 7.49 (2H, br s); MS (ES+) m/z 596 (M+1 , 55%), 203 (100%).
EXAMPLE 79
4-(5-(N,N-Dimethylaminomethvπ-1.2.3-triazol-4-yl)methyl-2-(R)- (1-(R)-f3-methylthio-5-(trifluoromethvnphenvnethoxy)-3-(S)- phenylmorpholine
The title compound was prepared from the triazole of Example 102 according to the method of Example 76 as a foam (116mg, 36%). 1H NMR (250MHz,CDCI3) δ 1.39 (3H, d, J=6.5Hz), 2.24 (6H, s), 2.32 (3H, s), 2.59 (1 H, dt, J=11.8, 3.3Hz), 3.25 (1 H, d, J=13.8Hz), 3.38-3.44 (2H, m), 3.52 (1 H, d, J=13.6Hz), 3.62 (1 H, dd,
J=11.2, 1.8Hz), 3.81 (1 H, d, J=13.9Hz), 4.23 (1 H, m), 4.39 (1 H, d, J=2.6Hz), 4.75 (1 H, q, J=6.5Hz), 6.71 (2H, s), 7.17 (1H, s), 7.34- 7.41 (3H, m), 7.49 (2H, br s); MS (ES+) m/z 536 (M+1 , 100%).
EXAMPLE 80
4-(5-(N.N-Dimethylaminomethyl)-1.2.3-triazol-4-yl)methyl-3-(S)- (4-fluorophenvn-2-(R)-(1-(RW3-.et -butylthio-5-(thfluoromethvn phenyl)ethoxy)morpholine
The title compound was prepared from the compound of Example 57 according to the method of Example 76 as a foam
(117mg, 68%). 1H NMR (360MHz,CDCI3) δ 1.19 (9H, s), 1.42 (3H, d, J=6.6Hz), 2.23 (6H, s), 2.57 (1 H, dt, J=12.0, 3.5Hz), 2.92 (1 H, d, J=11.6Hz), 3.24 (1 H, d, J=13.9Hz), 3.39-3.44 (2H, m), 3.51 (1 H, d, J=14.8Hz), 3.62 (1 H, m), 3.80 (1 H, d, J=13.9Hz), 4.23 (1 H, m), 4.41 (1 H, d, J=2.7Hz), 4.77 (1 H, q, J=6.5Hz), 6.89 (1 H, s), 7.14 (1 H, s),
7.31-7.35 (3H, m), 7.46 (2H, br s), 7.51 (1 H, s); MS (ES+) m/z 578 (M+1 , 100%).
EXAMPLE 81 4-(5-(N.N-Dimethylaminomethvn-1.2.3-triazol-4-yl)methyl-3-(S)-
(4-fluoroρhenvπ-2-(R)-(1-(R)-(3-methylsulphinyl-5-(trifluoromethyl) phenyl)ethoxy)morpholine
The thioether of Example 76 (155mg, 0.28mmol) was dissolved in trifluoroacetic acid (800μl) cooled to 0°C and treated with a 2.0M
solution of trifluoroperacetic acid in trifluoroacetic acid (153μl, 0.308mmol), with stirring for 30 minutes. The reaction mixture was poured into 0.5M sodium bicarbonate solution (50ml), extracted with dichloromethane (3 x 15ml), dried (MgSO4) and concentrated in vacuo. The resulting crude solid (200mg) was purified by flash silica gel chromatography in 8% methanol : dichloromethane to yield the title compound as unresolved stereoisomers as a white foam (81 mg, 51%). 1H NMR (360MHz,CDCI3) δ 1.44 and 1.46 (3H total, 2 x d, J=6.6Hz), 2.24 (6H, s), 2.56 (1 H, m), 2.59 and 2.62 (3H total, 2 x s), 2.88 (1 H, d, J=11.9Hz), 3.23 and 3.26 (1 H total, 2 x d,
J=13.9Hz), 3.42-3.55 (3H, m), 3.62 (1 H, br d, J=11.3Hz), 3.75 and 3.79 (1 H total , 2 x d, J=14.4Hz), 4.22 (1 H, m), 4.32 and 4.35 (1 H total, 2 x d, J=2.7Hz), 4.89 (1 H, m), 6.85 (1/2H, s), 7.04-7.13 (3H, m), 7.24 (1 H, s), 7.50 (2H, br s), 7.73 and 7.75 (1 H total, 2 x s); MS (ES+) m/z 570 (M+1 , 100%).
EXAMPLE 82 3- SH4-Fluoroρhenvn-2-(RH1-(RH3-methylsulphinyl-5- (trifluoromethyl) phenyl)ethoxy)-4-(5-pyrrolidinomethyl-1.2.3-triazol- 4-yl)methylmorpholine
The title compound as an unresolved mixture of stereoisomers was prepared from Example 77 according to the method of Example 81 as a foam (90mg, 63%). 1H NMR (360MHz,CDCI3) δ 1.44 and 1.46 (3H total, 2 x d, J=6.6), 1.86 (4H, br s), 2.50-2.60 (1 H, m), 2.59 and 2.62 (3H total, 2 x s), 2.70-2.90 (5H, m), 3.24 and 3.26 (1 H, 2 x d, J=14.0), 3.46 (1 H, d, J<2), 3.62 (1 H, br d, J=11.2), 3.71-3.86 (3H, m), 4.20 (1 H, m), 4.32 and 4.35 (1 H total, 2 x d, J=2.7), 4.89 (1 H, m), 6.89 (1/2H, s), 7.03-7.13 (3H, m), 7.25 (1/2H, s), 7.49 (2H, br s), 7.73 and 7.75 (1 H total, 2 x s); MS (ES+) m/z 596 (M+1 ), 100%).
EXAMPLE 83 3-(SH4-Fluorophenvn-2-(R 1-fR)-(3-methylsulρhinyl-5- (trifluoromethyl) phenyl)ethoxy)-4-(5-morpholinomethyl-1.2.3- triazol-4-yl)methylmorpholine
The title compound as an unresolved mixture of stereoisomers was prepared from Example 78 according to the method of Example 81 as a foam (113mg, 92%). 1H NMR (360MHz,CDCI3) δ 1.3 and 1.41 (3H total, 2 x d, J=6.6), 2.54 and 2.57 (3H total, 2 x s), 2.54- 2.65 (1 H, m), 2.82-2.89 (1 H, m), 3.05-3.25 (4H, vbr s), 3.35 (1 H, m),
3.50 (1H, m), 3.61 (1H, m), 3.72 and 3.74 (1 H, 2 x d, J=14.5), 3.85- 4.22 (6H, m), 4.29 and 4.33 (1 H, 2 x d, J=2.5), 4.81 (1 H, m), 6.99- 7.09 (3Y2H, m), 7.30 ( H, s), 7.42 (2H, br s), 7.64 and 7.66 (1 H total, 2 x s); MS (ES+) m/z 612 (M+1, 100%).
EXAMPLE 84 3-(S)-(4-FluorophenylV2-(RH1- RH3-methylsulphonyl-5- (trifluoromethyl) phenyl)ethoxy)-4-(5-morpholinomethyl-1 ,2,3- triazol-4-yl)methylmorpholine The sulphoxide of Example 83 (78mg, 0.128mmol) was dissolved in trifluoroacetic acid (500μl) cooled to 0°C and treated with a 2.0M solution of t fluoroperacetic acid in trifluoroacetic acid (70μl, 0.140mmol) with stirring for 21 _ hours. A further equivalent of trifiuoroperacetic acid (70μl, 0.140mmol) was added after this time and the product purified after 3 hours according to the method of
Example 81 to yield the title compound as a foam (27mg, 34%). 1H NMR (360MHz,CDCI3) δ 1.47 (3H, d, J=6.6Hz), 2.38-2.45 (4H, m), 2.57 (1 H, dt, J=11.9, 3.5), 2.90 (1 H, d, J=11.7Hz), 2.96 (3H, s), 3.26 (1 H, d, J=14.0Hz), 3.46-3.51 (2H, m), 3.56-3.68 (6H, m), 3.79 (1 H,
d, J=14.1 Hz), 4.22 (1 H, m), 4.35 (1 H, d, J=2.8Hz), 4.90 (1 H, q, J=6.8Hz), 7.07 (2H, t, J=8.6Hz), 7.17 (1 H, s), 7.50 (2H, br d), 7.67 (1 H, s), 7.97 (1 H, s); MS (ES+) m/z 628 (M+1 , 100%).
EXAMPLE 85
2-(R)-(1-(RW3.5-Bis(trifluoromethvnphenvnethoxy)-3-(S)-(4- fluorophenvπ-4-(2-(5-((SH+)-2-methoxymethylpyrrolidinomethvπ- 1.2.3-triazol-4-v0ethv0morpholine
Step A 2-fR 1-(RW3.5-Bis(thfluoromethvnphenyl)ethoxy)-4-
(but-3-vnviy-3-(SH4-fluorophenvOmorpholine
A solution of Description 5 (1.24g; 1eq), 3-butyn-1 -ol-tosylate (1.43g; 2.5 eq), K2CO3 (1.32g; 3.7 eq) and Nal (cat) in dry DMF (7ml) was heated at 100°C for 12h. After cooling to room temperature the reaction mixture was partitioned between H2O and
EtOAc. The layers were separated and the aqueous phase extracted with EtOAc (2x). The combined organic phases were dried (MgSO4) and concentrated and the residue purified by chromatography (hexanes/EtOAc 9:1→4:1 ) to provide the title compound as a clear cololourless oil. MS m/z 490 (MH+).
Step B 2-(R)-(1-(R)-(3.5-Bis(trifluoromethvnphenvnethoxy)-3- (SM4-fluorophenyl -(4-hvdroxybut-3-vnvDmorpholine
The acetylene of Step A (1.2g; 1.Oeq) was dissolved in dry THF (5ml) then cooled to -78°C and n-BuLi (2.5M in hexane; 1 ml;
1.05eq) was added. The reaction mixture was stirred at -78°C for 1 h, then HCHO gas was bubbled through the solution until it was saturated. The reaction mixture was warmed to room temperature and stirred for 1h. Work-up (NH4CI/EtOAc) followed by purification
on silica gel (hexanes/EtOAc 9:1→4:1) provided the title compound as a clear, viscous oil. MS m/z 520 (MH+).
Step C 2-(fRW1-(R)-(3.5-Bis(trifluoromethvnphenyl)ethoxy)-4- (4-chlorobut-3-vnyl)-3-(SH4-fluorophenvDmorpholine
The alcohol of Step B (0.42g; 1eq) was dissolved in dry THF (5ml) under N2 and triphosgene (84mg; 0.35 eq) was added followed by pyridine (128 μl; 2.0 eq). The reaction mixture was stirred at room temperature for V∑ , then diluted with EtOAc and washed with H O and brine, dried (MgS04) and concentrated to leave a yellow oil. This was purified by chromatography (hexanes/EtOAc 9:1→ :1 ) to provide the title compound as a clear, viscous oil. MS m/z 538, 540 (MH+).
Step D N-(4-Azidobut-3-vnvn-2-(R)-(1-(R)-(3,5- bis(trifluoromethvπphenyl)ethoxy)-3-(SW4-fluorophenvπmorpholine
The chloride of Step C (0.23g; 1eq) and NaN3 (31 mg; 1eq) in DMSO (0.8ml) was stirred at room temperature for 14h. Work-up (NH4CI/EtOAc) provided the title compound as an oil, which was used without further purification.
Step E 2-(R)-f1-fR)-(3.5-Bis(trifluoromethvnphenyl)ethoxy)-3- (S)-(4-fluorophenvn-4-(2-(5-((S)-f+)-2- methoxymethylpyrrolidinomethyl)-1.2,3-triazol-4-yl)ethyl)morpholine A solution of the azide of Step D (0.205g; 1 eq) and (S)-(+)-2- methoxymethylpyrrolidine (114μl; 3 eq) was heated at 80°C under N2 the solvent was removed in vacuo and the residue purified by chromatography using CH2CI2/MeOH/NH3 (98:2:0.1 then 97:3:0.1 ) as eluant to provide the title compound as a white foam. 1H NMR
(250MHz, CDCI3) δ 7.62 (1 H, s), 7.24 (2H, m), 7.14 (2H, s), 6.95 (2H, t, J=8.7Hz), 4.87 (1 H, q, J=6.5Hz), 4.30 (2H, m), 3.95 (1 H, d, J=14Hz), 3.70 (1 H, dd, J=2, 11.3Hz), 3.53-3.34 (7H, m), 3.19 (1 H, d, J=11.6Hz), 2.86-2.56 (6H, m), 2.29 (1 H, m), 2.09 (1 H, m), 1.88 (1 H, m), 1.70 (3H, m), 1.45 (3H, d, J=6.5Hz). MS m/z=660.
EXAMPLE 86 2-(R)-π-(S)-(3.5-Bis(trifluoromethyl)phenyl)-2-hvdroxyethoxy)-4- (5-(N.N-dimethylaminomethvn-1.2.3-triazol-4-yl)methyl-3-(S)-(4- fluorophenvOmorpholine
Step A 2- )-(1-fSK3.5-Bis(trifluoromethvnphenvn-2-.etf- butyldimethylsilyloxyethoxy)-3-(S)-(4-fluorophenyl)morpholine The product from Description 21 (2g) was dissolved in anhydrous dichloromethane (16ml), under nitrogen, and cooled to
0°C. 2,6-Lutidine (0.5ml) and -etf-butyldimethyltrifluoromethane sulfonate (1.0ml) were then added and the mixture stirred for 15 mins. The reaction mixture was washed (H2O, brine), dried (MgS04) and evaporated in vacuo. Purification by gravity silica column using 20%-50% ethylacetate/petrol as eluant afforded the title compound as a colourless oil.
1H NMR (250MHz, CDCI3) δ -0.04 (3H, s), 0.00 (3H, s), 0.87 (9H, s), 3.15-3.36 (2H, m), 3.64-3.70 (2H, m), 3.90-3.96 (1 H, m), 4.10 (1 H, d, J=2.2Hz), 4.22-4.53 (1 H, m), 4.53 (1 H, d, J=2.2Hz), 4.91 (1 H, t, J=5.9Hz), 7.04-7.14 (2H, m), 7.29-7.36 (4H, m), 7.74 (1 H, br s). MS (ES+) m/z=567.
Step B 2-(R)-(1-(S)-(3.5-Bis(trifluoromethvnphenvn-2-terr- butyldimethylsilyloxyethoxy)-3-(SH4-fluorophenyl)-4-(4-chlorobut- 2-vnyl)morpholine
Prepared in an analogous fashion to Step (a) of Example 12, Method B, using the product from Step A, above, to afford the title compound as a clear oil. 1H NMR (360MHz, CDCI3) δ 0.00 (3H, s), 0.04 (3H, s), 0.91 (9H, s), 2.95-3.09 (2H, m), 3.40 (2H, br s), 3.72- 3.83 (3H, m), 4.01 (1 H, dd, J=10.2, J=5.5Hz), 4.25 (2H, m), 4.50 (2H, m), 4.9 (1 H, t, J=5.9Hz), 7.15 (2H, t, J=8.7Hz), 7.29 (2H, s), 7.52 (2H, br s), 7.76 (1 H, s).
Step C 2-(RW1-(SH3.5-Bisftrifluoromethvnphenvn-2-ter.- butyldimethylsilyloxyethoxy -(5-(N,N-dimethylaminomethvO-1 ,2,3- triazol-4-yl)methyl-3-(SM4-fluorophenv0morpholine Prepared in an analogous fashion to Steps (b) and (c) of
Example 12, Method B, using the product of Step B, above, to afford the title compound. 1H NMR (250MHz, CDCI3) δ -0.02 (3H, s), 0.00 (3H, s), 0.88 (9H, s), 2.30 (6H, s), 2.60-2.70 (1 H, m), 2.93-2.98 (1 H, br d, J=11.6Hz), 3.30 (1 H, d, J=13.8Hz), 3.48-3.63 (3H, m), 3.68-3.74 (2H, m), 3.84-3.97 (2H, m), 4.33-4.41 (1 H, m), 4.46 (1 H, d, J=2.8Hz), 4.90 (1 H, t, J=5.6Hz), 7.16 (2H, t, J=8.7Hz), 7.25 (2H, br s), 7.59 (2H, vbr m), 7.74(1 H, br s).
Step D 2-(RH1-(SH3.5-Bis(trifluoromethyl)phenvn-2- hvdroxyethoxy)-4-(5-(N,N-dimethylamιnomethyl)-1 ,2.3-triazol-4- yDmethyl-3-(SH4-fluorophenyl)morpholine
The product of Step C, above, (0.2g) was stirred in anhydrous tetrahydrofuran (2ml) with tetrabutylammonium fluoride (1.0M) in tetrahydrofuran (0.42ml) for 30 minutes. The mixture was
partitioned between ammonium chloride solution and ethylacetate, and the organic layer washed (H20, brine), dried (MgSO4) and evaporated in vacuo. Purification by gravity silica column eluting with 4-10% MeOH/0.1 % NH4OH/dichloromethane afforded the title compound. 1H NMR (250MHz, CDCI3) δ 2.26 (6H, s), 2.51 (1 H, m),
3.09 (2H, m), 3.35 (2H, m), 3.51-3.63 (4H, m), 3.78 (2H, d, J=13.8Hz), 4.30^.36 (2H, m), 4.88 (1 H, m), 7.01-7.10 (4H, m), 7.50 (2H, vbr s), 7.59 (1 H, br s).
EXAMPLE 87
2-(R)-(1-(RW3.5-Bis(trifluoromethvnphenvnethoxy)-4-(5-N-ethyl- N-isopropylaminomethvP-1 (or 2 or 3)-methyl-1.2.3-triazol-4- vDmethyl-3-(S)-phenylmorpholine
The product from Example 101 (2g) was dissolved in N,N- dimethylformamide (4ml) at room temperature under nitrogen. lodomethane was added, followed by sodium hydride (60%) (14mg) and the mixture stirred for 16 hours. The reaction mixture was partitioned between ethylacetate and water and the organic layer was washed (H2O x 2, brine), dried (MgS0 ) and evaporated in vacuo. Purification by gravity silica chromatography eluting with
100% ethylacetate followed by 10% methanol/0.1 % NH4OH/dichloromethane afforded the title compound.
1H NMR (250MHz, CDCI3) δ 0.85-1.02 (9H, m), 1.44 (3H, d, J=6.6Hz), 2.25-2.40 (2H, m), 2.57-2.68 (1 H, m), 2.75-2.85 (1 H, m), 2.96 (1 H, br d, J=13.5Hz), 3.15 (1 H, d, J=13.5Hz), 3.38 (1 H, d,
J=2.7Hz), 3.44 (2H, s), 3.60-3.73 (2H, m), 4.07 (3H, s), 4.18 (1 H, m), 4.35 (1 H, d, J=2.8Hz), 4.83 (1 H, m), 7.15 (2H, br s), 7.33 (3H, m), 7.48 (2H, vbr s), 7.61 (1 H, br s). MS (ES+) m/z=613 (MH+, 100%).
EXAMPLE 88 2-(R)-(1-(SW3.5-Bis(trifluoromethvnphenvn-2-hvdroxyethoxy)-3- (S)-(4-fluorophenvn-4-(2.3-dihvdro-3-oxo-1.2.4-triazol-5- vOmethylmorpholine
The compound of Description 6 (0.5g), N-carbomethoxy-2- chloroacetamidrazone (Description 23) (182mg) and potassium carbonate (0.3g) were suspended in dimethylformamide (3.6ml) and the mixture was heated to 60°C for 2h. The mixture was then heated to 140°C for a further 2h. The mixture was cooled and the inorganic material was removed by filtration through celite. The solvent was removed in vacuo by azeotroping with xylene. The residue was purified on silica by flash chromatography using 1-10% methanol in dichloromethane. This afforded the title compound as a white powder (300mg). 1H NMR (360MHz, DMSO-d6) δ 2.38-2.41
(1 H, m), 2.78 (1 H, d, J=14.0Hz), 2.81-2.84 (1 H, m), 3.36 (1 H, d, J=14.0Hz), 3.45-3.48 (1 H, m), 3.52 (1 H, d, J=3.0Hz), 3.58-3.61 (2H, m), 4.81 (1 H, t, J=6.0Hz), 4.88 (1 H, br t), 7.09 (2H, t, J=9.0Hz), 7.33 (2H, s), 7.50 (2H, br t), 7.85 (1 H, s), 11.26 (1 H, s), 11.30 (1 H, s). MS (Cl+) m/z 551 (M+1 , 10%), 454 (M+-CH2triazolone, 20).
EXAMPLE 89 2-(R)-(1-(S)-(3,5-Bis(trifluoromethyl)phenyl)-2-hvdroxyethoxy)-3- (S)-(4-fluorophenyl)-4-(1.2,4-thazol-3-yl)methylmorpholine The compound of Description 6 (270mg), anhydrous potassium carbonate (250mg), and N-formyl-2-chloroacetamidhydrazone (92mg) (prepared according to I. Yanagisawa, J. Med. Chem. (1984), 27, 849) were heated at 60°C in anhydrous dimethylformamide for 1 h and then at 140°C for 2h. The reaction
mixture was cooled and diluted with water (100ml). The product was extracted into ethyl acetate (3 x 50ml) and the organic layer was washed with brine, dried (MgSO ) and evaporated in vacuo. The residue was purified by chromatography on silica using 7% methanol in dichloromethane as the eluant. This afforded the title compound (200mg, 60%) as a white solid. 1H NMR (360MHz, DMSO-d6) δ 2.47 (1 H, t, J=9.0Hz), 2.89 (1H, d, J=11.0Hz), 3.18 (1 H, d, J=14.0Hz), 3.44-3.49 (1 H, m), 3.55-3.61 (4H, m), 3.64 (1 H, d, J=6Hz), 4.25 (1 H, t, J=11.OHz), 4.34 (1 H, d, J=3.0Hz), 4.81 (1 H, t, J=5.0Hz), 7.11 (2H, t, J=9.0Hz), 7.34 (2H, s), 7.52 (2H, m), 7.85
(1H, s), 8.19 (1H, br s). MS (CI) m/z 535 (M+1 , 10%).
EXAMPLE 90 4- 2.3-Dihvdro-3-oxo-1 ,2.4-triazol-5-yl)methyl-3-(SH4- fluorophenvn-2- H1-fS)-(3-fluoro-5-(thfluoromethyl)phenvn-2- hvdroxyethoxy)morpholine
The compound of Description 22 (350mg), N-carbomethoxy-2- chloroacetamidrazone (150mg) (Description 23) and potassium carbonate (150mg) in dimethylformamide were heated at 60°C for 3h until all starting material was consumed. The mixture was then heated at 140°C for 3h. The mixture was cooled and filtered through celite to remove inorganics. The residue was evaporated using xylene to azeotrope residual dimethylformamide. The residue was purified by chromatography on silica using 1-10% methanol in dichloromethane as eluant. This afforded the title compound as a foam which was recrystallised from ether. 1H NMR (360MHz, DMSO-de) δ 2.34-2.46 (1 H, m), 2.74-2.84 (2H, m), 3.34-3.43 (3H, m), 3.50-3.60 (2H, m), 4.21-4.31 (2H, m), 4.68 (1 H, t, J=5.0Hz),
4.90 (1 H, t, J=7.0Hz), 6.54 (1 H, d, J=9.0Hz), 6.88 (1 H, s), 7.14 (t, J=9.0Hz), 7.42 (1 H, d, J=9.0Hz), 7.44 (2H, m).
EXAMPLE 91 4-(2.3-Dihvdro-2-oxo-1.3-imidazol-4-yl)methyl-2-(RH1-(S 3.5- bis(trifluoromethvθphenvπ-2-hvdroxyethoxy)-3-(SH4-fluorophenvO morpholine
A mixture of the compound of Description 6 (2g), 4-bromomethyl- 1 ,3-diacetyl-2-imidazolone (1.38g) (prepared by the method of Dolan and Dushinsky, JACS (1948) 70, 657) and potassium carbonate
(1.2g) in dimethylformamide (14ml) was stirred at room temperature for 30 minutes until all starting morpholine had reacted. The mixture was diluted with water (150ml) and extracted with ethyl acetate (3 x 50ml). The combined extracts were washed with brine and the organic solvent was evaporated in vacuo. The residual oil was dissolved in ethanol (20ml) and methylamine (2ml of 8M soln. in ethanol) was added. This solution was stirred for 1 h and the solvent was then removed in vacuo. The residual oil was purified on silica using 1-10% methanol in dichloromethane as eluant. This afforded the product (2g, 83%) as a white foam. This was further characterised by treatment with methanolic hydrogen chloride to afford a white solid which was recrystallised from water. 1H NMR (360MHz, DMSO-d6) δ 2.22-2.34 (1 H, m), 2.62 (1 H, d, J=14.0Hz), 2.89 (1 H, app d, J=11.OHz), 3.26 (1 H, d, J=14.0Hz), 3.38 (1 H, d, J=3.0Hz), 3.43-3.50 (1 H, m), 3.57-3.62 (2H, m), 4.19-4.28 (1 H, m),
4.32 (1 H, d, J=3.0Hz), 4.81 (1H, t, J=5.5Hz), 4.93 (1 H, t, J=6.0Hz), 6.00 (1 H, s), 7.09 (1 H, t, J=9.0Hz), 7.33 (2H, s), 7.54 (2H, br t), 7.86 (1 H, s), 9.63 (1 H, s), 9.83 (1 H, s). MS (CI) m/z 550 (M+1 , 20%), 454 (80) 116 (100).
EXAMPLE 92 4-(2.3-Dihvdro-2-oxo-5-pyrrolidinomethyl-1.3-imidazol-4- vnmethyl-2-(R -(1-(SW3.5-bis(trifluoromethvnphenvn-2- hvdroxyethoxy)-3-(S)-(4-fluorophenyl)morpholine
A mixture of the compound of Description 6 (1.8g), 4,5- bis(bromomethyl)-1 ,3-diacetyl-2-imidazolone (prepared by the method of Dolan and Dushinsky, JACS (1948) 70, 657) (2.2g) and potassium carbonate in dimethylformamide (13ml) were stirred at room temperature for 10 min until all starting material was reacted.
To the resulting brown mixture was added dropwise pyrrolidine (1.65ml, excess) resulting in an exothermic reaction. The solvent was removed in vacuo and the residue was extracted with ethyl acetate (3 x 50ml) and washed with brine. The organic phase was dried (MgSO4) and the solvent removed in vacuo. The brown residue was purified by medium pressure reverse phase d8 silica gel chromatography using 30% acetonitrile in 0.1 % aqueous trifluoroacetic acid as eluant. This afforded the title product as a buff coloured solid (1g). 1H NMR (360MHz, DMSO-d6) δ 1.61 (4H, br s), 2.26-2.30 (5H, m), 2.66 (1 H, d, J=14.0Hz), 2.83-2.87 (1 H, brd), 3.02 (1 H, d, J=13.5Hz), 3.15 (1 H, d, J=13.5Hz), 3.23 (1 H, d, J=14.0Hz), 3.37 (1H, d, J=3.0Hz), 3.42-3.47 (1 H, m), 3.57-3.60 (2H, m), 4.17-4.24 (1 H, m), 4.32 (1 H, d, J=3.0Hz), 4.79 (1 H, t, J=5.5Hz), 4.89 (1 H, t, J=5.5Hz), 7.08 (2H, t, J=9.0Hz), 7.32 (2H, s), 7.56 (2H, mc), 7.85 (1 H, s), 9.61 (1 H, s), 9.65 (1 H, s). MS (Cl+) m/z 633
(M++1 ), 454 (50%).
EXAMPLE 93
2- RH1- SH3.5-Bis(thfluoromethvnphenyl)-2- phosphoryloxyethoxy)-3-(SH4-fluorophenyl)-4-(2,3-dihvdro-3-oxo- 1.2.4-triazol-5-vDmethylmorpholine
The compound of Example 88 (200mg) in dry tetrahydrofuran (1 ml) was treated with dibenzyloxydiethylaminophosphine (200mg) and tetrazole (100mg). The reaction was stirred for 2 hours and then treated with a further 10Omg of dibenzyloxydiethyl aminophosphine followed after 1 hour by tetrazole (100mg). The reaction was stirred for a further 1 hour before adding 4-methylmorpholine-N-oxide (1.Og) and stirring for 16 hours. The reaction was poured into potassium carbonate solution and extracted into ethyl acetate. The organic layer was dried (MgSO ), filtered, evaporated and purified by chromatography on silica gel using methanol/dichloromethane (4:96) as eluent to yield an oil. This was dissolved in methanol (2ml) and ammonium formate
(100mg) and palladium hydroxide (20% on carbon) was added. The reaction mixture was heated to reflux for one hour and then filtered, evaporated and freeze dried from acetonitrile/water to give the ammonium salt of the title compound (93mg); H NMR (360MHz, D6-DMSO) δ 11.29 (1 H, s), 7.85 (1 H, s), 7.53 (2H, s),
7.36 (2H, m), 7.06 (2H, t, J=7.2Hz), 4.96 (1 H, t, J=5.4Hz), 4.34 (1 H, d, J=3.6Hz), 4.29 (1 H, t, J=11.2Hz), 3.92-3.85 (1 H, m), 3.68-3.63 (1 H, m), 3.62-3.55 (1 H, m), 3.49 (1 H, d, J=3.6Hz), 3.38 (1 H, d, J=14.4Hz), 2.82-2.79 (1 H, m), 2.77 (1 H, d, J=14.4Hz), 2.41-2.35 (1 H, m); MS (ES+) 631 (M+H.
EXAMPLE 94
2-(R) (1-(S 3.5-Bis(trifluoromethyl)phenvn-2- phosphoryloxyethoxy)-3-(S)- 4-fluorophenyl)-4-(1.2.4-triazol-3-yl) methylmorpholine
The ammonium salt of the title compound was prepared from the compound of Example 89 by the methodology of Example 93. 1H
NMR (250MHz, D6-DMSO + 0.1% TFA) δ 8.74 (1 H, s), 7.95 (1 H, s), 7.68 (2H, broad s), 7.54 (2H, s), 7.30 (2H, t, J=8.7Hz), 5.16 (1 H, dd, J=7Hz and 5Hz), 4.72 (1 H, d, J=1 Hz), 4.66 (1 H, d, J=1 Hz), 4.42 (1H, t, J=11Hz), 3.95-4.27 (3H, m), 3.72 (1H, d, J=11 Hz) and 3.41- 3.55 (1H, m).
EXAMPLE 95 4-(2.3-Dihvdro-3-oxo-1.2.4-triazol-5-vn-3-(S)-phenyl-2-(R)-(1- (S)-f3-(trifluoromethvπphenyl)-2-hvdroxyethoxy)morpholine Prepared from the compound of Description 30 following the method illustrated in Example 88. MS (Cl+) m/z 465 ((M+1 )+, 71%).
EXAMPLE 96 4-(2.3-Dihvdro-3-oxo-1.2.4-triazol-5-v0methyl-2-(RH1-(SW3- fluoro-5-(trifluoromethvπphenvπ-2-hvdroxyethoxy)-3-(S)- phenylmorpholine
The compound of Description 27 (600mg), N-carbomethoxy-2- chloroacetamidrazone (271 mg) and potassium carbonate (258mg) were reacted in dimethylformamide according to the procedure illustrated in Example 88. This afforded the product as a white solid which was recrystallised from ether/hexane (220mg, 30%). 1H NMR (360MHz, DMSO-de) δ 2.38 (1 H, m), 2.78 (1 H, d, J=14.0Hz), 2.84 (1 H, s), 3.38-3.39 (2H, m), 3.45 (1 H, d, J=14.0Hz), 3.50 (1 H, d, J=3.0Hz), 3.56 (1 H, d, J=11.OHz), 4.26 (1 H, t, J=11.OHz), 4.34 (1 H,
d, J=3.0Hz), 4.68 (1 H, t, J=6.0Hz), 4.85 (1 H, t, J=6.0Hz), 6.40 (1 H, d, J=9.0Hz), 6.96 (1 H, s), 7.33 (3H, m), 7.36 (1 H, d, J=9.0Hz), 7.49 (2H, m). MS (CI+) m/z 483 (M+1 , 20%).
EXAMPLE 97
4-(2.3-Dihvdro-3-oxo-1.2.4-triazol-5-yl)methyl-2-(RV(1-(S)-3- fluoro-5-(trifluoromethyθphenyl 2-phosphoryloχyethoxy)-3-fS)- phenylmorpholine
The ammonium salt of the title compound was prepared from the compound of Example 96 using the methodology of Example 93.
1H NMR (360MHz, DMSO-d6) δ 11.29 (1 H, s), 7.49-7.29 (5H, m), 7.38 (1H, d, J=10.8Hz), 6.96 (1 H, s), 6.45 (1 H, d, J=10.8Hz), 4.84 (1H, d, J=7.2Hz), 4.34 (1 H, d, J=3.6Hz), 4.28 (1H, t, J=10.8Hz), 3.80-3.76 (1 H, m), 3.57 (1 H, d, J=3.6Hz), 3.57-3.49 (2H, m), 3.47 (1 H, d, J=14.4Hz), 2.83-2.76 (1 H, m), 2.78 (1 H, d, J=14.4Hz), 2.46-
2.36 (1 H. m).
EXAMPLE 98 2-(R)-(1-(S)-f3.5-Bis(thfluoromethvnphenvn-2-hvdroxyethoxy)-4- (2.3-dihvdro-3-oxo-1.2,4-triazol-5-yl)methyl-3-(S)-phenylmorpholine
The compound of Description 17 was reacted with N- carbomethoxy-2-chloroacetamidrazone (Description 23) and potassium carbonate according to the procedure illustrated in Example 88. This afforded the product as a white solid. 1H NMR (360MHz, DMSO-d6) δ 2.42 (1 H, dt, J=12.0, 3.5Hz), 2.76 (1 H, d,
J=14.0Hz), 2.83 (1 H, d, J=12.0Hz), 3.39 (1 H, d, J=14.0Hz), 3.44- 3.47 (1 H, m), 3.50 (1 H, d, J=3.0Hz), 3.60 (2H, m), 4.22-4.28 (1 H, m), 4.40 (1 H, d, J=3.0Hz), 4.77-4.83 (2H, m), 7.25-7.34 (3H, m),
7.41 (2H, s), 7.48-7.50 (2H, m), 7.82 (1 H, s), 11.20 (1 H, s), 11.25 (1H, s), MS (CI) m/z 533 (M+1 , 30%) 434 (20), 117 (100).
EXAMPLE 99 2(RH1- SH3.5-Bis(trifluoromethyl)phenvn-2- phosphoryloxyethoxy)-4-(2.3-dihvdro-3-oxo-1.2.4-triazol-5- yl)methyl-3-(S)-phenylmorpholine
The ammonium salt of the title compound was prepared from Example 98 by the method of Example 93. 1H NMR (360MHz, de-DMSO) δ 11.26 (1 H, s), 7.83 (1 H, s), 7.48-7.24 (7H, m), 4.95
(1 H, t, J=5.4), 4.39 (1 H, d, J=3.6), 4.29 (1 H, t, J=11.2), 3.92-3.89 (1H, m), 3.60-3.64 (1 H, m), 3.55-3.59 (1H, m), 3.48 (1 H, d, J=3.6),
3.42 (1 H, d, J=14.4), 2.84-2.79 (1 H, m), 2.78 (1 H, d, J=14.4), 2.42 (1 H, m). HPLC on Zorbax Z-Ph (250 x 4.6mm i.d. 5μM) column eluting with 40% acetonitrile in 25mM KH2P04 with 0.2% thethylamine (pH 3.0), flow rate 1 ml/min, UV detector 210nM. Retention time 4.68 min.
EXAMPLE 100 3-(S)-Phenyl-4-(1.2.4-triazol-3-yl)-2-(RW1 -(S)-3-
(thfluoromethvθphenyl)-2-hvdroxyethoxy)morpholine
Prepared as a hydrochloride salt from the compound of Description 30 following the method illustrated in Example 89. MS (ES+) m/z 449 ((M+1 )+ 100%).
Examples 101 and 102 in Table 2 were prepared in a similar manner to that described in Example 12, Method B, via the appropriate N-(4-azidobut-2-ynyi)morpholine and the appropriate amine.
TABLE 1 (continued)
Ex. No. R1 R4 -NR7R8 Data
8 CF3 F -o 1H NMR (250MHz. CDCI3) δ 9.16 (1H, br s). 8.14 (1H. br s). 7.64 (1H, s), 7.38 (2H, b s), 7.09 (4H, m). 4.86 (1H, m), 4.22 (2H, m), 3.64 (1H, d, J=9.34Hz), 3.38 (2H, m), 3.16 (6H, m), 2.93 (1 H, d. J=11.28Hz), 2.75 (1H. d, J=11.3Hz), 2.36 (1H, m), 2.05 (2 m), 1.45 (3H, d, J=6.59Hz). MS (Cl+) m/z 603.
9 CF3 F 1H NMR (250MHz, CDCI3) δ 8.03 (1 H, s), 8.00 (1 H, s), 7.63 (1 H, s), 7.38 (2H, m), N N — CH,
\ / 7.06 (4H, m), 4.86 (1H, m), 4.28 (1H, d. J=2.8Hz), 4.19 (1 H, d, J=11.47Hz), 3.64 (1 H, d, J=9.41Hz), 3.38 (2H, m), 3.13 (2H, dd, J=13.61 , 17.28Hz), 2.92 (1 H, d, J=11.5Hz),
2.73 (1H, d, J=11.5Hz), 2.28-2.40 (12H, m), 1.45 (3H, d, J=6.6Hz). MS (Cl+) m/z 646
10 CF3 F 1H NMR (250MHz, DMSO) δ 10.52 (1 _H, s), 9.87 (1 _H, s), 9.80 (VJή, s), 9.66 f/.H, s),
-NH- (CH, ) ,— N 0 8.32 (1H, s), 7.86 (1 H, s), 7.53 (2H, br s). 7.37 (2H, br s), 7.09 (2H, m), 4.93 (1H, m), 2 2 \ / 4.32 (1H, d, J=2.76Hz), 4.02 (2H, m), 3.62 (1H, d, J=11.78Hz), 3.52 (5H, m), 3.26 (2H m), 2.86 (1H, m), 2.59 (1 H, m). 2.31 (6H. m), 1.97 (3H, d, J=7.37Hz), 1.36 (3H, d,
J=6.24Hz). MS (Cl+) m/z 676
11 CF3 F 1H NMR (250MHz, CDCI3) δ 7.63 (1 H, s), 7.39 (2H, br s), 7.12 (2H, s), 7.04 (2H. m),
-NH- (CH2 ) 2 — N
4.86 (1H, m), 4.28 (1H, d, J=2.7Hz), 4.18 (1H, m), 4.10 (1 H, s), 3.67 (1H, s), 3.60 (1H, m), 3.39 (2H, m), 2.36-2.92 (10H, m), 2.07 (1H. s). 1.95 (4H, m), 1.45 (3H, d, J=6.53Hz).
TABLE 1 (continued)
Ex. No. R1 R4 -NR7R8 Data
38 CF3 F 1H NMR (250MHz, CDCI3) δ 9.35 (1H, s), 8.94 (1H, s), 7.78 (1H, s), 7.71 (2H, br m), N S 7.13 (2H, s), 7.06 (2H, t, J=8.7Hz), 4.86 (1H, q, J=6.4Hz), 4.30 (1H, d, J=2.8Hz), 4.24
\ / (1H, m), 3.64 (1H, d, J=9.6Hz), 3.43 (1H, d, J=14Hz), 3.37 (1H, d, J=2.8Hz), 3.20 (1H d, J=14Hz), 3.10 (1H, d, J=14Hz), 2.95 (1H, d, J=11.3Hz), 2.75 (1 H, d, J=14Hz), 2. 62 (8H, s), 2.35 (1H, m), 1.49 (3H, d, J=6.4Hz). MS m/z 647 (MH+).
39 F F 1H NMR (250MHz, CDCI3) δ 10.06 (1H, s), 8.85 (1H, s), 7.40 (2H, br s), 7.08 (3H, t,
-0 J=8.7Hz), 6.77 (1H, s), 6.33 (1 H, d, J=8.7Hz), 4.75 (1H, q, J=6.4Hz), 4.29 (1 H, d, J=2.8Hz), 4.22 (1H, m), 3.62 (1H, d, J=9.8Hz), 3.49 (1H, d, J=14Hz), 3.38 (1H, d, J=2.8Hz), 3.16 (5H, m), 2.96 (1 H, d, J=11.4Hz), 2.81 (1 H, d, J=14Hz), 2.40 (1 H, m), 2.05 (2H, m), 1.40 (3H, d, J=6.4Hz). MS m/z 553 (MH*).
40 F F -N (CH3 ) 2 1H NMR (250MHz, CDCI3) δ 1.41 (3H, d, J=6.6Hz), 2.20 (6H, s), 2.34 (1H, m), 2.75 ' (1H, d, J=14.1Hz), 2.92 (1H, d, J=11.4Hz), 3.09 (2H, m), 3.37 (1H, d, J=2.8Hz), 3.44 (1 H, d, J=14.1Hz), 3.62 (1H, m), 4.22-4.29 (2H, m), 4.75 (1 H, m), 6.33 (1 H, d, J=9.0Hz), 6.77 (1H, s), 7.08 (3H, m), 7.37 (2H, br s), 8.18 (1H, s), 8.92 (1H, s). MS (ES+) m/z MO.
41 F F -o 1H NMR (360MHz, CDCI3) δ 7.36 (2H, br s), 7.07 (3H, t, J=8.5Hz), 6.77 (1H,- s), 6.33 (1H, d, J=8.5Hz), 4.76 (1H, q, J=6.4Hz), 4.28 (1H, d, J=2.7Hz), 4.22 (1 H, m), 3.62 (1H d, J=9.8Hz), 3.49 (1H, d, J=14Hz), 3.37 (1H, d, J=2.8Hz), 3.28 (2H, s), 2.91 (1H, d, J=7.9Hz), 2.75 (1H, d, J=9.7Hz), 2.45 (4H, m), 2.33 (1H, m), 1.74 (4H, m), 1.41 (3H, d, J=6.4Hz).
TABLE 2
Ex. No. R1 R4 -NR7R8 Data
14 CF3 F -NHCH3 HRMS (El+) (found M*. 561.1975. C25H26F7N5θ2 requires M+, 561.1975). Analysis Calcd. for C25H26F7N5O2.0.5H2O: C, 52.54; H, 4.94; N, 12.25; Found: C, 52.67; H, 4.64; N, 12.08%.
15 CF3 F -NH2 MS m/z (CI*) 548 (M+H).
16 CF3 F -o Analysis Calcd. for C28H3oF7N502: C, 55.90; H, 5.03; N, 11.64; Found: C, 55.71 ; H, 4.86; N, 11.53%. MS m/z (Cl+) 602 (M+H).
17 F F -o 1H NMR (360MHz, CDCI3) δ 1.40 (3H, d, J=6.6), 2.13 (2H. qn, J=7.1), 2.55 (2H, dt, J=12.0, 3.4), 2.88 (1H, d, J=11.7). 3.22-3.45 (5H, m), 3.57-3.66 (4H, m), 3.80 (1H, d, J=14.0), 4.20 (1 H. dt, J=11.6, 2.1), 4.32 (1 H, d, J=2.9), 4.76 (1 H, q. 6.5), 6.39 (1H, d, J=8.9), 6.80 (1H, s), 7.05-7.12 (3H. m). 7.48 (2H, br s). MS (Cl+) m/z 538 (M+1 , 100%).
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
18 F F -0 1H NMR (360MHz, CDCI3) δ 1.40 (3H, d, J=6.6), 1.81 (4H, br s), 2.53-2.61 (5H, m), 2.89 (1H. d, J=11.7), 3.27 (1H, d, J=14.0). 3.45 (1H, d, J=2.8), 2.59-3.63 (1 H, m), 3.6 (1H, d, J=13.7), 3.73 (1H, d, J=13.7), 3.83 (1H, d, J=14.0), 4.21 (1H, dt, J=11.6, 2.1), 4.32 (1H, d, J=2.8), 4.76 (1H, q, J=6.5), 6.37 (1H, d, J=9.1), 6.80 (1 H, s), 7.05-7.10 (3H, m), 7.46 (2H, br s). MS (CI*) 552 (M+1 , 100%).
19 F F 1H NMR (360MHz, CDCI3) δ 1.40 (3H, d, J=6.6), 2.4-2.5 (4H, m), 2.56 (1 H, dt, J=11.9, N 0 3.4), 2.90 (1H, d, J=11.6), 3.30 (1H, d, J=14.1), 3.48-3.52 (2H, m), 3.58-3.71 (6H, m),
\ / 3.85 (1H, d, J=14.2), 4.23 (1 H, dt, J=11.6, 2.3), 4.33 (1H, d, J=2.8), 4.77 (1 H, q, J=6.5), 6.37 (1H, d, J=8.8), 6.80 (1H, s), 7.05-7.10 (3H, m), 7.46 (2H, br s). MS (CI*) m/z 568 (M+1 , 100%).
20 H F -N (CH3 ) 2 1H NMR (250MHz, CDCI3) δ 1.40 (3H, d, J=6.5), 2.25 (6H. s). 2.55 (1H, dt. J=11.8, 3.4), 2.91 (1H, d, J=11.6), 3.23 (1H, d, J=13.9), 3.41-3.64 (4H, m), 3.80 (1 H, d, J=13.9), 4.24 (1H, t, J=11.5). 4.33 (1 H, d, J=2.7), 4.77 (1H, q, J=6.5). 6.80 (1 H, d, J=7.7), 6.95 (1H, s), 7.06 (2H, t, J=8.7), 7.16 (1H, t, J=7.7), 7.36 (1H, d, J=7.8), 7.48 (2H, br s), 9.3-9.9 (1H, br s). MS (CI*) 508 (M+1 , 100%).
21 CF3 F 1H NMR (250MHz, CDCI3) δ 7.63 (1H, s), 7.48 (2H, br s), 7.15 (2H, s), 7.05 (2H, t, N N— - CH, J=8.7Hz), 4.86 (1H, q, J=6.6Hz), 4.30 (1H, d, J=2.7Hz), 4.21 (1H, br t, J=11.4Hz), 3.7
\ / (1H, d, J=13.9Hz), 3.67 (1H, d, J=14.0Hz), 3.65 (1H, m), 3.56 (1H. d, J=14.0Hz), 3.43 (1H, d, J=2.7Hz), 3.20 (1H, d, J=13.9Hz), 2.85 (1H, d, J=11.5Hz), 2.56-2.48 (9H, m), 2.31 (3H, s), 1.42 (3H, d, J=6.6Hz).
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
25 CF3 F -0 1H NMR (360MHz, CDCI3) δ 1.44 (3H, d, J=6.6Hz), 2.14 (2H, m), 2.55 (1H, dd, J=3.4, 11.9Hz), 2.87 (1H, d, J=11.9Hz), 3.21-3.44 (6H, m), 3.58-3.67 (3H, m), 3.75 (1 H, d, J=14.0Hz), 4.2 (1H, t, J=9.3Hz), 4.31 (1H, d, J=2.8Hz), 4.85 (1H, m), .06 (2H, t, J=8.7Hz), 7.16 (1H, s), 7.47 (2H, br s), 7.63 (1H, s).
26 CF3 F -0 1H NMR (250MHz, CDCI3) δ 1.44 (3H, J=6.7Hz), 2.57 (1H, dd, J=3.4, 11.9Hz), 2.90 (1H, d, J=11.6Hz), 3.23 (1H, d, J=3.9Hz), 3.45-3.66 (6H, m), 3.75-3.84 (3H, m), 4.08- 4.26 (1H, m), 4.31 (1H, d, J=2.8Hz), 4.86 (1H, m), 5.78 (2H, s), 7.05 (2H, t, J=8.7Hz), 7.15 (2H, s), 7.47 (2H, brt), 7.64 (1H, s).
27 CF3 F -N (CH2CH2OCH3 ) 2 1H NMR (250MHz, CDCI3) δ 1.44 (3H, d, J=6.58Hz), 2.73 (5H, m), 2.95 (1 H, d, J=11.8Hz), 3.23 (1H, d, J=13.9Hz), 3.37 (6H, s), 3.41-3.49 (5H, m), 3.63-3.86 (4H, m) 4.18 (1H, t, J=11.5Hz), 4.30 (1 H, d, J=2.8Hz), 4.84 (1H, m), 7.06 (2H, t, J=8.7Hz), 7.14 (2H, s), 7.45 (2H, br t), 7.63 (1H, s). MS (ES+) m/z 664 (MH+, 100%).
31 CF3 H -N (CH3 ) CH2CH (0CH3 ) 2 1H NMR (250MHz, CDCI3) δ 1.43 (3H, d, J=6.5Hz), 2.17 (3H, s), 2.53 (2H, d, J=5.0Hz), 2.60-2.73 (1H, br dt), 2.95 (1 H, br d), 3.30 (3H, s), 3.32 (3H, s), 3.31 (1H, d, J=14.0Hz), 3.44 (1H, d, J=2.7Hz), 3.56 (1H, d, J=2.0Hz), 3.64 (1H, br d), 3.82 (1H, d, J=14.0Hz), 4.20-4.29 (1H, br t), 4.36 (1H, d, J=2.7Hz), 4.47 (1H, t, J=5.0Hzj, 4.85 (1 H q, J=6.5Hz), 7.14 (2H, s), 7.27-7.38 (3H,m), 7.45 (2H, br s), 7.61 (1H, s). MS (ES) m/ 632 (M++ 1 , 100%)
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
32 CF3 H -NH(CH2)20CH3 1H NMR (250MHz, CDCI3) δ 1.45 (3H, d, J=6.5Hz), 2.50 (1H, dt, J=3.4, 12.0Hz), 2.79 2.87 (3H, m), 3.16 (1H, d, J=14.0Hz), 3.35 (3H, s), 3.41 (1H, d, J=2.7Hz), 3.51-3.67 (3H, m), 3.75-3.87 (3H, m), 4.24 (1H, brt), 4.36 (1H, d, J=2.7Hz), 4.87 (1H, q, J=6.5Hz), 7.16 (2H, s), 7.33-7.39 (3H, m), 7.46 (2H, m), 7.61 (1H, s). MS (ES) m/z 588 (M++ 1,100%).
33 CF3 H -N(CH3) (CH2)2OCH3 1H NMR (250MHz, CDCI3) δ 1.43 (3H, d, J=6.5Hz), 2.24 (3H, s), 2.58 (2H, t, J=3.5Hz) 2.65 (1H, brt), 2.94 (1H, brd), 3.29 (1H, d, J=9.5Hz), 3.36 (3H, s), 3.43 (1H, d, J=2.0Hz), 3.49 (2H, t, J=3.5Hz), 3.56 (2H, s), 3.63 (1H, dd, J=1.3, 7.75Hz), 3.80 (1H, d, J=9.5Hz), 4.23 (1H, dt, J=1.5, 8.0Hz), 4.36 (1H, d, J=2.0Hz), 4.84 (1H, q, J=6.5Hz) 7.15 (2H, s), 7.32-7.36 (3H, m), 7.45 (2H, m), 7.61 (1H, s). MS (ES) m/z 602 (M++1, 100%).
34 CF3 H -N[CH(CH3)2] (CH2)2OCH3 1H NMR (250MHz, CDCI3) δ 0.99 (3H, d, J=6.5Hz), 1.02 (3H, d, J=6.5Hz), 1.43 (3H, d J=6.5Hz), 2.64-2.71 (3H, m), 2.91-2.98 (2H, m), 3.26(1 H, d, J=14.0Hz), 3.39 (6H, s), 3.43 (1H, d, J=2.6Hz), 3.49-3.81 (3H, m), 4.22 (1H, dt, J=2.0, 11.5Hz), 4.35 (1H, d, J=2.6Hz), 4.86 (1H, q, J=6.5Hz), 7.14 (2H, s), 7.31-7.35 (3H, m), 7.45 (2H, m), 7.61 (1H, s). MS (ES) m/z 630 (M++1, 100%).
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
35 CF3 H 1H NMR (250MHz, CDCI3) δ 0.29-0.42 (4H, m), 1.43 (3H, d, J=6.5Hz), 1.63 (1H, br qn), 2.72 (2H, t, J=5.0Hz), 2.7-2.74 (1H, m), 3.02-3.07 (1H, m), 3.27-3.37 (1H, m), N
\ 3.37 (3H, s), 3.43 (1 H, d, J=2.8Hz), 3.55 (2H, t, J=5.0Hz), 3.62-3.70 (3H, m), 3.82 (1
(CH2 ) 2OCH3 d, J=14.0Hz), 4.25 (1H, br t), 4.34 (1H, d, J=2.8Hz), 4.84 (1H, q, J=6.5Hz), 7.13 (2H, s), 7.33-7.36 (3H, m), 7.43 (2H, m), 7.61 (1H, s). MS (ES) m/z 628 (M++1 , 100%).
36 CF3 H -N (CH2CH2CH2CH3 ) 2 1H NMR (250MHz, CDCI3) δ 0.85 (6H, t, J=7.25Hz), 1.14-1.38 (9H, m), 1.44 (3H, d, J=6.5Hz), 2.34 (4H, br t), 2.63-2.73 (2H, m), 2.97 (1H, m), 3.34 (1H, d, J=14.0Hz), 3.41-3.47 (3H, m), 3.64 (1H, dd, J=2.0, 11. OHz), 3.79 (1H, d, J=14.0Hz), 4.26 (1H, br t), 4.35 (1 H, d, J=2.8Hz), 4.84 (1 H, q, J=6.5Hz), 7.14 (2H, s), 7.32-7.35 (3H, m), 7.43 (2H, m), 7.61 (1H, s).
37 CF3 H -N [CH (CH3 ) 2 ] 2 1H NMR (250MHz, CDCI3) δ 1.01 (12H, d, J=7.25Hz), 1.43 (3H, d, J=6.5Hz), 2.68 (1 H dt, J=3.5, 12.5Hz), 2.92-3.02 (3H, m), 3.32 (1H, d, J=14.0Hz), 3.44 (1H, d, J=2.8Hz), 3.48 (1H, br d), 3.52-3.72 (2H, m), 3.77 (1H, d, J=14.0Hz), 4.24 (1H, br t), 4.36 (1H, d J=2.8Hz), 4.85 (1H, q, J=6.5Hz), 7.14 (2H, s), 7.32-7.35 (3H, m), 7.45 (2H, m), 7.61 (1H, s).
43 CF3 F H NMR (250MHz, CDCI3) δ 1.44 (3H, d, J=6.6Hz), 1.52-1.92 (4H, m), 2.26 (1 H, m), 2.61-2.77 (2H, m), 2.93 (2H, m), 3.26 (2H, d, J=14.0Hz), 3.36 (5H, m), 3.61-3.89 (4H, m), 4.23 (1H, m), 4.30 (1H, d, J=2.8Hz), 4.86 (1H, m), 7.06 (2H, t, J=8.8Hz), 7.15 (2H
OCH3 s), 7.46 (2H, br s), 7.63 (1H, s). MS (ES+) m/z 645.
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
44 CF3 F -N [CH (CH3 ) 2 ] 2 1H NMR (250MHz, CDCI3) δ 1.30 (6H, d, J=6.5Hz), 1.31 (6H, d, J=6.5Hz), 1.75 (3H, J=6.6Hz), 2.95 (1H. m), 3.20-3.31 (3H, m), 3.57 (1H. d, J=14.1Hz), 3.78 (2H, m), 3.9 4.05 (3H, m), 4.53 (1H, m), 4.62 (1H, d, J=2.80Hz), 5.17 (1 H, m), 7.35 (2H, t, J=8.7Hz), 7.46 (2H, s), 7.76 (2H, m), 7.94 (1 H, s). MS (ES+) m/z 631.
45 CF3 F -N (CH2CH2CH3 ) CH2CH20H 1H NMR (250MHz, CDCI3) δ 7.64 (1H, s), 7.49 (2H, br s), 7.17 (2H, s), 7.06 (2H, t, J=8.7Hz), 4.86 (1H, q, J=6.5Hz), 4.31 (1H, d, J=2.7Hz), 4.26 (1H, t, J=9.6Hz), 3.74 (1H, d, J=13.7Hz), 3.60 (5H. m), 3.44 (1H, d , J=2.7Hz), 3.15 (1 H, d, J=13.7Hz), 2.96 (1H, d, J=11.7Hz), 2.68-2.49 (5H, m), 1.56-1.42 (5H, m), 0.87 (3H, t, J=7.3Hz). MS m/z 634 (MH+).
46 CF3 F 1H NMR (250MHz, CDCI3) δ 7.63 (1H, s), 7.57 (2H, br s), 7.15 (2H, s), 7.06 (2H, t, J=8.7Hz), 4.86 (1H, q, J=6.5Hz), 4.30 (2H, m), 3.82 (2H, m), 3.64 (2H, d, J=13.5Hz), 3.44 (1H, d, J=2.6Hz), 3.32 (2H, m), 3.15-3.03 (3H, m), 2.88 (1H, m), 2.66-2.47 (2H,
OH m), 1.87 (1H, m), 1.81-1.64 (3H, m), 1.43 (3H, d, J=6.5Hz). MS m/z 632 (MH+).
47 CF3 F 1H NMR (250MHz, CDCI3) δ 7.63 (1H, s), 7.57 (2H, br s), 7.15 (2H, s), 7.06 (2H, t,
-P J=8.7Hz), 4.86 (1H, q, J=6.5Hz), 4.32 (1H, d, J=2.7Hz), 4.22 (1H, m), 3.88 (1H, d, J=14.1Hz), 3.74 (1H, d, J=14.0Hz), 3.64-3.54 (3H, m), 3.44 (2H, m), 3.20 (1H, d,
\
OH J=14Hz), 3.00-2.81 (3H, m), 2.55 (1H, m), 2.34 (1H, m), 1.92 (1H, m), 1.71 (3H, m), 1.44 (3H, d, J=6.5Hz). MS m/z 632 (MH*).
I TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
48 CF3 F -N [CH (CH3 ) 2 ] CH2CH20H 1H NMR (250MHz, CDCI3) δ 7.64 (1H, s), 7.49 (2H, br s), 7.27 (2H, s), 7.06 (2H, t, J=8.7Hz), 4.86 (1H, q, J=6.5Hz), 4.31 (1H, d, J=2.7Hz), 4.14 (1H. m). 3.76-3.43 (7H, m), 3.17 (1H, d, J=13.8Hz), 3.04-2.89 (2H, m), 2.75-2.53 (3H, m), 1.43 (3H, d, J=6.5Hz), 1.5 (6H, d, J=6.6Hz). M/S m/z 634 (MH+).
49 CF3 F -N (CH3 ) C (CH3 ) 3 1H NMR (250MHz, CDCI3) δ 7.63 (1H, s), 7.45 (2H, br s), 7.15 (2H, s), 7.05 (2H, t, J=8.74Hz), 4.87 (1H, q, J=6.58Hz), 4.31 (1 H, d, J=2.79Hz), 4.23 (1H, m), 3.75 (1H, d, J=14.16Hz), 3.64 (1H, m). 3.54 (1H. d, J=14.40Hz), 3.48 (1H, d, J=14.40Hz), 3.46 (1 d, J=2.79Hz), 3.32 (1H, d, J=14.16Hz), 2.94 (1H, d, J=11.73Hz), 2.65 (1 H, td, J=10.3 3.51Hz), 2.09 (3H, s), 1.45 (3H, d, J=6.58Hz), 1.15 (9H, s). M/S (ES+) 618.
50 CF3 F 2 , 5-dime thylpyrrolidi.no MS (ES+) m/z 629 (MH+, 100%)
51 CF3 F -N (CH2CH3 ) 2 1H NMR (250MHz, CDCI3) δ 1.00 (6H, t, J=7.2Hz), 1.44 (3H, d, J=6.6Hz), 2.46-2.55 (4H, m), 2.62 (1H, m), 2.91 (1H, d, J=11.7Hz), 3.27 (1H, d, J=14.0Hz), 3.46 (1H, d, J=2.7Hz), 3.56 (2H. s). 3.62 (1H, m), 3.77 (1H, d, J=14.1Hz), 4.24 (1H, m), 4.31 (1H, d, J=2.8Hz), 4.86 (1H, m). 7.05 (2H, t, J=8.7Hz), 7.15 (2H, s), 7.47 (2H, br s), 7.64 (1H, s). MS (ES+) m/z 603
52 CF3 H -N (CH3 ) 2 Analysis Calcd. for C26H29N5O2F6.HCI.H20: C, 51.03; H, 5.27; N, 11.44. Found C, 51.21 ; H, 5.24; N, 11.10%. M.pt. 127-129°C.
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
53 CF3 H -N (CH2CH3 ) 2 1H NMR (250MHz, CDCI3) δ 1.03 (6H, t, J=7.1Hz), 1.44 (3H, d, J=6.6Hz), 2.51-2.70 (5H, m), 2.93 (1H, d, J=11.6Hz), 3.32 (1H, d, J=14.1Hz), 3.44 (1H, d, J=2.7Hz), 3.57- 3.66 (3H, m), 3.80 (1H, d, J=14.1Hz), 4.24 (1H, m), 4.35 (1H, d, J=2.7Hz), 4.85 (1H, m), 7.14 (2H, s), 7.27 (1H, s), 7.34 (3H, m), 7.45 (2H, br s), 7.61 (1H, s). MS (ES+) m/z 585.
54 CF3 H -N (CH2CH2CH3 ) 2 1H NMR (250MHz, CDCI3) δ 0.82 (6H, t, J=7.4Hz), 1.35-1.46 (7H, m), 2.36 (4H, m), 2.66 (1H, m), 2.95 (1H, d, J=11.6Hz), 3.35 (1H, d, J=14.2Hz), 3.44 (1 H, d, J=2.78Hz), 3.53 (2H, s), 3.64 (1H, m), 3.78 (1H, d, J=14.3Hz), 4.26 (1H, m), 4.35 (1H, d, J=2.8Hz), 4.85 (1H, m), 7.14 (2H, s), 7.33 (3H, m), 7.43 (2H, br s), 7.61 (1H, s). MS (ES*) m/z 613.
55 CF3 H - 1H NMR (250MHz, CDCI3) δ 1.44-1.56 (9H, m), 2.35 (4H, m), 2.61 (1 H, m), 2.92 (1H, d, J=11.7Hz), 3.29 (1H, d, J=14.0Hz), 3.40-3.56 (3H, m), 3.83 (1H, d, J=14.0Hz), 4.24 (1H, m), 4.36 (1H, d, J=2.8Hz), 4.86 (1H, m), 7.15 (2H, s), 7.34 (3H, m), 7.47 (2H, br s), 7.61 (1H, s). MS (ES+) m/z 597.
56 CF3 H 1H NMR (250MHz, CDCI3) δ 1.44 (3H, d, J=6.6Hz), 1.52-1.91 (4H, m), 2.28 (1H, m), 2.66-2.75 (2H, m), 2.93 (2H, m), 3.28-3.43 (7H, m), 3.62 (2H, m), 3.80 (2H, d, J=14.2Hz), 4.22 (1H, m), 4.35 (1H, d, J=2.7Hz), 4.85 (1H, m), 7.14 (2H, s), 7.33 (3H,
OCH3 m), 7.44 (2H, br s), 7.61 (1 H, s). MS (ES*) m/z 627.
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
57 F F -N(CH3)2 1H NMR (360MHz, CDCI3) δ 1.40 (3H, d, J=6.5Hz), 2.24 (6H, s), 2.57 (1H. m).2.89 (1H. d, J=11.8Hz), 3.27 (1H, d, J=14.0Hz), 3.46 (2H, s), 3.52-3.63 (2H. m), 3.82 (1H, d, J=14.1), 4.22 (1H, t, J=10.4Hz), 4.76 (1H, m), 6.37 (1H, d, J=8.9Hz), 6.80 (1H, s), 7.05-7.10 (3H, m), 7.46 (2H, brs).
58 F F -N(CH2CH3)2 1H NMR (360MHz, CDCI3) δ 1.01 (6H, t, J=7.1Hz), 1.39 (3H, d, J=6.6Hz), 2.48-2.63 (5H, m), 2.91 (1H, d, J=11.8Hz), 3.30 (1H, d, J=14.1Hz), 3.46 (1H, d, J=2.8Hz), 3.57 (2H, s), 3.60-3.63 (1H, m), 3.81 (1H. d, J=14.1Hz), 4.20-4.26 (1H, m), 4.32 (1H, d, J=2.8Hz), 4.76 (1H, m), 6.36 (1H, d, J=8.9Hz), 6.80 (1H, s), 7.04-7.09 (3H, m), 7.46 (2H, brs).
59 1H NMR (250MHz, CDCI3) δ 7.44 (2H, brs), 7.37 (3H, t, J=3.28Hz), 7.03 (1H, d, J=8.27Hz), 6.81 (1H, s), 6.23 (1H, d, J=9.32Hz), 4.76 (1H, q, J=6.57Hz), 4.34 (1H, d, J=2.80Hz), 4.22 (1H, m), 3.87-3.59 (4H, m), 3.43-3.32 (8H, m), 2.94 (2H, m), 2.72 (2H, m), 2.29 (2H, q, J=8.54Hz), 1.92-1.53 (4H, m), 1.39 (3H, d, J=6.59Hz).
OCH3
60 -N[C.I(CH3)2]2 NMR (250MHz, CDCI3) δ 7.45 (2H, brs), 7.37 (3H, t, J=2.99Hz), 7.03 (1H, d, J=8.29Hz), 6.82 (1H, s), 6.23 (1H, d, J=9.08Hz), 4.76 (1H, q, J=6.55Hz), 4.35 (1H, d, J=2.83Hz), 4.24 (1H, td, J=1.60Hz, 2.31 Hz), 3.82 (1H, d, J=14.20Hz), 3.68 (1H, d, J=13.92Hz), 3.63 (1H, m), 3.50 (1H, d, J=13.92Hz), 3.46 (1H, m), 3.36 (1H, d, J=14.20Hz), 2.97 (3H, m), 2.68 (1H, td, J=12.01Hz, 3.47Hz), 1.39 (3H, d, J=6.55Hz). MS m/z (ES*) 564.
TABLE 2 (continued)
Ex. No. R1 R4 -NR7R8 Data
61 1H NMR (250MHz, CDCI3) δ 7.42 (2H, br s), 7.36 (3H, t, J=3.01Hz), 7.03 (1H, d,
-Q J=8.29Hz), 6.81 (1H, s), 6.23 (1H, d, J=9.11Hz), 4.76 (1H, q, J=6.62Hz), 4.33 (1H, d, J=2.79Hz), 4.22 (1H, m), 3.85 (1H, d, J=14.06Hz), 3.62 (1H, m), 3.52 (2H, d, J=2.09Hz), 2.65 (1H, td, J=10.34Hz, 3.54Hz), 1.79 (4H, br m), 1.37 (8H, m). MS m/z (ES*) 560.
62 1H NMR (250MHz, CDCI3) δ 7.61 (1H, s), 7.42 (2H, br s), 7.32 (3H, m), 7.13 (2H, s),
-S 4.84 (1H, q, J=6.5Hz), 4.34 (1H, d, J=2.8Hz), 4.23 (1H, m), 3.81 (1H, d, J=14Hz), 3.6 (1H, dd, J=2.0, 11.2Hz), 3.48 (2H, s), 3.40 (1H, d, J=2.8Hz), 3.25 (1H, d, J=14Hz), 3.22 (2H, t, J=4.2Hz), 2.96 (1 H, d, J=11.7Hz), 2.64 (1H, m), 1.76 (4H, m), 1.43 (3H, d J=6.5Hz), 1.35 (4H, m). MS m/z 610 (MH*).
101 CF3 -N [ CH (CH3 ) 2 ] CH2CH3 1H NMR (250MHz,CDCI3) δ 0.87-0.95 (9H, m), 1.36 (3H, d, J=6.6Hz), 2.36-2.44 (2H, m), 2.61 (1H, dt, J=12.0Hz, 3.5Hz), 2.83-2.91 (2H, m), 3.28 (1H, d, J=14.1Hz), 3.37- 3.45 (3H, m), 3.57 (1H, m), 3.72 (1H, d, J=14.1Hz), 4.17 (1H, dt, J=11.7Hz, 2.4Hz), 4.29 (1H, d, J=2.8Hz), 4.78 (1H, q, J=6.6Hz), 7.07 (2H, s), 7.24-7.29 (3H, m), 7.37 (2H, vbr s), 7.54 (1H, s). MS (ES*) m/z 599 (MH*, 100%).
102 H -N (CH3 ) 2 1H NMR (360MHz,CDCI3) δ 1.39 (3H, d, J=6.6Hz), 2.25 (6H, s), 2.60 (1H, dt, J=11.9, 3.5Hz), 2.91 (1H, d, J=11.5Hz), 3.31 (1H, d, J=14.0Hz), 3.41-3.63 (4H, m), 3.87 (1H, d, J=14.0Hz), 4.23 (1H, br t, J=11.6Hz), 4.35 (1 H, d, J=2.8Hz), 4.76 (1H, q, J=6.5Hz), 6.27 (1H, d, J=9.2Hz), 6.83 (1H, s), 7.03 (1H, d, J=8.3Hz), 7.34-7.40 (4H, m), 7.47 (2H, br s). MS (ES*) m/z 508 (M+1 , 100%).
TABLE 3
Ex. No. R4 -ZNR7R8 Data
64 H 1H NMR (360MHz, d6-DMSO) δ 7.80 (2H, s), 7.54-7.48 (2H, m), 7.42 (2H, s), 7.36-7.28 (3H,
2 - ( CH2 ) 2- ) m), 4.92-4.98 (1H, q, J=6.5Hz), 4.38 (1 H, d, J=2.7Hz), 4.18-4.00 (3H, m), 3.70 (1 H, d, J=14.0 3.61 (1H, d, J=9.9Hz), 3.54 (1H, d, J=2.7Hz), 3.17 (1H, d, J=14.0Hz), 3.80-3.70 (1H, m), 2.58 2.50 (2H, m), 2.20-2.16 (4H, m), 1.37 (3H, d, J=6.5Hz), 1.32-1.28 (6H, m). M/S* 612.
65 H 1H NMR (360MHz, DMSO) δ 8.35 (1H, s), 7.82 (1H, s), 7.46-7.40 (2H, m), 7.36 (2H, s), 7.32-
1 - (CH2 ) 2-N > 7.22 (3H, m), 4.89-4.93 (1H, (1H, q, J=6.5), 4.34 (1H, d, J=2.8), 4.19 (2H, t, J=6.2), 4.09 (1 H, t, J=11.2), 3.60-3.52 (3H, m), 3.09 (1H, d, J=13.6), 2.93 (1H, d, J=11.7), 2.61 (2H, t, J=6.4), 2.50-2.38 (1H,m), 2.36-2.32 (4H, m), 1.44-1.40 (6H, m), 1.34 (3H, d, J=6.5). M/S+1 612.
66 H 2 - ( CH2 ) 2-N (CH2CH2CH3 ) 2 1H NMR (360MHz, d6-DMSO) δ 7.84 (1 H, s), 7.83 (1H, s), 7.45-7.49 (2H, m), 7.42 (2H, s), ' 7.32-7.31 (3H, m), 4.92-4.98 (1H, q, J=6.5Hz), 4.38 (1H, d, J=2.7Hz), 4.07-4.11 (1H, m), 3.88 3.95 (2H, m), 3.68 (1H, d, J=14.2Hz), 3.61 (1 H, d, J=11.4Hz), 3.53 (1 H, d, J=2.7Hz), 3.20 (1 H d, J=14.2Hz), 2.80 (1H, d, J=11.4Hz), 2.65-2.49 (3H, s), 2.17 (4H, t, J=7.1Hz), 1.37 (3H, d, J=6.5Hz), 1.18-1.12 (4H, m), 0.67 (6H, t, J=7.2Hz). MS* 628.
7.13 (2H, s), (1H, d, 3.00 1.54-1.40
(3H, m), H, m), 4.10 (2H, 2.92 (1H, d, 1.36 (3H, d,
(2H, t, J=8.7Hz d, J=14.8Hz),
(2H, m),
(3H, m), m), 3.82 (1 H, (1H, d, d, J=6.6Hz)
TABLE 3 (continued)
Ex. No. R4 -7NR7R8 Data
71 H 1H NMR (250MHz,CDCI3) δ 8.11 (1H, s), 7.60 (1H, s), 7.50-7.44 (2H, m), 7.38-7.30 (3H, m),
1 - (CH2 ) 2- N OH 7.13 (2H, s), 4.86-4.81 (1H, q, J=6.5Hz), 4.40-4.14 (4H, m), 3.83 (1H, d, J=14.2Hz), 3.78-3.6 (4H, m), 3.36 (1H. d, J=13.9Hz), 3.98 (1H, d, J=11.8Hz), 2.84-2.52 (5H, m), 2.34-2.18 (1 H, m 1.96-1.44 (5H, m), 1.44 (3H, d, J=6.5Hz). M/S ES* 628.
72 F 2 - CH2CH2-N (CH3 ) 2 1H NMR (250MHz,CDCI3) δ 7.80 (1H. s), 7.63 (1H, s), 7.52-7.42 (2H, m), 7.18 (2H, s), 7.07 (2H, t, J=8.7Hz), 4.91-4.86 (1H, q), 4.32 (1H, d, J=2.8Hz), 4.24-4.06 (3H, m), 3.76 (1H, d, J=14.0Hz), 3.64-3.60 (1H, m), 3.44 (1H, d, J=2.8Hz), 3.24 (1H, d, J=13.9Hz), 2.82-2.60 (4H, m), 2.25 (6H, s), 1.62-1.56 (6H, m), 1.46 (3H, d, J=6.6Hz). M/S ES* 660.
73 F 1 - CH2CH2-N (CH3 ) 2 1H NMR (250MHz,CDCI3) δ 8.07 (1H, s), 7.62 (1H, s), 7.50-7.40 (2H, m), 7.15 (2H, s), 7.03 (2H, t, J=8.8Hz). 4.87-4.83 (1H, q, J=6.6Hz), 4.35-4.25 (2H, m), 4.17 (2H, t, J=6.4Hz), 3.77 (1H, d, J=14.1Hz), 3.62-3.58 (2H, m), 3.34 (1 H, d, J=14.1Hz), 3.00 (1H. d, J=11.6Hz), 2.70 (2H, t, J=6.4Hz), 2.66-2.52 (2H, m), 2.25 (6H, s), 1.43 (3H, d, J=6.6Hz). M/S ES* 590.
74 F 1H NMR (360MHz,CDCI3) δ 7.81 (1H, s), 7.63 (1H, s), 7.52-7.42 (2H, m), 7.16 (2H, s), 7.06 (2H, t, J=8.7Hz), 4.90-4.86 (1 H, q, J=6.6Hz), 4.32 (1H, d, J=2.8Hz), 4.24 (1 H, m), 4.10-4.02 (2H, m), 3.74 (1 H, d, J=14.0Hz), 3.62-3.58 (1H, m), 3.46 (1H, d, J=2.8Hz), 3.30-3.28 (5H, m), 3.06-3.02 (2H, m), 2.88 (1H, m), 2.80-2.58 (4H, m), 2.22-2.18 (1H, m), 1.82-1.78 (1H, m),
1.70-1.58 (4H, m), 1.46 (3H, d, J=6.6Hz). M/S ES* 590.
The following examples illustrate pharmaceutical compositions according to the invention.
EXAMPLE 103A Tablets containing 1 -25mα of compound Amount mg
Compound of formula (I) 1.0 2.0 25.0
Microcrystalline cellulose 20.0 20.0 20.0
Modified food corn starch 20.0 20.0 20.0
Lactose 58.5 57.5 34.5 Magnesium Stearate 0.5 0.5 0.5
EXAMPLE 103B Tablets containing 26-1 OOmg of compound
Amount mg Compound of formula (I) 26.0 50.0 100.0 Microcrystalline cellulose 80.0 80.0 80.0
Modified food corn starch 80.0 80.0 80.0 Lactose 213.5 189.5 139.5
Magnesium Stearate 0.5 0.5 0.5
The compound of formula (I), cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 1.Omg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 10Omg of the active compound per tablet.
126 EXAMPLE 104 Parenteral injection
Amount
Compound of formula (I) 1 to 100mg
Citric Acid Monohydrate 0.75mg
Sodium Phosphate 4.5mg
Sodium Chloride 9mg
Water for injection to 10ml
The sodium phosphate, citric acid monohydrate and sodium chloride are dissolved in a portion of the water. The compound of formula (I) is dissolved or suspended in the solution and made up to volume.
EXAMPLE 105 Topical formulation
Amount Compound of formula (I) 1-1 Og
Emulsifying Wax 30g
Liquid paraffin 20g
White Soft Paraffin to 10Og
The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The compound of formula (I) is added and stirring continued until dispersed. The mixture is then cooled until solid.
Example 106A - (Surface-Active Agent) Injection Formulation
Compound of formula (I) up to 10mg/kg
Tween 80™ up to 2.5%
[in 5% aqueous mannitol (isotonic)]
/18124
127
The compound of formula (I) is dissolved directly in a solution of the commercially available Tween 80™ (polyoxyethylenesorbitan monooleate) and 5% aqueous mannitol (isotonic).
Example 106B - (Emulsion) Injection Formulation
Compound of formula (I) up to 30mg/ml
Intralipid™ (10-20%)
The compound of formula (I) is dissolved directly in the commercially available Intralipid™ (10 or 20%) to form an emulsion.
Example 106C - Alternative (Emulsion) Iniectable Formulation Amount
Compound of formula (I) 0.1 - 10mg
Soybean oil 100mg
Egg Phospholipid 6mg
Glycerol 22mg Water for injection to 1ml
All materials are sterilized and pyrogen free. The compound of formula (I) is dissolved in soybean oil. An emulsion is then formed by mixing this solution with the egg phospholipid, glycerol and water. The emulsion is then sealed in sterile vials.
Claims (1)
128
CLAIMS:
A compound of the formula (I):
( I ) wherein
R is hydrogen, halogen, C^alkyl, C.^alkoxy, CF3, NO2, CN, SRa, SORa, SO2Ra, CO2Ra, CONRaRb, C^alkenyl, C2^alkynyl or C^alkyl a b substituted by C1 4alkoxy, where R and R each independently represent hydrogen or C^alkyl;
2
R is hydrogen, halogen, C.^alkyl, C^alkoxy substituted by C^alkoxy or CF3;
3
R is hydrogen, halogen or CF3;
4 R is hydrogen, halogen, C.^alkyl, C.^alkoxy, CF3, NO2, CN,
SRa, SORa, SO2Ra, CO2Ra, CONRaRb, C2j3alkenyl, C^alkynyl or C..4alkyl a b substituted by C. 4alkoxy, where R and R each independently represent hydrogen or C1 4alkyl;
R5 is hydrogen, halogen, C^alkyl, C1 6alkoxy substituted by C^alkoxy or CF3;
6
R is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O, =S or a d^alkyl group, and optionally substituted by a group of the formula ZNR7R8 where
Z is C^alkylene or C^cycloalkylene; R7 is hydrogen, C alkyl, C^-cycioalkyl or C^cycloalkylC^alkyl, or C^alkyl substituted by C1 ,alkoxy or hydroxyl;
8
R is hydrogen, C^alkyl, C^7cycloalkyl or C^cycloalkylC^alkyl, or C2 4alkyl substituted by one or two substituents selected from C^alkoxy, hydroxyl or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;
7 8 or R , R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or d^alkyl optionally substituted by a
or hydroxyl group, and optionally containing a double bond, which ring may optionally contain an oxygen or sulphur ring atom, a group S(O) or S(O)2 or a second nitrogen atom which will be part of a NH or NR moiety where R is C^alkyl optionally substituted by hydroxy or C^alkoxy; or R7, R8 and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
7 or Z, R and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom; R and R are each independently hydrogen or C, .alkyl, or R
9b and R are joined so, together with the carbon atoms to which they are attached, there is formed a C^7 ring;
X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo; and Y is a C^alkyl group optionally substituted by a hydroxyl group; with the proviso that if Y is
R6 is substituted at least by a group of formula ZNR7R8 as defined above; or a pharmaceutically acceptable salt or prodrug thereof.
2. A compound as claimed in claim 1 of formula (la):
da) wherein A is fluorine or CF3;
2
A is fluorine or CF3;
3
A is fluorine or hydrogen;
6 and X, Y and R are as defined in claim 1 ; or a pharmaceutically acceptable salt or prodrug thereof.
3. A compound as claimed in claim 1 or claim 2 wherein Y represents a
group substituted by a hydroxy group; or a pharmaceutically acceptable salt or prodrug thereof.
4. A compound as claimed in claim 1 or claim 2 wherein Y represents a
group, with the proviso that R6 is substituted at least by a group of the formula ZNR7R8as defined in claim 1 ; or a pharmaceutically acceptable salt or prodrug thereof.
5. A compound as claimed in any one of claims 1 to 4
6 wherein R represents a heterocyclic ring selected from:
or a pharmaceutically acceptable salt or prodrug thereof.
6. A compound as claimed in claiml or claim 2 of formula
( lb) 1 2 3 wherein A , A and A are defined in claim 2 and wherein Z, R7 and R8 are as defined in claim 1 ; or a pharmaceutically acceptable salt or prodrug thereof.
7. A compound as claimed in claim 1 or claim 2 of formula
(lc):
wherein A1, A2 and A3 are as defined in claim 2 and Q1 is CH, N or C-ZNR7R8 wherein Z, R7 and R8are as defined in claim 1; or a pharmaceutically acceptable salt or prodrug thereof.
8. A compound as claimed in claim 1 or claim 2 of formula
(Id):
( Id)
1 . 2 wherein A , A and A are defined in claim 1 , Q is CH or N and Z, R7 and R8 are as defined in claim 1; or a pharmaceutically acceptable salt or prodrug thereof.
9. A compound selected from: 2-(R)-(1-(RH3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(2,3-dihydro-5-(N,N- dimethylamino)methyl-2-oxo-1 ,3-imidazol-4-yl)methyl-3-(S)-(4-fluorophenyl) morpholine; 4-(2,3-dihydro-5-(N,N-dimethylamino)methyl-2-oxo-1 ,3-imidazol-4-yl)methyl- 3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl) ethoxy)morpholine;
3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(thfluoromethyl)phenyl) ethoxy)-4-(2,3-dihydro-2-oxo-5-pyrrolidinomethyl-1 ,3-imidazol-4- yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(thfluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (2,3-dihydro-2-oxo-5-pyrrolidinomethyl-1 ,3-imidazol-4-yl)methylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (2,3-dihydro-5-(4-hydroxypiperidino)methyl-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine;
3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl) ethoxy)-4-(2,3-dihydro-5-morpholinomethyl-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (2,3-dihydro-5-morpholinomethyl-2-oxo-1 ,3-imidazol-4-yl)methylmorpholine; 4-(5-azetidinylmethyl-2,3-dihydro-2-oxo-1 ,3-imidazol-4-yl)methyl-2-(R)-(1- (R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morphoiine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (2,3-dihydro-5-(N-methylpiperazinyl)methyl-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-
(2,3-dihydro-5-(N-(2-morpholinoethyl)aminomethyl)-2-oxo-1 ,3-imidazol-4- yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (2,3-dihydro-2-oxo-5-(N-(2-pyrrolidinoethyl)aminomethyl)-1 ,3-imidazol-4- yl)methylmorpholine; 2-(R)-(1-(RH3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino) methyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (N-(N'-methylaminoethyl)-1 ,2,4-triazol-3-yl)methylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(SH4-fluorophenyl)-4- (5-(N-methylaminomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine; 4-(5-aminomethyl)-1 ,2,3-triazol-4-yl)methyl-2-(R)-(1 -(R)-(3,5- bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (5-pyrrolidinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine; 4-(5-(azetidinylmethyl)-1 ,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)-2-(R)- (1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)morpholine;
3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl) ethoxy)-4-(5-(pyrrolidinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine; 3-(S)-(4-fluoroρhenyl)-2-(R)-(1-(RH3-fluoro-5-(thfluoromethyl)phenyl) ethoxy)-4-(5-(morpholinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine; 4-(5-(N,N-dimethylaminomethyl)-1 ,2,3-thazol-4-yl)methyl-3-(S)-(4- fluorophenyl)-2-(R)-(1-(R)-(3-(trifluoromethyl)phenyl)ethoxy)morpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (5-(N'-methylpiperazinomethyl)-1 ,2,3-thazol-4-yl)methylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-(1 -(2- pyrrolidinoethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-phenyl-4-(2-(2- pyrrolidinoethyl)-1 ,2,3-triazol-4-yl)methylmorpholine; 2-(R)-(1-(R)-(3,5-bis(thfluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (5-(morpholinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine;
4-(5-azetidinylmethyl)-1 ,2,3-triazol-4-yl)methyl-2-(R)-(1-(R)-(3,5- bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-4-fluorophenyl)morpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4- (5-(pyrrolinomethyl)-1 ,2,3-triazol-4-yl)methylmorpholine; 2-(R)-(1 -(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-
(bis(methoxyethyl)aminomethyl)-1 ,2,3-triazol-4-yl)methyl-3-(SH4- fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(2-chloro-5- morpholinomethyl-1 ,3-imidazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N- dimethylaminomethyl)-1 ,3-imidazol-4-yl)methyl-3-(S)-(4-fluorophenyl) morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N- dimethylaminomethyl)-1 ,2,4-triazol-3-yl)methyl-3-(S)-(4-fluorophenyl) morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-N-(2,2- dimethoxyethyl)-N-methylaminomethyl)-1 ,2,3-triazol-4-yl)methyl-3-(S)- phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(2- methoxyethyl)aminomethyl-1 ,2,3-thazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(thfluoromethyl)phenyl)ethoxy)-4-(5-(N-(2-methoxyethyl)-
N-methyl)aminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(thfluoromethyl)phenyl)ethoxy)-4-(5-(N-isopropyl-N-(2- methoxyethyl)aminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine; 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N-cycloρropyl-N-(2- methoxyethyl)aminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-N,N- dibutylaminomethyl-1 ,2,3-triazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-N,N- diisopropylaminomethyl-1 ,2,3-thazol-4-yl)methyl-3-(S)-phenylmorpholine;
2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4- fluorophenyl)-4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)methylmorpholine; 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4- fluorophenyl)-4-(1 ,2,4-triazol-3-yl)methylmorpholine;
4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)methyl-3-(S)-(4-fluorophenyl)-2-(R)-(1 -
(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
4-(2,3-dihydro-2-oxo-1 ,3-imidazol-4-yl)methyl-2-(R)-(1 -(S)-(3,5- bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl) morpholine;
4-(2,3-dihydro-2-oxo-5-pyrrolidinomethyl-1 ,3-imidazol-4-yl)methyl-2-(R)-(1 -
(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl) morpholine; 4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)-3-(S)-phenyl-2-(R)-(1 -(S)-(3-
(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
4-(2,3-dihydro-3-oxo-1 ,2,4-triazol-5-yl)methyl-2-(R)-(1 -(S)-(3-fluoro-5-
(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-phenylmorpholine;
2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-4-(2,3-dihydro- 3-oxo-1 ,2,4-triazol-5-yl)-3-(S)-phenylmethylmorpholine;
3-(S)-phenyl-4-(1 ,2,4-thazol-3-yl)-2-(R)-(1 -(S)-3-(thfluoromethyl)phenyl)-2- hydroxyethoxy)morpholine; or a pharmaceutically acceptable salt or prodrug thereof.
10. A compound as claimed in claim 1 of formula (le):
137
(le) 1 2 3 4 5 6 9a 9b wherein R, R,R,R,R,R,R ,R and X are as defined in claim 1 and P in a circle is PO(OH)O".M+, PO(O")2.2M+, or PO(O")2.D2+; wherein M+ is a pharmaceutically acceptable monovalent counterion; D2+ is a pharmaceutically acceptable divalent counterion.
11. A compound as claimed in claiml or claim 2 of formula
(If):
(If) 1 2 3 6 wherein A , A and A are as defined in claim 2, X and R are as defined in claim 1, and P in a circle is PO(OH)0-.M+, PO(0")2.2M+, or PO(0")2.D2+; wherein M+ is a pharmaceutically acceptable monovalent counterion; and D2+ is a pharmaceutically acceptable divalent counterion.
12. A compound as claimed in claim 1 or claim 2 of formula
(ig):
( ig)
1 2 3 1 wherein A , A and A are as defined in claim 2, Q is CH, N or C-ZNR7R8 wherein Z, R7 and R8 are as defined in claim 1 , and P in a circle is PO(OH)O".M+, PO(O")2.2M+, or PO(O")2.D2+; wherein M* is a pharmaceutically acceptable monovalent counterion; and D2+ is a pharmaceutically acceptable divalent counterion.
13. A compound as claimed in claim 1 or claim 2 of formula (Ih) and pharmaceutically acceptable salts thereof:
( Ih) wherein A , A and A are as defined in claim 2, Q is CH, N or C-ZNR 7 Rr,8'
7 8 2 wherein Z, R and R are as defined in claim 1 ; Q is CH or N, and P in a circle is PO(OH)O'.M+, PO(0") 2M+, or PO(O") D2+;
wherein M+ is a pharmaceutically acceptable monovalent counterion; and D2+ is a pharmaceutically acceptable divalent counterions.
14. A compound selected from: 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-3-(S)-(4- fluorophenyl)-4-(2,3-dihydro-3-oxo-1,2,4-triazol-5-yl)methylmorpholine; 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-3-(S)-(4- fluorophenyl)-4-(1 ,2,4-triazol-3-yl)methylmorpholine; 4-(2,3-dihydro-3-oxo-1 ,2,4-thazol-5-yl)methyl-2-(R)-(1-(S)-3-fluoro-5- (trifluoromethyl)phenyl)-2-phosphoryloxyethoxy)-3-(S)-phenylmorpholine; 2-(R)-(1-(SH3,5-bis(thfluoromethyl)phenyl)-2-phosphoryloxyethoxy)-4-(2,3- dihydro-3-oxo-1 ,2,4-triazol-5-yl)methyl-3-(S)-phenylmorpholine; or a pharmaceutically acceptable salt thereof.
15. A compound as claimed in claim 1 of formula (Ii):
( Ii ) wherein R1, R2, R3, R4, R5, R6, R9a, R9b, X and Y are as defined in claim 1; or a pharmaceutically acceptable salt or prodrug thereof.
16. A compound as claimed in any preceding claim for use in therapy.
17. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 15 in association with a pharmaceutically acceptable carrier or excipient.
18. A method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound according to Claim 1 , or a salt or prodrug thereof, or a composition comprising a compound according to Claim 1, or a salt or prodrug thereof.
19. A method according to Claim 18 for the treatment or prevention of pain or inflammation.
20. A method according to Claim 18 for the treatment or prevention of migraine.
21. A method according to Claim 18 for the treatment or prevention of emesis.
22. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of a physiological disorder associated with an excess of tachykinins.
23. The use of a compound as claimed in claim 1 for the manufacture of a medicament for the treatment of pain or inflammation.
24. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of migraine.
141
25. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of emesis.
26. A process for the preparation of a compound of formula (I) as claimed in claim 1, which comprises:
(A) reacting a compound of formula (II):
1 2 3 4 5 wherein R , R , R , R , R and Y are as defined in relation to formula (I) by reaction with a compound of formula (III):
1 _6a
X -X-R (III)
6a 6 where X is as defined in claim 1 , R is a group of the formula R as defined
1 in claim 1 or a precursor therefor and X is a leaving group such as bromine
6-_ __ or chlorine; and, if R is a precursor group, converting it to a group R ; or
6
(B) wherein R represents 1 ,2,3-triazol-4-yl substituted by
7 8
CH.NR R and X is -CH -, by reaction of a compound of formula (IV)
142
( IV) with an azide, followed by reduction of the carbonyl group adjacent to
7 8
■NR R ; or
(C) wherein R represents 1 ,2,3-triazol-4-yl substituted by
-7_8
CH2NR R and X is -CH -, by reaction of a compound of formula (V)
7 8 with an amine of formula NHR R ; or
6
(D) wherein R represents substituted or unsubstituted 1 ,3,5-triazine, by reaction of compounds of formula (VI):
143
(VI ) with substituted or unsubstituted 1 ,3,5-triazine; or
6
(E) wherein R represents substituted or unsubstituted 1 ,2,4-triazine, by reaction of a compound of formula (VII) with a dicarbonyl compound of formula (VIII):
(VIII )
(VII )
35 7_8 wherein R represents H or a suitable substituent such as ZNR R ; or
6
(F) wherein R represents a substituted 1 ,2, 4-triazolyl grc by reaction of a compound of formula (II) with a compound of formula (IX)
( IX )
18 wherein X is as defined in claim 1 , Hal is a halogen atom, and R is H, CONH2 or OCH3 (which is converted to an oxo substituent under the reaction conditions), in the presence of a base, followed where necessary by conversion to a compound of formula (I); or
6
(G) wherein R represents thioxotriazolyl, by reaction of a compound of formula (X)
(X ) with a compound of formula HNCS, in the presence of a base; or
(H) wherein R6 is substituted by a group of ZNR7R8, reacting a compound of formula (XII):
(XI I ) wherein each LG, which may be the same or different, is a leaving group, and X and Z are as defined in claim 1 , followed by reaction of the resultant
7 8 7 8 compound with an amine NHR R to complete the ZNR R moiety; or
(J) by interconversion of a compound of formula (I) into another compound of formula (I);
each process being followed, where necessary, by the removal of any protecting group where present; and when the compound of formula (I) is obtained as a mixture of enantiomers or diastereoisomers, optionally resolving the mixture to obtain the desired enantiomer; and/or, if desired, converting the resulting compound of formula (I) or a salt thereof, into a pharmaceutically acceptable salt or prodrug thereof.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9326480 | 1993-12-29 | ||
GB9326480A GB9326480D0 (en) | 1993-12-29 | 1993-12-29 | Therapeutic agents |
GB9407189 | 1994-04-12 | ||
GB9407189A GB9407189D0 (en) | 1994-04-12 | 1994-04-12 | Therapeutic agents |
GB9408065A GB9408065D0 (en) | 1994-04-22 | 1994-04-22 | Therapeutic agents |
GB9408065 | 1994-04-22 | ||
GB9416428A GB9416428D0 (en) | 1994-08-15 | 1994-08-15 | Therapeutic agents |
GB9416428 | 1994-08-15 | ||
PCT/GB1994/002819 WO1995018124A1 (en) | 1993-12-29 | 1994-12-23 | Substituted morpholine derivatives and their use as therapeutic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
AU1322395A AU1322395A (en) | 1995-07-17 |
AU685209B2 AU685209B2 (en) | 1998-01-15 |
AU685209C true AU685209C (en) | 1998-08-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995018124A1 (en) | Substituted morpholine derivatives and their use as therapeutic agents | |
EP0777659B1 (en) | Morpholine derivatives and their use as therapeutic agents | |
US5512570A (en) | Treatment of emesis with morpholine tachykinin receptor antagonists | |
EP0734381B1 (en) | Morpholine tachykinin receptor antagonists | |
US5610159A (en) | N-oxides of morpholine derivatives and their use as therapeutic agents | |
US5719149A (en) | Morpholine derivatives and their use as therapeutic agents | |
JP2634372B2 (en) | Morpholine and thiomorpholine tachykinin receptor antagonists | |
US6638930B2 (en) | Morpholine and thiomorpholine tachykinin receptor antagonists | |
AU685209C (en) | Substituted morpholine derivatives and their use as therapeutic agents | |
HRP950222A2 (en) | Substituted morpholine derivatives and their use as therapeutic agents |